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ABSTRACT 
Mesenchymal stem cells (MSCs) are highly relevant for regeneration of mesoderm tissues 
such as bone and cartilage. The promising role of MSCs in cell-based therapies and tissue 
engineering appears to be limited due to a decline of their regenerative potential with 
increasing donor age. In this research we have studied and treated to understand how 
aging influences in proliferation and pluripotency capacities from these cells and also into 
their immunogenic potential.  
Six age groups from bone marrow mesenchymal stem cells of Wistar rats were studied 
(newborn, infant, young, pre-pubertal, pubertal and adult). Quantitative proteomic assay 
was performance by iTRAQ-8-plex and the proteins statistically significant modulated 
were grouped in pluripotency, proliferative and metabolism processes. Proliferation 
makers, CD117 and Ki67 were measure by flow cytometry assay. Real time polymerase 
chain reaction analysis of pluripotency markers Rex1, Oct4, Sox2 and Nanog were done. 
Biological differentiation was realized using specific mediums for 14 days to induce 
osteogenesis, adipogenesis and chondrogenesis and differentiated cells were analysed 
using histochemical techniques. Enzymatic analysis of several enzymes as L-lactate 
dehydrogenase and glucose-6-phosphate isomerase were done to validate iTRAQ data. 
To deeply study these differences we have analyzed by Next Generation Sequencing six 
age groups from bone marrow mesenchymal stem cells. A total of 9628 genes presented 
differences of expression among age groups and those genes were grouped into metabolic 
pathways. We focused our research in young, pre-pubertal and adult groups which 
presented the highest amount of genes differentially expressed related with inflammation 
mediated by chemokine and cytokine signalling pathway when compared with newborn 
group which was used as a control. Afterwards, extracellular vesicles from those groups 
were isolated and characterized by nanoparticle tracking analysis and flow cytometry and 
several micro-RNAs were checked by qRT-PCR because of their relationship with the 
pathway of interest. Since miR-21-5p was statistically significant highest in extracellular 
vesicles from mesenchymal stem cells of pre-pubertal group, we realized a functional 
experiment inhibiting it expression and investigating the modulation of Toll-Like 
Receptor 4 and their link to damage-associated molecular patterns. 
Aging affects proliferation, pluripotency and immunogenic profiles of bone marrow 
mesenchymal stem cells. Also its affects production, content of pro-inflammatory miRs 
and affectivity of bone marrow mesenchymal stem cell-derived extracellular vesicles. 
These findings are important to the understanding about influence of the aging on 
mesenchymal stem cells and to advance in the development EV-based therapies. 
 
 
 
 
RESUMEN 
Las células madre mesenquimales (CMMs) tiene una gran relevancia en la regeneración 
de tejidos mesenquimales como hueso y cartílago. El prometedor papel de las CMMs en 
terapia celular e ingeniería tisular parece estar limitado debido a la pérdida de potencial 
de regeneración con el incremento de la edad del donante. En esta investigación hemos 
tratado de entender como el envejecimiento influye en la capacidad de proliferación y 
pluripotencia en estas células y también en su potencial inmunogénico. 
CMMs de médula ósea procedentes de ratas Wistar de seis estadios de edad (neonato, 
infantil, juvenil, pre-pubertal, pubertal e adulto) fueron usadas en este estudio. Se llevo a 
cabo un ensayo proteómico cuantitativo usando iTRAQ 8-plex y las proteínas 
estadísticamente moduladas fueron agrupadas en tres procesos: pluripotencia, 
proliferación y metabolismo energético. Se midieron mediante citometría de flujo los 
marcadores de proliferación CD117 y Ki67. El análisis de los marcadores de pluripotencia 
Rex1, Oct4, Sox2 y Nanog usando reacción en cadena de la polimerasa a tiempo real. 
Evaluación biológica mediante diferenciaciones dirigidas usando medios específicos de 
osteogénesis, adipogénesis y condrogenénesis durante 14 días, las células diferenciadas 
fueron analizadas usando técnicas histoquímicas. También se realizaron ensayos 
enzimáticos de varias enzimas como L-lactato deshidrogenasa y glucosa-6-fosfato 
isomerasa para validar los datos obtenidos del iTRAQ. Para profundizar en el estudio de 
las diferencias obtenidas a nivel proteómico hemos analizado el transcriptoma de los seis 
grupos de edad de CMMs de médula ósea usando Next Generation Sequencing. Un total 
de 9628 genes se encontraron modulados significativamente entre los grupos de edad y 
estos fueron agrupados en rutas metabólicas. Encontramos en los grupos juvenil, pre-
pubertal y adulto una gran cantidad de genes diferencialmente expresados relacionados 
con inflamación mediada por la ruta de señalización de quimiocinas y citoquinas 
comparados con el grupo control. Además, las vesículas extracelulares de estos grupos 
de edad fueron aisladas y caracterizadas usando el análisis de tráfico de nanopartículas y 
citometría de flujo y la expresión de varios micro-ARNs relacionados con la ruta de 
interés, se evaluaron por qPCR-RT. El miR-21-5p fue estadísticamente 
significativamente alto en vesículas extracelular de CMMs del grupo pre-pubertal, 
mediante experimentos funcionales inhibiendo su expresión , investigamos la modulación 
del receptor tipo Toll 4 y los patrones moleculares asociados al daño. 
El envejecimiento afecta al perfil de proliferación, pluripotencia e inmunogénico de 
CMMs de médula ósea, También afecta la producción, contenido de micro-ARNs pro-
inflamatorios y la efectividad de las vesículas extracelulares procedentes de células madre 
mesenquimales de médula ósea. Estos descubrimientos son importantes para entender la 
influencia del envejecimiento en las células madre mesenquimales y el avance en el 
desarrollo de terapias basadas en vesículas extracelulares de las mismas. 
 
 
RESUMO 
As células nai mesenquimais (CNMs) teñen unha gran relevancia na rexeneración de 
tecidos mesenquimais coma óso e cartilaxe. O prometedor papel das CNMs en terapia 
celular e inxenería tisular parece estar limitado debido a perda do potencial de 
rexeneración co incremento da idade do doante. Nesta investigación tratamos de entender 
coma o envellecemento inflúe na capacidade de proliferación e pluripotencia e no 
potencial inmunoxénica destas células. 
CNMs de medula ósea procedentes de ratas Wistar de seis estadios de idade (neonato, 
infantil, xuvenil, pre-púbere, púbere e adulto) foron empregadas neste estudo. Levouse a 
cabo un ensaio proteómico cuantitativo empregando iTRAQ 8-plex e as proteínas 
estadísticamente moduladas agrupáronse en tres procesos: pluripotencia, proliferación e 
metabolismo enerxético. Medironse empregando citometría de fluxo os marcadores de 
proliferación CD117 e Ki67. A analise dos marcadores de pluripotencia Rex1, Oct4, Sox2 
e Nanog empregando a reacción en cadea da polimerasa a tempo real. A evaluación 
biolóxica mediante diferenciacións dirixidas empregando medios específicos de 
osteoxénesis, adipoxénesis e condroxénesis durante 14 días, as células diferenciadas 
foron evaluadas empregando técnicas histoquímicas. Tamén leváronse a cabo ensaios 
enzimáticos de varias enzimas coma L-lactato deshidroxenasa e glicosa-6-fosfato 
isomerasa para validar os datos obtidos do iTRAQ. Para profundizar no estudo das 
diferencias obtidas a nivel proteómico analizouse o transcriptoma dos seis grupos de 
idade das CNMs empregando Next Generation Sequencing. Un total de 9628 xenes 
atoparonse modulados significativamente entre os grupos de idades e estos foron 
agrupados en rutas metabólicas. Atopamos nos grupos xuvenil, pre-púbere e adulto una 
gran cantidade de xenes diferencialmente expresados relacionados coa inflamación 
mediada pola ruta de sinalización de quimiocinas e citoquinas comparadas co grupo 
control. Ademais, as vesículas extracelulares dos grupos de idade foron aisladas e 
caracterizadas empregando a análise de tráfico de nanopartículas e citometría de fluxo e 
a avaliación da expresión de varios micro-ARNs relacionados coa ruta de interese 
mediante qPCR-RT. O miR-21-5p foi estadísticamente significativamente alto nas 
vesículas extracelulares de CNMs do grupo pre-púbere, mediante experimentos 
funcionais, inhibindo a súa expresión, investigamos a modulación do receptor tipo Toll 4 
e os patrones moleculares asociados ao dano. 
O envellecemento afecta ao perfil de proliferación, pluripotencia e inmunoxénico das 
CNMs de medula ósea. Tamén afecta a producción, contido de micro-ARNs pro-
inflamatorios e a efectividade das vesículas extracelulares procedentes de CNMs de 
medula ósea. Estos descubrimentos son importantes para entender a influencia do 
envellecemento nas CNMs e o avance no desenvolvemento de terapias baseadas nas 
vesículas extracelularas das mesmas. 
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ng/ml Nanograme per militer 
NGF Nerve growth factor 
NGS Next Generation Sequencing 
nm Nanometer 
nM Nanomolar 
nt Nucleotide 
NTA Nanoparticle tracking analysis 
º C º Celsius 
Oct4 Octomer-binding transcription factor 4 
Or Oil red 
OS Osteogenic medium 
P Pubertal 
P/PP Pubertal vs pre-pubertal 
P0 Passage zero 
p53/p21 Tumor antigen p53/cyclin-dependent kinase inhibitor 1A 
P70s6k Ribosomal protein S6 kinase beta-1 
p-Akt Phospho-Akt 
PBS Phosphate-buffered saline 
PDDF Presence of characteristic enlarged 
PDGF Platelet-derived growth factor receptor A 
PDIA1 Protein disulfide-isomerase A1 
PGE2 Prostaglandin E2 
PI Propidium iodide 
PI3K/Akt Phosphatidylinositol-3-kinase/Akt  
p-Mtor Phospho-mTOR 
PP Pre-pubertal 
PP/Y Pre-pubertal vs young 
pri-miRNAs Long miRNA precursors 
PRKD1 Protein kinase D1 
qRT-PCR Real time quantitative polymerase chain reaction  
Raptor Regulatory-associated protein of mTOR 
Rb/p16 Retinoblastoma protein/cyclin-dependent kinase inhibitor 2A 
rBM-MSCs Rat bone marrow-mesenchymal stem cells 
Rex1 Zinc finger protein 42 homolog 
rhTGF-β3 Recombinant human transforming growth factor-βeta 3  
Rictor Rapamycin-insensitive companion of mTOR 
RIN RNA integrity 
RISC RNA-induced silencing complex 
RNA Ribonucleic acid 
RNA Pol II RNA Polymerase II 
RNAi RNAinhibitor 
RNAs Ribonucleic acids 
Rnase A Ribonuclease A 
RNA-seq RNA-sequencing 
rno Rattus novergicus 
RNU6 RNA, U6 small nuclear 1 
ROCKi Rho-associated protein kinase inhibitor 
ROS Reactive oxygen species 
rpm Revolutions per minute 
rrTNFα Recombinant rat tumor necrosis factor alpha 
RT Retrotranscption 
s Second(s) 
S Synthesis 
S100  S100 calcium-binding protein 
S100A4 S100 calcium-binding protein A4 
S100A6 S100 calcium-binding protein A6 
Saf O Safranine O 
SASP Senescence-associated Secretory Phenotype 
SA-β-gal Senescence-associated β-galactosidase 
SDS-PAGE SDS polyacrylamide gel  
Sec1/Munc-18 Protein transport protein SEC1/ Mammalian uncoordinated-18 
Ser2448 Serine2448 
Ser/thr Serine/threonine 
SIPS Stress-induced premature senescence 
SNAREs 
(Soluble N-ethylmaleimide sensitive fusion proteins Attachment 
Protein) Receptors 
SOD-2 Superoxide dismutase-2 
Sox2 (Sex determining region Y)-box 2 
SPRY229 SPRY domain-containing SOCS box protein 3 
St.Clara Saint Clara 
St.Louis Saint Louis 
T Temperature 
T cells Tregs cells 
TAB2 TGF-βeta activated kinase 1/MAP3K7 Binding Protein 2 
TAK1 TGF-βeta activated kinase 1 
TBS Tris buffered saline  
TBST Standard buffer tris buffered saline with 0.1% (v/v) Tween® 20  
TCEP Tris-(2-carboxyethy) phosphine 
TEAB Tryethylammonium bicarbonate  
TFA Trifluoroacetic acid  
TGF-β Transforming Growth Factor-beta 
TGF-β1 Transforming growth factor-beta1 
TIMP-2 TIMP metallopeptidase inhibitor-2 
TLR Toll-like receptor 
TLR4 Toll-like receptor type 4 
TMRM Tetramethylrhodamine methyl ester  
TNF Tumour necrosis factor 
TSAP6 Tumour suppresour-activated pathway  6 
Tsg101 Tumor susceptibility gene 101 protein 
V Voltie(s) 
v/v Volume/volume 
VEGF Vascular endothelial growth factor 
w/v Weight/volume 
Wnt Wingless-type MMTV integration site family 
Wnt5a Wnt family member type 5A 
xg G-force or relative centrifugal forces 
Y Young 
Y/I Young vs infant 
yBM-MSCs Bone marrow-mesenchymal stem cells from young group 
yEVs 
Mesenchymal stem cell-derived extracellular vesicles from 
young group 
yMSCs Mesenchymal stem cells from young group 
Y-RNA Small non-coding RNA 
α-ciano Alpha-ciano 
β-actin beta-actin 
γH2AX Histone variant gamma H2AX 
Δratio Differential of ratio 
ΔΔCt Delta(delta(threshold cycles)) 
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1.1 Mesenchymal stem cells 
 
1.1.1 Definition 
Mesenchymal stem cells (MSCs) are multipotent fibroblast-like cells that can be 
found in almost all tissues and they can differentiate into bone1, cartilage2, muscle3, 
tendon, ligament4, fat5, and a variety of other connectives tissues6,7. MSCs were first 
reportein in 1968 by Friendenstein et al.8 when human bone marrow cells were 
cultured in plastic dishes colonies of adhered fibroblastoid cells proliferative. 
MSCs are adult stem cells which have a great self-renewal capacity, is the process by 
which a stem cell divides asymmetrically or symmetrically to propagate one or two 
daughter stem cells with similar development potential as the mother cells9 while 
maintaining pluripotency, namely the capacity to self-maintained in undifferentiated 
state10 (Figure 1.1). 
The International Society for Cellular Therapy (ISCT) suggested the following 
criteria for the identification of MSCs11: 
 Adherence to plastic. 
 Differentiation into chondrocytes, osteoblasts and adipocytes under standard in 
vitro differentiating conditions. 
 Expression of surface markers CD105, CD73, CD29 and CD90, in the absence of 
CD45, CD34, CD14, CD11b, CD79α.  
 
Figure 1.1. Definition of mesenchymal stem cells. 
 
1.1.2 Sources for mesenchymal stem cells 
MSCs have been isolated from many different adult tissues, including bone marrow12, 
adipose tissue13, synovial membrane14, connectives tissues of dermis15, skeletal 
muscle16, peripheral blood17, liver18, lung19 and blood vessels20 and from rather 
“young sources” such as amniotic fluid21, amniotic membrane22, umbilical cord 
blood23, umbilical cord stroma24, or placenta25. In the last years the number of tissues 
with a potential for tissue engineering has increased6,26 (Figure1.2). 
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Figure 1.2. Several sources from MSCs. 
 
Therefore, there are more studies about differences at cellular and molecular levels 
such as, cell morphology, surface markers27, differentiation28, proliferation27,1, 
transcriptomic29 and proteomic30 analyses among MSCs from several tissue sources. 
 
1.1.3 Properties of mesenchymal stem cells supporting therapeutic 
application 
To date, the clinical use of stem cells presents some disadvantages because stem cells 
from certain sources, such as somatic nuclear transfer, embryo destruction, or even 
induced pluripotent stem cells (iPSCs) obtained by reprogramming have raised deep 
ethical issues depending on the country work31,32. Besides, they could produce 
neoplastic disorders and immunologic rejection when they are injected in in vivo 
models32. For these reasons, MSCs are a good alternative because they don´t produce 
immunologic disorders due to their autologous origin and there are not ethical issues 
about their clinical use31. Additionally MSCs posses the following properties: 
1.1.3.1 Differentiation 
MSCs can differentiate both in vivo and in vitro, into various mesenchymal cells 
and exhibit remarkable plasticity given their ability to trans-differentiate, or undergo 
an abrupt alteration in phenotype, thereby giving rise to cells possessing the 
characteristics of different lineages33,34.  
 
 1. INTRODUCTION 
- 5 - 
 
1.1.3.2 Paracrine effects and immunomodulation 
It is the capacity of MSCs to secrete a wide variety of cytokines, chemokines, and 
growth factors. 
Several studies based on examination of MSCs secretome in vivo and the strategies 
to modulate the secretion of molecules of MSCs have identified high levels of 
proteins  involved in immune response such as interleukin-6 (IL-6), IL-8, monocyte 
chemoattractant protein (MCP-1), and transforming growth factor-β (TGF-β); 
extracellular matrix remodelers like TIMP metallopeptidase inhibitor 2 (TIMP-2), 
fibronectin, periostin, collagen, decorin, metalloproteinase inhibitors; growth 
factors and their regulators such as vascular endothelial growth factor (VEGF), 
granulocyte-macrophage colony-stimulating factor (CM-CSF), bone 
morphogenetic protein 2 (BMP-2), basis fibroblast growth factor (bFGF), and 
insulin-like growth factor-binding protein 3 (IGFBP3), IGFBP4, IGFBP735. 
Also, MSCs can the modulate immune response system and they were effective for 
treatment of various immune response disorders in both human and animal 
models36–38. However, the underlying mechanism of that modulation is not fully 
understood. The most accredited theory points to the important cell-to-cell contact 
and/or the release of soluble immunosuppressive factors. They interacted with a 
broad range of immune cells and displayed an ability to suppress the excessive 
response of T and B cells, dendritic cells, macrophages and natural killer cells39,38. 
Besides, MSCs can also induce regulatory T cells (Tregs) and maintain the 
capability of Tregs to suppress self-reactive T-effector responses40 (Figure 1.3). 
In the last years, it was proposed that MSCs interact with their environments both 
by negatively regulating the immune response in the case of major inflammation 
and by stimulating the immune response system by releasing pro-inflammatory 
molecules if the level of inflammatory cytokines is low41. 
1.1.3.3 Homing mechanism 
The homing mechanism of MSCs lies in their ability to reach damaged tissue in 
response to a correct combination of signalling molecules from the injured tissue 
and corresponding receptors. Homing-related molecules in general can be up-
regulated by inflammatory cytokines such as tumour necrosis factor (TNF) and IL-
142, suggesting that different inflammation states might promote distinct MSC 
engraftment and therapeutic efficiencies43 (Figure 1.3). 
 
 1. INTRODUCTION 
- 6 - 
 
 
Figure 1.3. Properties of MSCs. From 
http://www.iem.cas.cz/research/departments/transplantation-immunology.html at June 30, 2016. 
 
1.1.4 Applications in clinical use 
MSCs have emerged as a novel strategy to therapeutic application of the US National 
Institute of Health 493 MSC-based clinical trial have been reported as of June 15, 
2015; most were performed to evaluate the biomedical potential of MSCs in treating 
haematological diseases including Graft-versus-host disease (GVHD), diabetes, 
inflammatory diseases, and disease in the liver, kidneys, and lungs, as well as 
cardiovascular, bone and cartilage, neurological (Figure 1.4). MSCs have the ability 
to differentiate into several mesenchymal linages27 and contribute to the replacement 
of the damaged tissue, but rather act as trophic mediators, promoting tissue repair by 
production and release of soluble factors that inhibit inflammation, reduce fibrosis, 
and induce angiogenesis44 among other functions.  
Phases of investigation of 493 MSC-based clinical trials and the most representative 
treated pathologies are shown in the figure 1.4 According to these data, most clinical 
trials occurred in an early phase (phase I, I/II, or II), demonstrating that more 
investigation about the therapeutic effectiveness of MSCs is required. 
Several studies indicate that donor heterogeneity, ex vivo expansion, immunogenicity, 
and cryopreservation can be considered the Achilles´-heel of MSC-base therapies. 
Therefore, it is necessary that researchers and clinical discoveries will address the 
mechanisms influencing their therapeutic use. 
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Figure 1.4. Number and percentage of MSC-based clinical trials classified by disease type. 
Data from www.clinicaltrial.gov at June 30, 2015. 
 
 
1.2  Aging 
 
1.2.1 Definition 
Aging is the decline in the homeostasis and regenerative capacity of all tissues and 
organs and it is the greatest risk factor for the development of chronic diseases which 
comprise the majority of global disease burden and are the most common causes of 
mortality. Mammalian aging can be delayed with genetic, dietary, and 
pharmacological approaches. Given that the elderly population is dramatically 
increasing. (http://www.healthmetricsandevaluation.org/data-visualizations at 
July 9, 2016).  
Actually, in the world the number of people aged 65 or older will outnumber children 
under age 5. Driven by falling fertility rates and increasing in life expectancy, 
population aging will continue, even accelerate. The number of people aged 65 or 
older are projected to grow from an estimated 1.5 billion in 2050, with most of the 
increase in developing countries45. Actually, there is an urgent need to extend 
healthspan. 
 
1.2.2 The hallmarks of aging 
Defining the causes of aging is a difficult work because it is impeded by the 
complexity of the phenotype coupled with the costs and duration of longevity studies 
but in recent years, progress has accelerated, bringing geroscience to the forefront. 
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Firstly, genetic and environmental interventions and pathways that regulate longevity 
were studied in yeast (particularly the budding yeast, Saccharomyces cerevisiae)46,47 
and invertebrate model organisms, such as Caenorhabditis elegans47,48. Conserved 
molecular pathways impacting aging have been identified, such as insulin/ insulin-
like growth factor signalling (IIS). Secondly, mammalian studies have generated a 
more detailed understanding of age-associated pathologic changes. Additionally, 
studies about effects of environmental interventions on the lifespan have been 
performed. Those studies have revealed key genes and pathways for cellular ageing 
such as IIS and the mammalian target of rapamycin (mTOR) which are implicated in 
mediating the effects of dietary restriction49,50. 
In the last years, López-Otín et al.51 have identified and categorized the cellular and 
molecular hallmarks of aging. These hallmarks are not independent factors driving 
aging; rather, they were highly intertwined processes, and understanding the interplay 
among them is critical (Figure 1.5). 
 
Figure 1.5. The Hallmarks of aging. From López-Otín et al.51. 
 
1.2.2.1 Genomic instability 
The accumulation of genetic damage throughout life is the most studied cause of 
aging52. In this hallmark are included several areas of aging research such as 
mechanisms for the maintaining the appropriate length and functionality of 
telomeres53,54 and for ensuring the integrity of mitochondrial DNA (mtDNA)55, as 
well as defects in the nuclear architecture known as laminopathies which causes 
premature aging syndromes56. 
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1.2.2.2 Telomere attrition 
Telomere attrition is associated with aging in mammal models because pathological 
telomerase dysfunction accelerates aging in mice and humans57, while experimental 
stimulation of telomerase can delay aging in mice58. 
1.2.2.3 Epigenetic alterations 
This hallmark contains a variety of epigenetic alterations affecting lifespan of cells 
and tissues such as DNA methylations patterns59, post-translational modification of 
histones60,61 and chromatin remodelling62,63. The important goals of this hallmark 
are biomarker development between chronological age and biologic aging, link age-
related environment inputs to epigenetic signatures and test small molecules that 
regulate enzymes controlling epigenetic events48,64,65. 
1.2.2.4 Loss of proteostasis 
Proteostasis involves mechanisms for the stabilization of correctly folded proteins, 
most prominently the heat-shock family of proteins, and mechanisms for the 
degradation of proteins by the proteasome or the lysosome66,67. Many studies have 
demonstrated that proteostasis is altered with aging66, also chronic expression of 
unfolded, misfolded or aggregated proteins contribute to the development of some 
age-related pathologies, such as Alzheimer´s disease, Parkinson´s disease and 
cataracts68.  
Some important studies to advance this hallmark through identification of 
proteostasis pathways that are owerwhelming in specific chronic disease states, 
examination crosstalk between proteostasis machinaries and understand non-cell-
autonomous signalling and activation of proteostasis pathways. 
1.2.2.5 Deregulated nutrient-sensing 
There are several conserved pathways related to deregulated nutrient-sensing such 
as IIS pathways, which is related to metabolism of glucose in the cells69, mTOR 
pathway which is also involved in anabolism metabolism and aging50,70 and AMPK 
and sirtuins, acting in the opposite direction to IIS and mTOR71. 
This hallmark have important focus as determination role of signal transduction 
pathways linked to metabolism in the aging process and pharmacological 
manipulation that mimics a state of limited nutrient availability like rapamycin72. 
1.2.2.6 Mitochondrial dysfunction 
This detrimental process has been long associated with aging because the efficacy 
of the respiratory chain tends to diminish with increasing age, thus increasing 
electron leakage and reducing ATP generation73. But. there are less clear different 
aspects for example, knowledge about bridge continuum from physiological to 
molecular stresses, differentiation between toxic stress and hormesis, is the 
mechanism to response to harmless doses of toxins and other stressors. It could 
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constitute to one of the mechanisms that allows stressed cells to avoid senescence 
and death74. 
1.2.2.7 Cellular senescence 
It is a stable arrest of the cell cycle coupled to stereotyped phenotypic changes75. 
This phenomenon was described by Hayflick76. To date, it is known that the 
senescence observed by Hayflick et al.76 is caused by telomere shortening, but there 
are other aging-associated stimuli that trigger senescence independently of 
telomeric process77,78. The most famous non-telomeric DNA damage is de-
repression of INK4/ARF locus75. The controversy of cell senescence as a beneficial 
compensation on aging and cancer or deleterious and accelerate aging. 
1.2.2.8 Stem cell exhaustion 
The most obvious characteristic of aging is the decline in the regenerative potential 
of tissues. For example, hematopoiesis declines with age, resulting in a decreasing 
production of adaptive immune cells, a process termed immunosenescence79. 
The important goals in this hallmark are:  
 To determine whether declining adult stem cell function drives to aging and 
chronic disease. 
 To examine how aging and associated diseases impair adult stem cell 
function. 
 To define how macromolecular damage accumulates in aging adult stem 
cells pools. 
 
1.2.2.9 Altered intercellular communication 
A prominent aging-associated alteration in intercellular communication is 
“Inflammaging”, which may result from multiples causes such as the accumulation 
of pro-inflammatory tissue damage, the failure of an ever more dysfunctional 
immune system to effectively clear pathogens and dysfunctional host cells, the 
propensity of senescent cells to secrete pro-inflammatory cytokines through 
activation of the NF-kB transcription factor, chemokines and extracellular matrix 
(ECM) remodelling proteases, is named the senescence-associated secretory 
phenotype (SASP)80,81.  
Also, there are other processes related to cellular communication which induce 
senescence in neighbouring cells via gap junction-mediated cell-cell contacts and 
processes involving ROS82. 
 
1.2.3 Mechanisms of aging on mesenchymal stem cells 
Aging is associated with a marked decline in functionalities of adult stem cells, 
namely tissue homeostasis, repair and regeneration83.  
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The combination of cell-intrinsic changes leads to decline in cellular function, which 
in turn contributes to tissue dysfunction and organism aging (Figure 1.6). The 
intrinsic changes are: 
 Genomic changes: include accumulation measurable genomic lesions, 
including single- and double-strand DNA breaks, chromosomal 
translocations, telomere shortening84. 
 Epigenetic changes: include DNA methylation and post-translation 
modification of histones, are dynamically maintained by a balance among 
chromatin-remodeling complexes and, thus, reversible85 and altered 
expression of cofactors of histones86. 
 Proteomic changes: maintenance of the intracellular proteome requires 
timely removal of improperly folded or damaged proteins that can 
otherwise impede normal cellular function66.The machineries and cellular 
processes, which maintain protein homeostasis are autophagosomes, 
chaperones, lysosomes and the ubiquitin-proteosome system68.  
Also the extrinsic influences, such as inflammatory cytokines and Wnt activators 
influence in the aging process of the tissue and organism. The niche is profoundly 
influenced by the systemic milieu and dynamically changing to regulate stem cell 
function, a feature that is especially relevant with regard to the process aging87 
(Figure 1.6). 
 
 
Figure 1.6. Extrinsic and intrinsic influences on stem cell aging. Adapted from Liu et al.88.  
 
MSCs have been reported to be highly resistant to apoptosis induced by different 
genotoxic insults and preferentially respond to injury with activation of stress-induced 
premature senescence (SIPS), which had been widely studied in MSCs, particularly 
for its clinical implications89. Also, it was demonstrated that the senescence activation 
pathway in MSCs is independent of the tissue source89–92. 
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Senescent MSCs activate p53/p21 and Rb/p16 pathways to block the cell cycle and 
sustain growth arrest but they continue to be metabolically active93. The cells in a 
senescent state are characterized by a large, flat morphology, display changes in gene 
expression, typically exhibit a senescence-associated β-galactosidase (SA- β-gal), for 
persistent DNA damage response (DDR) activation, as highlighted by the presence of 
characteristic enlarged (PDDF), containing γH2AX and 53BP1 foci94 and SASP81,91 
(Figure 1.7). 
 
 
Figure 1.7. Phenotype characterization of senescence MSCs. Adapted from Turinetto V et al.95 
Senescence impacts on migratory ability96,97, differentiation potential98, 
immunomodulation ability97, loss of proliferation capacity and tumour progression92. 
 
 
1.3 Extracellular vesicles 
 
1.3.1 Definition 
Extracellular vesicles (EVs) are membrane-contained vesicles released in an 
evolutionally conserved manner by cells ranging from organisms such as 
prokaryotes. 
During the past decades, EVs have been recognized as potent vehicles of intercellular 
communication in different model systems with respect to other cell-to-cell 
communication strategies, such as quorum sensing, juxtacrine signalling, autocrine 
signalling, paracrine signalling, endocrine signalling and direct cell-to-cell 
communication (desmosomes, adherents and gap junctions). 
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1.3.2 Types of extracellular vesicles 
EVs can be isolated from all types of body fluids including blood, urine, 
bronchoalveolar lavage fluid, breast milk, amniotic fluid, synovial fluid, pleural 
effusions and ascites99 and from several cell types100–104. 
The term EVs comprise a highly heterogeneous and dynamic group of nanoparticles. 
Therefore, International Society of Extracellular Vesicles (www.isev.org)105 have 
promoted the collaboration work since 2011 by the members to unify the 
nomenclature and the methodologies of EVs by the contents, size, membrane 
composition, cellular source, state and environmental conditions. 
Actually, three main subgroups of EVs have defined depend on size, sucrose gradient 
and origin (Table 1.1 and Figure 1.8). 
Vesicle 
 
Size (Diameter)/nm 
 
Sucrose gradient/ 
g.ml-1 Origin 
 
Exosomes 
 
40-100  
 
1.13-1.19 
 
Luminal budding into 
MVBs 
Release by fusion of 
MVB with cell 
membrane 
Microvesicles 
Microparticles 
Ectosomes 
50-1000 1.04-1.07 
Outward budding of cell 
membrane 
Apoptotic 
bodies 
1-5000 1.16 and 1.28 
Outward blebbing of 
apoptotic cell membrane 
 
Table 1.1 Different types of EVs. Adapted from Rani et al.106. 
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Figure 1.8. Different types of EVs. Adapted from Cocucci et al.107 
 
1.3.3 Composition of Extracellular Vesicles 
Public on-line databases that catalogue EV-associated components, are available. 
These include Vesiclepedia (www.microvesicles.org/)108, EVpedia 
(www.evpedia.info)109 and ExoCarta (www.exocarta.org)110. 
 
1.3.3.1 Protein and protein-associated of EVs 
Protemic studies of EVs released by primary cell cultures, cell lines, tissue 
cultures or isolated from biofluids have yielded extensive number of protein 
abundance in different types of EVs. In general, EVs are highly  abundant in 
cytoskeletal, cytosolic, heat shock, plasma membrane proteins and proteins 
involved in vesicle trafficking. 
Also there are some studies where it have identifying some markers of EV sub-
populations that are often used as markers, such as tetraspanins (CD9, CD63, 
CD81 and CD82) which are considered marker of exosomes, 14-3-3 protein, 
major histocompatibility complex (MHC) molecules and heat shock proteins 
(HSPs), Tsg101 and the Endosomal Sorting Complex Required for Transport 
(ESCRT-3) binding protein a Alix which are considered marker of exosomes111–
113 (Figure 1.9). 
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Figure 1.9. Protein composition of EVs. From Mathivanan et al.114. 
 
Several studies reported about changes in the glycosylation patterns of EVs115–118, 
protein signature of different EVs which may be involved in biogenesis, 
sorting119,120, uptake110 and EV-associated cytokines121,122 (Figure 1.9). 
1.3.3.2 RNA composition 
EVs contain intact mRNA123, mRNA fragments124, long non-coding RNA125,126, 
miRNA127,128, piwi-interacting RNA125, ribosomal RNA125 and fragments of 
tRNA, vault- and Y-RNA129,130. It occurred an increased of studies about activity 
of RNA in EVs because they are more enriched in EVs with respect to parental 
cells101. EVs contained RNAs are involved in cell differentiation131–133, 
proliferation132,134, immune regulation135, modulation stress134 condition and 
other117,136–138. 
1.3.3.3 DNA contain 
The study of the DNA contained in EVs represents a relatively new approach to 
the field. Oncogenic DNA was found in apoptotic bodies139. Also, mitochondrial 
DNA (mtDNA), single-stranded DNA, double-stranded DNA (dsDNA) and 
oncogene amplifications have been detected in EVs140,141. 
1.3.3.4 Lipid composition 
EVs are generally enriched in sphingomyelin, cholesterol and glycosphingolipids 
similar to raft domain142. Some studies reported that the specific lipid that confers 
the stability of EVs may be used to improve liposomal drug delivery 
systems143,144, sorting, biogenesis142,145. 
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1.3.4 Formation and sorting EVs 
 
1.3.4.1 Exosome biogenesis 
The membrane of late endosomes invaginates and forms small vesicles that are 
pinched off into the endosomal space. These are the intralumenal vesicles (ILVs) 
and the whole is the MVE. Notice that the internal face of an ILV membrane 
corresponds to the cytoplasmic face of the endosome limiting membrane, and the 
content of the ILV is originated from the cytosol prior to ILV formation. A set of 
MVEs fuse their limiting membranes to the plasma membrane and the ILVs with 
their cargo into the extracellular space146.  
Formation of ILVs in the late endosome involves the endosomal sorting complex 
required for transport (ESCRT) proteins. ESCRT proteins are components of four 
ESCRT complexes, ESCRT-0, ESCRT-I, ESCRT-II, and ESCRT-III. Each of 
these complexes is sequentially and transiently recruited to the forming MVE until 
a vesicle is fully shaped and released as an ILV into the endosomal space146,147 
(Figure 1.10). 
However, increasing evidences about the key role of some lipids such as ceramide 
in ILV formation, independently of ESCRT complexes146. 
As mentioned above, a set of MVE fuses with the plasma membrane while other 
MVEs follow a degradative route and fuse with lysosomes (Figure 1.10). 
Some studies identified the existence of different populations of MVEs: 
 MVEs rich in GTPase Rab7 and ILVs containing phosphatidylinositol-3-
phosphate and ubiquitinated proteins are sorted to lysosomes148. 
 MVEs rich in GTPase Rab11 and ILVs with high amounts ceramide are 
sorted for exosome secretion149,150. 
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Figure 1.10. Formation and sorting EVs. Membrane-associated (triangles) and transmembrane 
proteins (rectangles) and RNAs (curved symbols) are selectively incorporated into the ILV of MVEs 
or into MVs budding from the plasma membrane. MVEs fuse with the plasma membrane to release 
exosomes into the extracellular milieu. MVs and exosomes may dock at the plasma membrane of 
a target cell (1). Bound vesicles may either fuse directly with the plasma membrane (2) or be 
endocytosed (3). Endocytosed vesicles may then fuse with the delimiting membrane of an endocytic 
compartment (4). Both pathways result in the delivery of proteins and RNA into the membrane or 
cytosol of the target cell. Fusion and endocytosis are only represented for exosomal vesicles, but 
plasma membrane-derived MVs may have similar fates. From Raposo et al.151. 
 
MSC releases EVs differently depending on the external stimulation, such as 
hypoxia and inflammatory152. Tumour suppressor-activated pathway 6 (TSAP6) 
is found regulate EV formation153 and this pathway is regulated by p53 thereby 
enhancing EV production154,155. 
1.3.4.2 Microvesicles biogenesis 
Microvesicles result from outward budding and fusion of the plasma membrane. 
Membrane budding initiated by the activity of aminophospholipid translocase, 
responsible for placing phosphatidylserine to the outer membrane. ADP-
ribosylation factor 6 plays an important role in enabling MV budding156,157 and 
contractile protein myosin light chain kinase 2 in release of MVs157–159 (Figure 
1.11). 
 
1.3.5 EVs uptake 
 
1.3.5.1 Endocytosis 
It is the most evidence process of internalization because EVs are usually taken 
up into endosomal compartment via endocytosis. It was identified inside cells 
from as early as 15 minutes after initial introduction160,161. By using a range of 
inhibitor to block specific pathways and other experimental techniques such as 
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RNAinhibitor (RNAi) to knockdown certain genes the role of the endocytosis 
processes responsible for EV uptake and  they found several subtypes of 
endocytosis, such as clathrin-mediated endocytosis117,162,163, caveolin-dependent 
endocytosis162,164–167, macropinocytosis168, phagocytosis168,169 and involvement 
lipid raft170 (Figure 1.11). 
1.3.5.2 Cell surface membrane fusion 
It is via direct fusion between the EV membrane with cell plasma membrane171. 
Several proteins participate in this process including SNAREs, Rab proteins and 
Sec1/Munc-18 related proteins150,172,173. 
1.3.5.3 Cell specific EV uptake 
Results from some studies show that fluorescently labelled EVs can be taken up 
by virtually every cell type tested174,175, whereas other suggest that vesicular 
uptake is a highly specific process which can only occur if cell and EV share the 
right combination of ligand and receptor. 
 
 
Figure 1.11. Origin of EVs. It is generally via (a) endocytosis or inward budding of plasma membrane 
that consist of lipid rafts and is mediated by clathrin-dependent or caveolae-dependent pathway, This 
gives rise to (b) early endosomes leading to the formation of numerous ILVs within a membrane 
maturing to MVBs. Finally MVBs fuse with plasma membrane releasing ILVs as exosomes. (c) 
Ectosomes are vesicles shed from the cell surface and (d) apoptotic bodies are also known as 
apobodies and are released by cells undergoing apoptosis. EVs are internalized by the target cells 
through several pathways including (e) endocytosis, (f) fusion, and (g) phagocytosis. From Rani et 
al.106. 
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1.3.6 Applications in clinical use 
Recent animal model-based studies suggest that EVs have significant potential as a 
novel alternative to whole cell therapies106,176 and they were used to discovery 
biomarkers of diseases177,178. 
Compared to MSC, EVs may have a superior safety profile and can be safely stored 
without losing function106 but it is necessary to advance to clinical use of MSC-EVs 
for common human diseases because there are unresolved questions, such as 
definition, standardisation, cost-effective production, optimal dosing and, most 
importantly, safety. 
There are more studies about therapeutic effects of MSC-derived EVs in 
cardiovascular disease179, acute kidney injury135, liver disease180, lung diseases181, 
cutaneous wound healing182, Alzheimer´s disease183 and drug delivery143,184.  
 
 
1.4 miRNAs 
 
1.4.1 Definition 
miRNAs are small, noncoding RNAs, 19-24 nucleotides in length, which regulate 
gene expression post transcriptionally185. 
 
1.4.2 Biogenesis of miRNAs 
miRNA biogenesis pathway starts in the nucleus186. Firstly, they are transcribed by 
RNA polymerase II (RNA Pol II) as an approximately 70-nucleotide (nt) long stem-
loop primary structure named primary-miRNA transcripts, pri-miRNAs (long 
miRNA precursors), which are processed by DROSHA RNase III enzyme into 
precursors to generate pre-miRNAs structure185.  
Finally, the two strands of the duplex are separated from each other by the Dicer–
TRBP complex. Next, the RNA-induced silencing complex (RISC), which also 
consists of the Argonaute protein and the target mRNA, is complementary bound by 
specific miRNAs. Consequently, the target mRNAs translation is repressed resulting 
in translational silencing or induction of mRNA degradation by RNases187 (Figure 
1.12). 
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Figure 1.12. Process miRNAs biogenesis. From Jin Jung et al.188  
 
1.4.3 miRNAs in EVs 
Secretion of miRNAs in EVs is a novel form of the intercellular communication. 
However, the mechanisms governing miRNA and miRNA-binding protein secretion 
into EVs remain largely unknown. Recently, mutant KRAS shown to regulate the 
content of RNA-binding protein in EVs189,190. 
 
1.4.4 Role in biological process 
miRNAs have crucial regulatory roles in development of hematopoietic linage, 
maturation, and differentiation of B,T lymphocytes191 and MSCs192, proliferation of 
neutrophils, monocytes193,194 and MSCs195, secretion of type 1 interferon (IFN) and 
inflammatory cytokine/chemokine193, and effectiveness of immune system 
response196,194, immunosenescence 197, inflammaging198, cancer199 and other200. In 
the last years, miRs have been suggested possible therapeutic approaches for age-
related life-threatening diseases201,202. 
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Mesenchymal stem cells have self-renewal capacity and multiple differentiation 
potentials, and a priori, could play important roles in regenerative medicine but the 
promising role of MSCs in cell-based therapies and tissue engineering appears to be 
limited due to a decline of their regenerative potential with increasing donor age. For that, 
we proposed the following aims to understand whether aging affects the properties of 
MSCs: 
1. Determination of proliferation profile of rat bone marrow mesenchymal stem cells 
at different ages. 
2. Determination of pluripotency profile of rat bone marrow mesenchymal stem cells 
at different ages. 
3. Proteome and transcriptome descriptive study of rat bone marrow mesenchymal 
stem cells at different ages. 
4. Pro-inflammatory phenotype of rat bone marrow mesenchymal stem cells at 
different ages. 
5. Characterization of rat bone marrow mesenchymal stem cell-derived extracellular 
vesicles at different ages. 
6. Evaluation of relationship between miRNAs and Toll like receptor 4 pathway in 
rat bone marrow mesenchymal stem cell-derived extracellular vesicles at different 
ages. 
7. Effect of miR-21-5p on pro-inflammatory and pluripotent capabilities from Toll-
like receptor 4 in rat bone marrow mesenchymal stem cells. 
8. Influence of rat bone marrow mesenchymal stem cells-derived extracellular 
vesicles on their self-renewal using an in vitro model. 
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3.1 Isolation and culture of rBM-MSCs  
 
The animals were euthanized with Fluorane (Izasa, A Coruña, Spain) and sacrificed by 
cervical dislocation method. Femurs were dissected from male Wistar rats (Animal 
Service, Complejo Hospitalario Universitario de A Coruña, Spain) at different ages: 
newborn (0 days old), infant (7 days old), young (14 days old), pre-pubertal (35-38 days 
old), pubertal (45 days old) and adult (+2 months old). All methods were carried out in 
“accordance” with the approved guidelines of the Spanish law (32/2007). All 
experimental protocols were approved by The Animal Ethical Committee of Galicia. The 
protocol used by Karaoz et al.12 was followed in this work. Briefly, the end of the bones 
were cut away and a 21-gauge needle that was inserted into shaft of the bone marrow was 
extruded by flushing with 5 ml D-Hank´s solution supplemented with 100 IU/ml 
penicillin-100 mg/ml streptomycin (all from Life Technologies, Madrid, Spain). Marrow 
plug suspension was dispersed by pipetting, successively filtered through 70-µm mesh 
nylon filter (BD Biosciences, Bedford, United States) and centrifuged at 2000 xg for 10 
minutes. Supernatant containing thrombocytes and erythrocytes was discarded, and the 
cell pellet was re-suspended in the RPMI supplemented with 10% (v/v) fetal bovine serum 
(FBS), 1% (v/v) penicillin, 1% (v/v) streptomycin (all from Life Technologies, Madrid, 
Spain). The cells from four rats were seeded into 100 cm2 dish plate (Corning Inc., New 
York, United States) and incubated at 37ºC with humidified atmosphere 5% CO2. rBM-
MSCs were isolated on the basis of their ability to adhere to culture plates. On the third 
day, red blood cells and other non-adherent cells were removed by the pre-plating 
technique and fresh medium was added to allow further growth. The adherent cells grown 
to 70% confluence were defined passage zero (P0) cells. After 5 min of centrifugation, 
1x106 rBM-MSCs were seeded on two 100 cm2 dish plates (Corning Inc., New York, 
United States) in RPMI supplemented with 10% (v/v) FBS, 1% (v/v) penicillin and 1% 
(v/v) streptomycin (all from Life Technologies, Madrid, Spain). The culture medium was 
added and replaced every 3 or 4 days for 2 weeks. rBM-MSCs have been expanded for 2 
passages to use in the following techniques.  
 
 
3.2 Characterization of rBM-MSCs by flow cytometry 
 
To characterize the populations of rBM-MSCs from chronologically different animals, 
their rBM-MSCs were washed twice in phosphate-buffered saline (PBS) (MP 
Biomedicals, Illkrich, France), then pre-blocked with 2% (v/v) rat serum (Life 
Technologies, Madrid, Spain) in PBS (MP Biomedicals, Illkrich, France). The following 
direct antibodies were used at different dilutions and wavelenght detection windows 
(Table 8.1) to check mesenchymal and hematopoietic markers of the different 
populations of rBM-MSCs from chronologically different animals. 
2x105 cells were analyzed by FACSAria flow cytometer (BD Science, Madrid, Spain). 
FACS data was generated by DIVA software (BD Science, Madrid, Spain). 
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3.3 Proliferation analysis by flow cytometry 
 
rBM-MSCs from adult cultured with medium RPMI supplemented with 10% (v/v) FBS, 
1% (v/v) penicillin, 1% (v/v) streptomycin (all from Life Technologies, Madrid, Spain) 
with 10 nM rapamycin (Sigma-Aldrich, St.Louis, United States) for 2 days. After 
incubation with the drug, the cells were washed with PBS (MP Biomedicals, Illkrich, 
France), then fixed in 4% (w/v) (Sigma-Aldrich, St.Louis, United States) for 10 min. 
After the fixation, the cells were washed twice in phosphate-buffered saline (PBS) (MP 
Biomedicals, Illkrich, France), then pre-blocked with 2% (v/v) rat serum (Life 
Technologies, Madrid, Spain) in PBS (MP Biomedicals, Illkrich, France).  
The following direct antibodies against CD117 and Ki67 were used at different dilutions 
and wavelenght detection windows (Table 8.1) to check proliferation profile of the 
different populations of rBM-MSCs from chronological different animals. The stained 
cells were washed twice with PBS (MP Biomedicals, Illkrich, France) and 2x105 cells 
were analyzed by FACSAria flow cytometer (BD Science, Madrid, Spain). FACS data 
was generated by DIVA software (BD Science, Madrid, Spain). 
 
 
3.4 Reactive oxygen species analysis by flow cytometry 
 
Intracellular reactive oxygen species (ROS) accumulation was measured using 2´,7´-
dichlorodihydrofluorescein diacetate (H2DCF-DA) (Thermo Fisher, Waltham, United 
States). Upon oxidation by ROS, the non-fluorescent H2DCF-DA is converted to the 
highly fluorescent 2´,7´-dichlorofluorescein diacetate (HDCF-DA)203. MitoSOXTM Red 
mitochondrial superoxide indicator *for live-cell imaging* (Life Technologies, Madrid, 
Spain) was used to determine mitochondrial ROS, including superoxide dismutase 
activity204. Tetramethylrhodamine methyl ester (TMRM) (Life Technologies, Madrid, 
Spain), a permanent dye that accumulates in active mitochondria with intact potential205, 
was used to detect functional mitochondria in the rBM-MSCs at different ages following 
functional mitochondrial staining protocol from commercial.  
 
 
3.5 Cell cycle analysis 
 
Cell cycle analysis of rBM-MSCs from adult cultured with medium RPMI supplemented 
with 10% (v/v) FBS, 1% (v/v) penicillin, 1% (v/v) streptomycin (all from Life 
Technologies, Madrid, Spain) with different concentrations of imatinib mesylate (5µM 
and 10µM) or JK184 (0.1 ng/ml and 1 ng/ml) (all from Sigma-Aldrich, St.Louis, United 
States) for 2 days. After incubation with the drug, the cells were washed with PBS (MP 
Biomedicals, Illkrich, France), then fixed in 70% (v/v) ethanol (Panreac, Darmstadt, 
Germany). Posteriorly, the cells were incubated with 1 mg/ml RNase A (Sigma-Aldrich, 
St.Louis, United States) and 100 µg/ml propidium iodide (PI) (Sigma-Aldrich, St.Louis, 
United States). The cells cultured in RPMI 0% for 48 h were used such positive control 
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and the cells cultured in RPMI supplemented with 10% FBS (v/v), 1% (v/v) penicillin, 
1% (v/v) streptomycin and 1.5 mg/ml methyl-(5-[2-thienylcarboyl]-1-H-benzimidazol-2-
YL) carbamate) (Nodocazole) (all from Sigma-Aldrich, St.Louis, United States) 
overnight. 
2x105 cells were analyzed by FACSAria flow cytometer (BD Science, Madrid, Spain). 
FACS data was generated by DIVA software (BD Science, Madrid, Spain). 
 
 
3.6 Pro-inflammatory phenotype analysis  
 
3.6.1 Determination expression of CD200 by flow cytometry 
rBM-MSCs at different ages were cultured with RPMI supplemented with 10% 
(v/v) FBS, 1% (v/v) penicillin and 1% (v/v) streptomycin (all from Life 
Technologies, Madrid, Spain) and 1 ng/ml recombinant rat tumor necrosis factor-
α (rrTNFα) (Immunotools, Gladiolenweg, Germany) for 2 days. After that, cells 
were washed with Hank´s balanced salt solution (HBSS) (Life Thecnologies, 
Madrid, Spain) and they were stained with anti-CD200 (Table 8.1). The stained 
cells were washed twice with PBS (MP Biomedicals, Illkrich, France) and 2x105 
cells were analyzed by FACSAria flow cytometer (BD Science, Madrid, Spain). 
FACS data was generated by DIVA software (BD Science, Madrid, Spain). 
 
3.6.2  Activation TLR4 in rBM-MSCs 
rBM-MSCs at different ages were cultured with RPMI supplemented with 10% 
(v/v) FBS, 1% (v/v) penicillin and 1% (v/v) streptomycin (all from Life 
Technologies, Madrid, Spain) and 10 ng/ml lipopolysaccharides (LPS) (Sigma-
Aldrich, St. Louis, United States) for 4 hours. 
 
 
3.7 Characterization MSC-derived EVs by flow cytometry 
 
MSC-derived EVs were stained with 10µM 3-3-Diethylthiadicarbocyanineiodide (DiI) 
(all from Sigma-Aldrich, St.Louis, United States). MSC-EVs were incubated using anti-
CD63 Dynabeads (Thermo Fisher, Waltham, United States) overnight at 4ºC and they 
were detected by FACs (Becton Dickinson, Mountain View, United States). MSC-
derived EVs with dynabeads were washed twice with PBS (MP Biomedicals, Illkrich, 
France) and 2x105 cells were analyzed by flow cytometry. Anti-CD63 Dynabeads 
(Thermo Fisher, Waltham, United States) alone were used as negative control. 
 
 
3.8 Proliferation assay 
 
Different numbers of cells (0, 1000, 2000, 4000, 8000 and 16000 cells), were plated for 
triplicate at 96-well plates (Corning Inc., New York, United States) and allowed to adhere 
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for 8 h to calculate the proliferation curve. The number of cells was calculated using 
CellTiter 96® Aqueous Non-Radiactive Cell Proliferation Assay (Promega, Madison, 
United States) following manufacturer´s instructions. 4000 cells were plated for each cell 
line in triplicate at 96-well plates (Corning Inc., New York, United States), and the total 
number of cells was calculated at different points (0, 1, 2, 5 and 6 days).  
 
 
3.9 Cytotoxicity assay 
 
Cell Counting Kit-8 (Dojindo Molecular Technologies, Rockville, United States) was 
used to check cytotoxicity in our cell cultures when they were supplemented with imatinib 
mesylate or JK184. Briefly 5000 cells/well were cultured with RPMI supplemented with 
10% (v/v) FBS, 1% (v/v) penicillin, 1% (v/v) streptomycin (all from Life Technologies, 
Madrid, Spain) and imatinib mesylate (5µM and 10µM) or JK184 (0.1 ng/ml and 1 ng/ml) 
(all from Sigma-Aldrich, St. Louis, United States) at 96-well plate (Corning Inc., New 
York, United States) at 37ºC, 5% CO2 for 2 days. After the incubation with 10 µl of CCK-
8 solution in each well for 2 h, the absorbance was measured at 450 nm using a SUNRISE 
spectrophotometer (TECAN, Mannedorf, Switzerland). It was used as negative control 
cells cultured with RPMI supplemented with 10% (v/v) FBS, 1% (v/v) penicillin, 1% 
(v/v) streptomycin (all from Life Technologies, Madrid, Spain) for 2 days. 
 
 
3.10 Biological characterization  
 
rBM-MSCs from different ages were cultured with RPMI supplemented with 10% (v/v) 
FBS, 1% (v/v) penicillin, 1% (v/v) streptomycin (all from Life Technologies, Madrid, 
Spain) in cell culture chambers (Millipore, Billeica,  United States) until reaching 80% 
confluency. 
 
3.10.1 Adipogenic differentiation 
Cells at 80% confluency were incubated with RPMI supplemented with 1 µM 
dexamethasone, 10 µg/ml insulin, 0.5 mM of 3-isobutyl-1-methylxantine (all from 
Sigma-Aldrich, St. Louis, United States). After 2 days, cells were incubated with 
RPMI supplemented with 10% (v/v) FBS (all from Life Technologies, Madrid, 
Spain) and 5 µg/ml insulin (Sigma-Aldrich, St.Louis, United States). This medium 
was replaced every 3 days for 14 days. 
 
3.10.2 Chondrogenic differentiation 
rBM-MSCs from different ages were cultured with RPMI supplemented with 15% 
(v/v) knockout (KO) serum, 1% (v/v) penicillin, 1% (v/v) streptomycin (all from 
Life Technologies, Madrid, Spain), 10 µl/ml ascorbic acid (Sigma-Aldrich, 
St.Louis, United States), 10µM dexasomehasone (Sigma-Aldrich, St.Louis, 
United States), 1 ng/ml recombinant human transforming growth factor-beta 3 
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(rhTGF-β3) (ProsSpec-Tany TechnoGene Ltd., Ness Ziona, Israel), 10-7 M 
retinoic acid (Sigma-Aldrich, St.Louis, United States), 6 µl/ml transferrine 
(Sigma-Aldrich, St.Louis, United States) in chambers (Millipore, Billeica, United 
States) for 14 days. The medium was replaced every 3 days. 
 
3.10.3 Osteogenic differentiation 
rBM-MSCs from different ages were cultured in chamber (Millipore, Billeica, 
United States) with osteogenic commercial medium (Lonza, A Coruña, Spain) for 
14 days. The medium was replaced every 3 days. 
 
 
3.11 Histochemical analysis  
 
All the cell cultures were fixed with 4 % (w/v) paraformaldehyde (Sigma-Aldrich, 
St.Louis, United States) for 10 min. After the fixation, cells were washed with PBS (MP 
Biomedicals, Illkrich, France) and they were incubated with 60% (w/w) isopropyl alcohol 
(PANREAC, Barcelona, Spain).  
Adipogenic cultures were stained with 0.5% (w/v) oil red O (Sigma-Aldrich, St.Louise, 
United States) solution for 20 min to check lipid drops formation in cells differentiated 
towards adipocyte-like cells. After that, cells were washed with 1% (v/v) isopropyl 
alcohol (PANREAC, Barcelona, Spain) and distilled water (LABESFAL, Santiago de 
Besteiros, Portugal). 
After the fixation, osteogenic cultures were washed with PBS (MP Biomedicals, Illkrich, 
France). After they were stained with 2% (v/v) alizarin red aqueous solution at pH 4.2 
(Sigma-Aldrich, St.Louise, United States) to check alkaline deposits in cell differentiated 
towards osteocyte-like cells. Then the slides were air dried and mounted with glicerol 
mounting medium (Dako, Glostrup, Denmark). 
Chondrogenic cultures were fixed with 4% (w/v) paraformaldehyde (Sigma-Aldrich, 
St.Louise, United States) for 10 min. Then cells were washed with PBS (MP Biomedicals, 
Illkrich, France) and they were stained with safranin O (Sigma-Aldrich, St.Louise, United 
States) for 30 min to evaluate the distribution of proteoglycan in the extracellular matrix 
generated by cells differentiated towards chondrocyte-like cells.  
Also chondrogenic cultures were washed with PBS (MP Biomedicals, Illkrich, France) at 
pH 7.4. Then they were incubated with 5% (w/v) ferric ammonium sulfate (MERCK, 
Darmstadt, Germany) for 30 min. After, they were washed twice with distilled water 
(LABESFAL, Santiago de Besteiros, Portugal). Cells were incubated with weirgert´s 
hematoxylin (1% (w/v) ferric hematoxylin (Sigma-Aldrich, St.Louis, United States) in 
absolute alcohol (PANREAC, Barcelona, Spain) for 10 min. Later, they were washed 
twice with distilled water (LABESFAL, Santiago de Besteiros, Portugal) and the cells 
were incubated with picric acid satured in ethanol at 96% (v/v) (all from Sigma-Aldrich, 
St. Louis, United States) for 6 min and then they were washed five times with distilled 
water (LABESFAL, Santiago de Besteiros, Portugal). The cells were stained with 
Ponceau-fuchsin (Masson) (MERCK, Darmstadt, Germany) for 8 min. After, cells were 
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washed twice with 1% (w/v) phosphomolybdic acid (MERCK, Darmstadt, Germany) and 
they were incubated with aniline blue (MERCK, Darmstadt, Germany).  
Finally, the cells were washed twice with distilled water (LABESFAL, Santiago de 
Besteiros, Portugal) and the slides were mounted with glicerol mounting medium (Dako, 
Glostrup, Denmark). 
 
 
3.12 Densitometry analysis 
 
AnalySIS Image Processing (Soft Imaging system GmbH V.5.0, Olympus, Münster, 
Germany) was used to perform a densitometry quantification of the staining obtained by 
histochemistry analysis. Three 200 mm2 fields in size from each staining: safranine O; oil 
red; modified Masson´s and alizarin red were quantized using arbitrary units provided by 
the computer program. Values were expressed as percentage of positive stain for each 
tintion. All values were referenced with respect to values obtained from cells cultured 
with the control medium (RPMI supplemented with 5% (v/v) KO serum, 1% (v/v) 
penicillin and 1% (v/v) streptomycin (all from Life Technologies, Madrid, Spain).  
 
 
3.13 Total RNA and miRNAs isolation 
 
Total RNA, including miRNAs and other RNAs, were isolated using TRIzol® Reagent 
(Invitrogen, Carlsbad, United States) according to manufacturer´s instructions. 
 
 
3.14 Determination of RNA integrity 
 
The quality of 1 µl of each RNA sample from rBM-MSCs at different ages was assessed 
using Agilent Bioanalyzer 2100 (Agilent, St.Clara, United States) to determine the RNA 
integrity score  (RIN) with the Nanochip Agilent 6000 (Agilent, St.Clara, United States) 
according to manufacturer´s instructions. Samples with a RIN score > 7 were retained 
and converted to cDNA by SureSelect Strand Specific RNA library (Agilent, St.Clara, 
United States). 
 
 
3.15 Real time quantitative polymerase chain reaction (qRT-
PCR) analysis 
 
RNA was transformed to complementary DNA (cDNA) using NZY First-Strand cDNA 
synthesis kit (NZYTECH, Lisboa, Portugal) according to manufacturer´s instructions. 
cDNA was amplified using specific primers for different rat genes (Table 8.3). The 
design of primers was carried out using the software Primer3: WWW primer tool 
(http://biotools.umassmed.edu/bioapps/primer3).  
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qRT-PCR was carried out using LightCycler 480 Instrument Roche Applied Science 
using Light Cycler 4800 SYBR Green I Master kit (Roche, Basilea, Switzerland). The 
amplification program consisted on initial denaturation of 92ºC for 2 min followed by 40 
cycles at 92ºC for 15 s, annealing at 55-62ºC, depending on the gene, for 30 s and 
extension at 72ºC for 15 s. qRT-PCR were done in triplicate, with each set of assays 
repeated three times. For control experiments no reverse transcriptase was used. 
 
 
3.16 miRNAs analysis 
 
cDNA was generated with QuantiMir RT Kit (System Biosciences, Palo Alto, United 
States) according to the manufacturer’s instructions. The Product from retrotranscription 
reaction was amplified using specific primers for miRNAs (Table 8.4) and the universal 
QuantiMir reverse primer (System Biosciences, Palo Alto, United States). The 
amplification program consisted on initial denaturation at 50°C for 2 min followed by a 
cycle at 95°C for 10 min and 50 cycles of annealing at 95°C for 15 s and extension at 
60°C for 1 min. qRT-PCR analyses were done in triplicate, with each set of assays 
repeated three times. Also, for miRNA detection, cDNA of hsa-miR-21-5p was generated 
using 10 ng of total RNA using TaqMan-sepecific retrotranscription primers and TaqMan 
microRNA reverse transcription kit (Applied Biosystems, California, United States) 
according to manufacturer´s instructions. Thereafter, qRT-PCR was performed using 
predesigned assays for hsa-miR-21-5p and RNU6 (Applied Biosystems, California, 
United States). qRT-PCR reactions were carried out as follows: 50ºC for 2 min, 95ºC for 
10 min, followed by 40 cycles at 95ºC for 15 s and 60ºC for 1 min.  
To minimize the effects of unequal quantities of starting RNA and to eliminate potential 
sources of inconsistency, relative expression levels of each gene was normalized to 
hypoxanthine guanine phosphoribosyl transferase (HPRT), miR-16 or RNU6 using the 2-
ΔΔ Ct method206. For control experiments no reverse transcriptase was used. 
 
 
3.17 Protein extraction and preparation procedures 
 
Cell monolayers were grown until a 70% confluency at 6-wells culture plates (Corning, 
New York, United States). They were washed three times with PBS (MP Biomedicals, 
Illkrich, France) and harvested using a scraper with sodium dodecyl sulphate (SDS) lysis 
buffer (20% (v/v) glycerol, 500 mM Tris-HCl, pH 6.8 , 10% (w/v) SDS and 10% protease 
inhibitor cocktail (all from Sigma-Aldrich, St.Louis, United States). These samples were 
incubated at 100ºC for 10 min followed by two consecutive cycles of vortexing and 
sonication. After that, samples were centrifuged at 4 ºC for 10 min at 11000 xg. Proteins 
were quantified (total protein A280) using a NanodropTM 1000 instrument (Thermo 
Scientific, Waltham, United States). Protein extracts were aliquoted and stored at -80ºC 
until further analysis. 
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3.18 Silver-staining of proteins in polyacrylamide gels 
 
To check the protein integrity and to correct putative differences in proteins 
quantification, proteins were separated according to their molecular weight using SDS 
PolyAcrylamide Gel Electrophoresis (SDS-PAGE), 10% (w/v) bis-acrylamide (Sigma-
Aldrich, St.Louis, United States). 2 µg of total protein from rBM-MSCs from different 
ages were loaded into a SDS-PAGE gels. Previous, samples were treated with 1% (v/v) 
loading buffer after incubation at 100ºC for 10 min. Gels were run at 80-120 V for 120 
min in electrophoresis units (Bio-Rad, California, United States). Gels were fixed for 30 
min. And washed twice with distilled water (Grifolds, Barcelona, Spain) for 10 min. Gels 
were sensed with sensitizer buffer for 1 min followed by two washes with distilled water 
(Grifolds, Barcelona, Spain), 1 min each one. Then, they were incubated for 1 hour with 
a silver stain followed by one rinse using distilled water (Grifolds, Barcelona, Spain). The 
silver stain was revealed with a revealling buffer for 5 minutes and the reaction was 
stopped using stop buffer (All reagents were described in Table 8.5)207. Densitometry 
analysis of the band intensities was performed using ImageQuant 5.2 software (GE 
Healthcare, Little Chalfont, United Kingdom). 
 
3.19 iTRAQ®-8plex labelling. Amine-Modifying Labelling 
Reagents for Multiplexed Relative and Absolute Protein 
Quantification 
 
Firstly, 100 µg proteins from rBM-MSCs at different ages were precipitated using acetone 
according to manufacturer´s instructions (PIERCE, Rockford, United States). Then, 
proteins were denatured with 2% (v/v) SDS in 1 M tryethylammonium bicarbonate 
(TEAB) (AB Sciex, Foster City, United States).Then samples were reduced for 1 h at 
60ºC using 50 mM tris-(2-carboxyethy) phosphine (TCEP) (AB Sciex, Foster City, 
United States) and cysteine-blocked with 84 mM iodoacetamide (all from Sigma-Aldrich, 
St.Louis, United States) at room temperature in dark for 30 min. Proteins were digested 
with spectrometry grade trypsin Gold Mass (Promega, Madison, United States) at a 
concentration of 1:50 trypsin/protein for 16 h at 37ºC. Each peptide solution was labelled 
for 1.5 h at room temperature using iTRAQ® reagent (AB Sciex, Foster City, United 
States) as follows: newborn: 119 and 121 as a control; infant: 114; young: 116; pre-
pubertal: 118; pubertal: 115 and adult: 117. The reaction was stopped by adding deionized 
water (Grifols, Barcelona, Spain) and labelled samples were combined. The mixture was 
desalted using home-made stage-tips208 (Figure 3.1). 
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Figure 3.1. Workflow of iTRAQ-8plex. 
 
 
3.20 Relative quantification by two dimensional-liquid 
chromatography coupled offline to matrix-associated laser 
desorption ionization-time of flight (2D-LC-MALDI-
TOF/TOF) analysis 
 
In a first step, the desalted peptides were fractionated by basic reverse phase extraction at 
1400 High-performer liquid chromatography (HPLC) system (Agilent, St.Clara, United 
States). The extraction was done in a nanoHPLC system (Tempo, AB Sciex, Framingham, 
United States) into a C18 silica-based column (New Objective, Woburn, United States) 
with an internal diameter of 300 Â. The injection volume was 5 µl, and peptides were 
eluted during a 90 min-gradient with a constant flow rate of 0.35 µl/min. Eluting peptides 
were automatically mixed with 4 mg/ml α-ciano in 70% (v/v) acetonitrile (AcN) (Sigma-
Aldrich, St.Louis, United States), 0.1% trifluoroacetic acid (TFA) (LabScan, Bangkok, 
Thailand) and deposited on a MALDI LC-plate using SunCollect MALDI spotter 
(SunChrom, Friedrichsdorf, Germany). The chromatograms, composed by 350 spots, 
each one comprising a 15 s deposition, were analyzed in a 4800 MALDI-TOF/TOF 
platform (AB Sciex, Framingham, United States). 4000 series Explorer v.4.2 software 
was used to generate the spectra and peak list. After manual deposition of mass calibrate, 
plate model and default calibration of the MALDI plate were done with a laser voltage of 
34000 kV and 1500 shots/spectrum. Automated precursor selection was done using a Job-
wide interpretation method (up to 12 precursors/fraction, Signal to Noise loxer threshold= 
50) excluding trypsin autolytic peptides and other background ions, with a laser voltage 
of 4200 and 2000 shots/spectrum. Collision-induced dissociation (CID) energy range: 
medium. LC-MALDI-TOF/TOF data were analyzed using ProteinPilot 4.0 software (AB 
Sciex, Framingham, United States). Protein Pilot Search parameters were as follows: 
sample type: iTRAQ 8-plex; cys-alkylation: iodoacetamide; digestion: trypsin; 
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identification (ID) focus: biological modifications; database: last SwissProt release 
2013_12 of 11-Dec-2013 of UniprotkB/TreEMBL contains 48701576 sequence entries, 
comprinsing 15448487119 amino acids; species filtering: none; Search effort: Thorough 
ID and detection protein threshold unused ProtScore (Conf) > 1.3 (95.0%). Scoring model 
was defined using the Paragon algorithm. In the case of the high complexity samples, 
False Discovery Rate-FDR- was estimated in less than 1% by doing the searching in 
parallel against a decoy database using “PSPEP on” mode. 
 
 
3.21 Immunoblot analysis 
  
Immunoblot analysis was performed with 40 µg of total protein extracted from rBM-
MSCs. Firstly, proteins were separated according to their molecular weight using SDS-
PAGE, the percentage (w/v) bis-acrylamide (Sigma-Aldrich, St.Louis, United States) of 
resolving gels were determined by the size of protein. The transference was performed as 
a semi-dry transfer way using transfer buffer with 20% (v/v) methanol (Panreac, 
Barcelona, Spain) for small proteins (<100 kDa) or 10% (v/v) methanol (Panreac, 
Barcelona, Spain) for large ones (>100 kDa). After that, the membrane of nitrocellulose 
was blocked using blocking buffer consisting of 5% (w/v) bovine serum albumin (BSA) 
for phospho-proteins and 5% (w/v) milk (all from Sigma-Aldrich, St.Louis, United 
States). The incubation was performed for other proteins, for 1 h in agitation at room 
temperature. Membranes were probed with antibodies diluted in blocking buffer at 4ºC 
overnight. The following day, membranes were washed three times for 5 min with 
standard buffer tris buffered saline with 0.1% (v/v) Tween® 20 (TBST). Then, HRP-
conjugated secondary antibodies diluted in blocking buffer were incubated for 1 h at room 
temperature. Next, membranes were washed three times in standard buffer TBST for 5 
min with agitation and twice using tris buffered saline (TBS) for 5 min in agitation. 
AmershamTM ECLTM Western Blotting Analysis System (GE Healhcare, Little Chalfont, 
United Kingdom) was used to visualize proteins. Adequate concentration for each 
antibody was determined empirically. Blots were digitized using the LAS 3000 image 
analyser (GE Healthcare, Little Chalfont, United Kingdom). Densitometry analysis of the 
band intensities was performed using ImageQuant 5.2 software (GE Healthcare, Little 
Chalfont, United Kingdom). (All reagents were described in Table 7.2).  
 
 
3.22 Enzymatic analysis  
 
5x105 cells from each group of different age were used for the assessment of enzyme 
activities. Cells were homogenized with buffer lysis (250 mM sucrose, 50 mM HEPES, 
0.5 mM ethylenediaminetetraacetic acid (EDTA) (all from Sigma-Aldrich, St.Louis, 
United States) and one tablet cOmpleteTM protease inhibitor cocktail (Roche, Mannheim, 
Germany)). Enzymes activities were determined using a SUNRISE spectrophotometer 
(TECAN, Mannedorf, Switzerland). Reactions rates were determined by the increase or 
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decrease in absorbance of NAD(P)H (Sigma-Aldrich, St.Louis, United States) at 340 nm 
at 37ºC. 
Lactate dehydrogenase (LDH) (EC 1.1.1.27) was determined in rBM-MSCs using 50 mM 
Trizma base at pH 7.4, 0.15 mM NADH and 5 mM sodium pyruvate (omitted for control) 
(all from Sigma-Aldrich, St.Louis, United States). Glucose-6-phosphate-1-
dehydrogenase (G6PDH) (EC 1.1.1.49) and 6-phosphogluconate dehydrogenase, 
decarboxylating (6PGDH) (EC 1.1.1.343) was determined in rBM-MSCs using 78 mM 
Trizma base, 5 mM MgCl2 at pH 7.4, 0.1 mM NADP, 0.5 mM D-Glucose-6-phosphate 
disodium salt hydrate and 6-phosphogluconic acid trisodium salt (omitted for control) (all 
Sigma-Aldrich, St.Louis, United States). 
 
 
3.23 Next Generation Sequencing (NGS) using RNA sequencing 
technique 
 
The study was designed to screen the complete transcriptome per age group of Wistar 
rats, covering coding, intronic and splicing regions of complete genes from Wistar rat. 
Sample preparation was carried out as recommended by Agilent SureSelect Strand-
Specific RNA Library Prep (Agilent, St.Clara, United States) for Illumina multiplex 
sequencing method209. 1 µg of total RNA per sample was used. Fragmented DNA was 
end-repaired and the sequencing data was generated on Hiseq 1500 (Illumina, San Diego, 
United States) on a rapid mode flowcell (Illumina, San Diego, United States). All samples 
were sequencing twice (Figure 3.2) and they were prepared in duplicate. 
 
Figure 3.2. Workflow of RNA-sequencing. 
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3.24 Isolation rBM-MSC-derived EVs 
 
rBM-MSCs from newborn (0 days), young (14 days), pre-pubertal (35-38 days) and adult 
(+2 months) were cultured with RPMI 1640 Medium with GlutaMAXTM supplement and 
10% FBS-free exosomes (all from Thermo Fisher Scientific, Massachusetts, United 
States), 100 IU/ml penicillin-100 mg/ml streptomycin (all from Life Technologies, 
Madrid, Spain). Firstly, cells were cultured until 80% confluence and supernatants were 
collected each 48 h. Supernatants were centrifuged at 252 xg for 10 min at 4ºC and filtered 
using 0.22 µm sterilized filter (GE Healthcare Life Sciences, Little Chalfont, United 
Kingdom) to eliminate debris. Supernatants were transferred into ultracentrifugation 
tubes (Beckman Coulter, Mississauga, Canada) and they were ultra-centrifuged at 100000 
xg for 2 h at 4ºC in an Optimal-90K ultracentrifuge with 60 Ti rotor (Beckman Coulter, 
Mississauga, Canada). Supernatant containing exosomes-free media were removed and 
the pellets were re-suspended in 200 µl PBS (MP Biomedicals, Illkrich, France). 
 
 
3.25 Quantification of protein in rBM-MSC-derived EVs 
 
Proteins from rBM-MSC-derived EVs content were measured with a Micro-BCA kit 
(Thermo Scientific, Rockford, United States) according to manufacturer´s instructions. 
 
 
3.26 Characterization of rBM-MSC-derived EVs by size 
 
3.26.1 Nanoparticle Tracking Analysis (NTA) 
MSC-derived EVs size distribution was estimated by the Brownian motion of the 
particles in NanoSight LM12 using Nanoparticle Tracking Analysis 2.3 software 
(Nanosight Ltd, Amesbury, United Kingdom). MSC-derived EVs were diluted in 
PBS (MP Biomedicals, Illkrich, France), until a suitable concentration for analysis 
was reached. Particle concentration was evaluated for the particles between 30–
150 nm in diameter. 
 
3.26.2 Electron microscopy 
MSC-derived EVs were concentrated using Vivaspin concentrators (Sartorius, 
Gottingen, Germany). MSC-derived EVs were taken up in small volumes of 
deionized water, which were placed on nickel grids and allowed to dry for 45 min 
at 37ºC. The grids with MSC-derived EVs were fixed with 4% (w/v) 
paraformaldehyde (Sigma-Aldrich, St.Louis, United States) for 10 min and then 
washed by transferring them onto several drops of deionized water (Grisfold, 
Barcelona, Spain). Excess fluid was removed and the grids were allowed to dry 
before examination on a JEOL JEM1400 Transmission Electron Microscope 
(JEOL Ltd, Tokyo, Japan). 
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3.27 miRNA transitory transfections 
 
rBM-MSCs from pre-pubertal group with 80 % of confluence were incubated with 40 nM 
hsa-miR-21-5p miRVanaTM miRNA inhibitor or 40 nM control negative miRVanaTM (all 
from Applied Biosystem, Madrid, Spain) following manufacturer´s instructions. 
 
 
3.28 In vitro Model using rBM-MSC-derived EVs 
 
2.5x105 rBM-MSCs from old individuals were cultured at 6 well-plate (Corning Inc, New 
York, United States) for 8 hours and 2x107 MSC-derived EVs from young individuals 
were added to these well-plate and vice versa. At different times (2, 3 and 6 days) were 
collected the cells and RNA and protein isolations from the cells were performed.  
 
 
3.29 Fluorescence microscopy 
 
2.5x105 rBM-MSCs from old individuals were cultured in slides (Sigma-Aldrich, 
St.Louis, United States) which were pre-treated with poli-D-lysine (Sigma-Aldrich, 
St.Louis, United States) at 6-well-plate (Corning Inc, New York, United States) for 8 h ( 
this time was named 1 day). 2x107 MSC-derived EVs from young individuals were 
marked with 10 µM DiI (3-3´-diethylthiacarbocyanineiodide) which was added in each 
well and vice versa and it was added PBS (MP Biomedicals, Illkrich, France) in control. 
At different times (2, 3 and 6 days), the cells were washed three times with PBS (MP 
Biomedicals, Illkrich, France) and fixed with 4% (w/v) paraformaldehyde (Sigma-
Aldrich, St.Louis, United States) for 10 min and slides were mounted using ProLong® 
Gold Antifade Mountant with DAPI (4´,6-diamidino-2-phenylindole) (Thermo Fisher 
Scientific, California, United States). Slides were observed with microscopy Olympus 
BX61 using digital chamber DP71 (Olympus, Tokyo, Japan) with software DP Controller 
and DP Manager.  
 
 
3.30 Bioinformatics analysis 
 
Biological functional analysis of different modulated proteins detected by iTRAQ 
quantification, were categorized according to their function, biological process and 
cellular component using the database of  functional protein association networks String 
9.0210 (string-db.org). Proteins with statistically significant changes were identified by 
filtering according to these criteria: 1) they had to be present in two biological replicates; 
2) changes between groups had to be statistically significant (P<0.05); and 3) fold change 
had to be greater than 1.2 and lower than 0.8 (Figure 8.1). This approach selected 201 
differentially expressed proteins for further analysis. 
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The identification of markers from extracellular vesicles in proteomic analysis was done 
using EVs databases: Vesiclepedia (www.microvesicles.org/)108, EVpedia 
(www.evpedia.info)109 and ExoCarta (www.exocarta.org)110. 
An average of 25 million paired-end 100 bases pairs (bp) reads was obtained per sample 
in transcriptome analysis. The raw RNA-sequencing reads for each sample were aligned 
to the reference rat genome browser (rn6assembly) using Bowtie2 (bowtie-
bio.sourceforge.net/index.shtml/) and Tophat2 (http://tophat.cbcb.umd.edu/). After 
alignment, raw sequence read depths was converted to estimate transcript abundance 
measures as fragments per kilo base of exons per million (FPKM) values cufflinks 
(http://cufflinks.cbcb.umd.edu/) differentially expressed genes and transcripts were 
calculate with Cuttdiff and fold change had to be greater than 1.23 and lower than 0.78. 
Each group was compared with previous age group. Identified genes with statistically 
significant changes (P<0.05) were categorized according to their function, biological 
process and cellular component using the R/Bioconductor package RamiGO 
(http://bioconductor.org/packages/release/bioc/html/RamiGO.html)211. 
MicroRNA.org (http://www.microrna.org) was a resource of microRNA target 
predictions and expression profiles used in this work. Target predictions were based on a 
development of the miRanda algorithm212 and TargetScan213. 
 
 
3.31 Statistics analysis 
 
All experiments were performed in triplicate and one representative is shown. Non-
parametric statistical analyses were performed by Mann-Whitney-U and Kruskal-Wallis 
tests using GraphPad Prism6 (GraphPad Software, La Jolla, United States). Each group 
was compared with previous age group. A P-value less than 0.05 or 0.01 was considered 
statistically significant. All the results were presented as standard error of the mean. 
iTRAQ and RNA-sequencing were performed in duplicated. Proteomic results were 
normalized with ProteinPilot software 4.5 based on ParagonTM Algorthim 4.5.0. 
Differentially expressed genes and transcripts from RNA-seq were calculated with 
Cuttdiff analysis using CummeRbund software 
(http://compbio.mit.edu/cummerbund/). 
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4.1 Characterization of rBM-MSCs 
Characterization of rBM-MSCs at different ages by flow cytometry revealed that no 
statistical differences exist between groups in respect to the levels of mesenchymal and 
hematopoietic markers used. CD34 and CD45 positive cells were less than 1% and CD29 
positive cells were 30±5% and CD90 positive cells  were 75±5% in all groups studied 
(Figure 4.1). 
 
Figure 4.1. Characterization by flow cytometry. Percentage of cells positives for MSCs markers (CD29 
and CD90) and for hematopoietic markers (CD34 and CD45). One representative experiment is shown. 
 
4.2 Study of proliferation of rBM-MSCs at different ages 
Flow cytometry assays to detect CD117 and Ki67 positive cells indicated that MSCs from 
pubertal and young groups had the statistical significant (P<0.05) higher CD117 positive 
cells of MSCs (74.6±0.07 and 71.9±3.10 respectively) when compared with to other 
groups studied, newborn: 61.5±0.37; adult: 61.1±6.35; infant: 60.5±1.58 and pre-pubertal: 
35.2±2.14. On the other hand, pre-pubertal and infant groups had the statistical significant 
(P<0.05) lower Ki67 positive cells percentage (14.65±0.41 and 15.63±0.24 respectively) 
than the rest of the groups studied, newborn: 18.0±0.55; young: 19.3±0.43; pubertal: 
22.9±0.40; adult: 29.0±0.16 (Figure 4.2A). 
Proliferation assays results indicated that MSCs from young (21.0x103±200), newborn 
(17.0x103±100), adult (16.0x103±100) and pubertal (15.0x103±300) groups had a 
statistically significant higher (P<0.05) proliferation capacity compared to pre-pubertal 
(10.0x103±500) and infant (9.00x103±500) groups (Figure 4.2B). 
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Figure 4.2. Proliferation profile from rBM-MSCs at different age. (A) Proliferation assay of studied age 
groups for 6 days. (B) Percentage of proliferation markers (CD117 and Ki67), from studied groups by flow 
cytometry. One representative experiment is shown. #P<0.05 compared with previous age group and 
*P<0.01 compared with previous age group, were considered statistically significant using Mann-Withney-U 
and Kruskal-Wallis tests. 
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4.3 Evaluation of biological capacity of rBM-MSCs at different 
ages 
Differentiation capacity of the groups studied was tested through direct mesoderm 
induction using specific culture medium. It was observed that pre-pubertal group 
presented statistically significant (P<0.05) highest stain for safranine O, modified 
Masson´s and oil red by histochemistry analysis followed by pubertal with respect to other 
groups. Infant group presented the highest staining, statistically significant (P<0.05) for 
alizarin red with respect to other groups and the adult group presented the lowest 
statistically significant (P<0.05) differentiation potential with respect to other groups 
(Figure 4.3).  
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Figure 4.3. Evaluation of the biological capacity of rBM-MSCs at different ages. (A) Representative 
images of rBM-MSCs of studied age groups after 14 days with specific differentiation medium. Specific 
medium is indicated on the top; OS= osteogenic medium; AD= adipogenic medium; CH= chondrogenic 
medium. Stain is indicated at the bottom; Ar= alizarin red; Or= oil red; Saf.O= safranine O and MM= Modified 
Masson´s stain. Straight size is 200 µM. (B) Densitometry study of rBM-MSCs at different ages after 14 days 
with specific differentiation medium after histochemical techniques. AnalySIS Image Processing computer 
was used to quantify the signal of different stain obtained. One representative experiment is shown. #P<0.05 
compared with previous age group and *P<0.01 compared with previous age group, were considered 
statistically significant using Mann-Withney-U and Kruskal-Wallis tests. 
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4.4 Evaluation of pluripotency markers in rBM-MSCs at 
different ages 
Nanog, Oct4, Rex1 and Sox2 gene expression were tested by qRT-PCR analysis to check 
the pluripotency potential of the studied groups. The results show the statistically 
significant (P<0.05) highest expression of Nanog in the young group when compared to 
other groups. In contrast, Nanog decreased in a statistically significant (P<0.05) way in 
the pre-pubertal group in respect to the other groups (Figure 4.4). 
 
 
Figure 4.4. Pluripotency profile from rBM-MSCs at different ages. Histogram represents gene 
expression of pluripotency markers, Rex1, Nanog, Sox2 and Oct4. Real-time reverse transcriptase PCR 
(qRT-PCR) analysis normalized by expression of HPRT gene used as housekeeping. One representative 
experiment is shown. #P<0.05 compared with previous age group was considered statistically significant 
using Mann-Withney-U and Kruskal-Wallis tests. A.U= arbitrary units. 
 
 
4.5 Analysis of proteome in rBM-MSCs at different ages 
All proteins from BM-MSCs of rat Wistar at different ages studied were compared among 
them. In summary, each group was composed of a pool from 6 animals and 2 different 
iTRAQ experiments were performed. To generate the quantitative proteome using 
iTRAQ labelling, first the labelling was determined efficiency, which exceeded 99%. 
Next, the cut-off for significant fold-change was determined based on biological 
replicates of two iTRAQ experiments which were chosen based on the following criteria: 
containing more than 3 unique peptides (>95%) and P value <0.05 for the 114/119 
reporters ions. Accordingly, 90% of the commonly observed proteins in the biological 
replicates fell within 25% of the respective experimental variation (Figure 4.5). The fold-
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change thresholds of >1.20 or <0.80 was set to identify true differences among expression 
of reporter ions. 
 
Figure 4.5. Statistic analysis of iTRAQ-8plex. 
 
The results obtained in the iTRAQ analysis indicated that 1072 proteins were identified, 
201 of them statistically significant modulated among groups (Figure 4.6A and Table 
8.6). These proteins have been grouped by three biological processes attending String 9.0 
software; those groups were proliferation (60 proteins), pluripotency (86 protein) and 
energy metabolism (55 proteins) (Figure 4.6B and Table 8.6). Significant activated 
pathways obtained by comparing modulated proteins detected by iTRAQ analysis 
employing functional annotations according to the String 9.0 software and classified in 
three biological process for better comprehension were shown in Figure 4.6B.  
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Figure 4.6. iTRAQ of modulated proteins in rBM-MSCs. (A) Summary of protein identification and relative 
quantification. (B) Significantly modulated biological processes after String 9.0 analysis of the modulated 
proteins. GO=gene ontology. 
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Several proteins found in our analysis associated with proliferation were 60S ribosomal 
proteins with different sedimentation speed such as, 60S RP L4,60S RP L6, 60S RP 
L7,60S RP L9,60S RP L10, 60S RP L23 and 60S RP L24; also vinculin which gene 
expression was validated using qRT-PCR analysis (Figure 4.7B), all of them were 
statistically significant (P<0.05) higher in newborn and adult groups when compared to 
the other groups. Superoxide dismutase-2 (SOD-2) and Lamin A were increased with 
increasing age similar as it occurred in iTRAQ analysis; all of them were validated by 
western blot (Figure 4.7A). Proteins found in our iTRAQ analysis were associated with 
proliferation like histones H1.5; H2B and H4 also protein disulfide-isomerase A1 
(PDIA1) which were statistically significant (P<0.05) high regulated in infant and 
pubertal group with respect to other groups (Table 8.6).  
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Figure 4.7. Validation iTRAQ analysis. (A) Western-blot analysis of Lamin A/C, vimentin and SOD-2 and 
densitometry analysis of Lamin A/C, vimentin and SOD-2 normalized by tubulin as housekeeping. The 
molecular weight of each protein is shown in the left. At the bottom the the group´s source of rBM-MSCs 
used. (B) Vinculin gene expression using qRT-PCR analysis normalized by expression of HPRT gene used 
as housekeeping. One representative experiment is shown. #P<0.05 compared with previous age group and 
*P<0.01 compared with previous age group, were considered statistically significant using Mann-Withney-U 
and Kruskal-Wallis tests. 
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4.6 Mitochondrial function in rBM-MSCs in different age 
groups  
MitoSOXTM and total ROS were analyzed by flow cytometry to study in depth the age-
related increase of SOD-2 detected previously by quantitative proteomic (Table 8.6), 
infant and pre-pubertal groups were statistically significant (P<0.01 and P<0.05, 
respectively with lower percentage positive cell levels (11.1±4.15 and 32.0±1.25, 
respectively) for MitoSOXTM. Beside, the pre-pubertal group was statistically significant 
(P<0.01) lower for DCFH when compared to other groups (Figures 4.8A and 4.8B). The 
permanent dye TMRM analysis indicated a decrease in functional mitochondria which 
was statistically significant (P<0.01) in infant and adult groups with 53.5±3.01 and 
27.43±2.74 positive cells respect to newborn and pubertal groups respectively (Figure 
4.8C). 
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Figure 4.8. Mitochondrial function in rBM-MSCs at different ages. (A) Mitosox signal measured by flow 
cytometry to check mitochondrial ROS. (B) DCFH signal measured by flow cytometry to check intracellular 
ROS. (C) TMRM dye accumulated in active mitochondria with intact potentials. One representative 
experiment is shown. #P<0.05 compared with previous age group and *P<0.01 compared with previous age 
group, were considered statistically significant using Mann-Withney-U and Kruskal-Wallis tests. 
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4.7 Glucolitic metabolism of rBM-MSCs at different ages 
Proteins found in our proteomic study associated with energy metabolism were lactate 
dehydrogenase (LDH), glucos-6-phosphate dehydrogenase (G6PDH) and 6-
phosphogluconate dehydrogenase (6PGDH), which were validated through analysis of 
their activity by enzymatic assays. LDH activity was increased in young group when 
compared to infant and newborn groups, levels decreased in pre-pubertal group in a 
statistically significant way (P<0.05) and finally its activity increased in pubertal and 
adult groups (Figure 4.9A), G6PDH and 6PGDH were statistically significant increased 
(P<0.05) in pubertal and adult groups when compared to the other groups (Figure 4.9B). 
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Figure 4.9.Glucolitic metabolism profile from rBM-MSCs at several ages. (A) Lactate-deshidrogenase 
(LDH) activity measured by spectrophotometer analysis. (B) Pentose phosphate pathway activity measured 
by spectrometer analysis. G6PDH= glucose-6-phosphate-1-dehydrogenase; 6GPDH= 6-phosphogluconate-
dehydrogenase. One representative experiment is shown. #P<0.05 compared with previous age group, was 
considered statistically significant using Mann-Withney-U and Kruskal-Wallis tests. 
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4.8 mTOR pathway in rBM-MSCs at different ages 
It was evaluated mTOR pathway which is key of energy metabolism and proliferation 
processes in rBM-MSCs at different ages. Immunoblot analysis indicated that mTOR and 
Raptor were statistically significant (P<0.05) lower in pre-pubertal and pubertal groups 
in compared to the other groups. Adult group presented the statistically significant 
(P<0.01) most increased level of mTOR and Raptor (Figure 4.10). 
 
 
Figure 4.10. mTOR pathway profile from rBM-MSCs at different ages. (A) Western-blot of mTOR and 
Raptor and tubulin was used as housekepping. (B) Densitometry analysis of western-blot of mTOR and 
Raptor normalized against to tubulin using Image Quant 5.2. One representative experiment is shown. 
*P<0.01 compared with previous age group was considered statistically significant using Mann-Withney-U 
and Kruskal-Wallis tests. 
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4.9 Relationship of mTOR pathway with proliferation markers 
(CD117 and Ki67) in rBM-MSCs from adult group 
rBM-MSCs from adult group were treated with different concentrations of imatinib 
mesylate (IM) (5µM and 10 µM) or JK184 (0.1 ng/ml and 1 ng/ml), which inhibit CD117 
and Ki67 respectively, for 2 days. Viability assay indicates that the used concentrations 
of IM and JK184 did not affect the cells in culture (Figure 4.11A). JK184 promoted a 
statistically significant (P<0.01) decrease in the expression of Ki67 at 1 ng/ml dose in 
culture (Figure 4.11B). Also, we observed the inhibition capacity on proliferation of 
these drugs over the cells and we obtained cells arrested in G2/M phase when they were 
treated with IM (5 µM and 10 µM) or JK184 (0.1 ng/ml and 1 ng/ml). The same results 
were found when rBM-MSCs were treated with 1 mg/ml nodocazole used as positive 
control (Figure 4.11C). 
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Figure 4.11. Inhibition of proliferation markers (CD117 and Ki67) in rBM-MSCs from adult group. (A) 
Viability assay of rBM-MSCs from adult group incubated with 5 µM or 10 µM of IM and 0.1 ng/ml or 1 ng/ml 
of JK184 in the culture medium. (B) Flow cytometry of Ki67 from rBM-MSCs from adult group incubated with 
0.1 ng/ml or 1 ng/ml of JK184. (C) Analysis of cell cycle by flow cytometry of rBM-MSCs from adult group 
incubated with 5 µM or 10 µM of IM and 0.1 ng/ml or 1 ng/ml of JK184 in the culture medium. One 
representative experiment is shown. *P<0.01 compared with control, was considered statistically significant 
using Mann-Withney-U and Kruskal-Wallis tests. IM= imatinib mesylate; control= rBM-MSCs incubated with 
growth medium without drug. 
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mTOR, p-Akt/Akt, AMPKα and p70S6K decreased statistically significant (P<0.01 and 
P<0.05) in adult group when the cells were incubated with IM or JK184 (Figure 4.12, 
4.13 and 4.14A).  
 
 
Figure 4.12. PI3K/Akt pathway in rBM-MSCs from adult group treated with 5 µM or 10 µM IM and 0.1 
ng/ml or 1 ng/ml JK184. (A) Western-blot of p-Akt, Akt and tubulin used as housekeeping. (B) Densitometry 
analysis of western-blot of p-Akt and Akt normalized against to tubulin using Image Quant 5.2. One 
representative experiment is shown. #P<0.05 compared with control, was considered statistically significant 
using Mann-Withney-U and Kruskal-Wallis tests. IM= imatinib mesylate; control= rBM-MSCs incubated with 
growth medium without drug. 
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Figure 4.13. Level of p70S6k and AMPKα in rBM-MSCs from adult group treated with 5 µM or 10 µM 
IM and 0.1 ng/ml or 1 ng/ml JK184. (A) Western-blot of p70S6K, AMPKα  and β-actin used as 
housekeeping. (B) Densitometry analysis of western-blot of p70S6K and AMPKα normalized against to β-
actin using Image Quant 5.2. One representative experiment is shown.*P<0.01 compared with control, were 
considered statistically significant and #P<0.05 compared with control using Mann-Withney-U and Kruskal-
Wallis tests. IM= imatinib mesylate; control= rBM-MSCs incubated with growth medium without drug. 
 
Also, p-mTOR, rictor, raptor and Gβl were statistically significant (P<0.01) decreased 
with respect to control (Figure 4.14B and Figure 4.15) in adult group when the cells were 
incubated with JK184. 
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Figure 4.14. mTOR pathway in rBM-MSCs from adult group treated with 5 µM or 10 µM IM and 0.1 
ng/ml or 1 ng/ml JK184. (A) Western-blot mTOR and tubulin used as housekeeping and densitometry 
analysis of western-blot of mTOR normalized against to tubulin using Image Quant 5.2. (B) Western-blot p-
mTOR, Gβl and tubulin used as housekeeping and densitometry analysis of western-blot of p-mTOR, Gβl 
normalized with respect to tubulin using Image Quant 5.2. One representative experiment is shown.*P<0.01 
compared with control, were considered statistically significant and #P<0.05 compared with control using 
Mann-Withney-U tests and Kruskal-Wallis. IM= imatinib mesylate; control= rBM-MSCs incubated with growth 
medium without drug. 
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Figure 4.15. mTOR pathway in rBM-MSCs from adult group treated with 5 µM or 10 µM IM and 0.1 
ng/ml or 1 ng/ml JK184. (A) Western-blot of rictor, raptor and β-actin used as housekeeping. (B) 
Densitometry analysis of western-blot of rictor and raptor normalized with respect to β-actin using Image 
Quant 5.2. One representative experiment is shown.*P<0.01 compared with control and #P<0.05 compared 
with control, were considered statistically significant using Mann-Withney-U and Kruskal-Wallis tests. IM= 
imatinib mesylate; control= rBM-MSCs incubated with growth medium without drug. 
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Also, cells that were treated with 10 nM rapamycin to inhibit mTOR pathway presented 
lower levels of CD117 and Ki67 (4.57±2.95 and 7.60±2.94 respectively) than control 
(Figure 4.16). 
 
Figure 4.16. Proliferation markers (Ki67 and CD117) in rBM-MSCs from old group treated with 10 nM 
rapamycin. One representative experiment is shown. #P<0.05 compared with control, was considered 
statistically significant using Mann-Withney-U tests and Kruskal-Wallis. Control= rBM-MSCs incubated with 
growth medium without drug. 
 
 
4.10 Transcriptome analysis using Next Generation Sequencing 
(NGS) of rBM-MSCs 
NGS analysis indicated that a total of 9628 genes presented differences of expression 
among groups of age as shown in Figure 4.17. Genes were divided into up-regulated in 
red and down-regulated in blue between age groups chronologically continuous. The 
results indicated that 4741 genes modified their expression between newborn and infant 
groups; 4939 genes modified their expression between infant and young groups; 6339 
genes modified their expression between young and pre-pubertal groups; 6568 genes  
modified their expression between pre-pubertal and pubertal groups and 6849 
genesmodified their expression between pubertal and adult groups.  
  4. RESULTS 
- 68 - 
 
 
Figure 4.17. Next Generation Sequencing study. (A) Modified expression genes among rBM-MSCs 
obtained in the RNA-sequencing. N= newborn; I= infant; Y= young; PP= pre-pubertal; P= pubertal; A=adult, 
blue genes= down-regulated; red genes= up-regulated. (B) Hierarchical clustering of modulated genes 
among rBM-MSCs age groups into pathways common in all of them.N=newborn; I=infant; Y= young; PP= 
pre-pubertal; P= pubertal; A= adult; I/N= infant vs newborn; Y/I= young vs infant; PP/Y= pre-pubertal vs 
young; P/PP= pubertal vs pre-pubertal; A/P= adult vs pubertal 
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Hierarchical clustering of genes involved into five common pathways between six groups 
studied the R/Bioconductor package RamiGO was shown in the Figure 4.17B. In detail, 
it was done a study assigning genes to metabolism pathways where genes modulated 
between newborn and infant groups were grouped at eight metabolism pathways. 
However genes modulated from infant until adult groups were grouped between 12 and 
15 metabolism pathways. Genes involved into hormonal changes, as gonadotropin 
releasing hormone pathway (PO6664), were increasing their number of from infant age 
group until adult group (76, 89, 116, 112 and 121 genes respectively). Genes involved in 
programmed death as apoptotic signalling pathway (PO00006) were observed modulated 
among young, pre-pubertal and adult groups (46, 57 and 66 respectively). Genes involved 
into inflammation mediated by chemokine and cytokine signalling pathwyay (PO00031) 
were modulated in infant, young and pubertal groups (78,82 and 103 genes respectively) 
(Figure 4.18 and 4.19).  
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Figure 4.18. Metabolic pathways with statistically significant changes among rBM-MSCs Part I. 
Modulated genes were categorized according to their function, biological process and cellular component 
using RamiGO. The small number on the right of each bar indicated the modulated genes involved in each 
pathway. GO= gene ontology. 
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Figure 4.19. Metabolic pathways with statistically significant changes among rBM-MSCs Part II. 
Modulated genes were categorized according to their function, biological process and cellular component 
using RamiGO. The small number on the right of each bar indicates the modulated genes involved in each 
pathway. GO= gene ontology. 
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4.11 Analysis of pro-inflammatory potential in rBM-MSCs at 
different ages  
rBM-MSCs from different ages were treated with 10 ng/ml rrTNFα for 2 days to activate 
immunogenic response and it was checked CD200 by flow cytometry. It was obtained 
high percentage of positive cells (13.5±3.11%) statistically significant (P<0.05) in pre-
pubertal group when compared to other groups and the lowest expression statistically 
significant (P<0.05) in adult group (1.80±1.11) (Figure 4.20A).  
Also, TLR4 protein concentration was checked by western blot after 4 hours with 10 
ng/ml LPS treatment to activate TLR4 pathway (Figure 4.20B). It was observed an 
increase of TLR4 with increasing age of the cells that were treated with LPS.  
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Figure4.20. Pro-inflammatory phetopype of rBM-MSCs at several ages. (A) Percentage of positive cells 
for CD200 treated with 10 ng/ml rrTNFα. (B) Western-blot analysis of TLR4. β-actin was used as 
housekeeping and densitometry analysis of TLR4 normalized with respect to β-actin of rBM-MSCs treated 
with 10 ng/ml LPS. The molecular weight of each protein is shown in the left. At the bottom the the group´s 
source of rBM-MSCs used. N= Newborn; Y= Young; PP= pre-pubertal; A= adult; -= without 10 ng/ml LPS; 
+= with 10 ng/ml LPS. One representative experiment is shown. #P<0.05 compared with previous age group, 
*P<0.01 compared with previous age group were considered statistically significant using Mann-Withney-U 
and Kruskal-Wallis tests. 
 
  4. RESULTS 
- 74 - 
 
4.12 Characterization of rBM-MSC-derived EVs 
Nanoparticle tracking analysis (NTA) was made to verify the extracellular vesicles (EV) 
nature obtained after the ultracentrifugation at 100,000 xg. The size of extracellular 
vesicles were 160±18 nm as exosomes and there weren´t significant differences among 
groups (Figure 4.21A). rBM-MSC- derived EVs were visualized by electronic 
microscopy as small vesicles, typically 40-80 nm in diameter (Figure 4.21B). Flow 
cytometry analysis of exosomes attached to anti-CD63 beads revealed that they were 
positive for the tetraspanins CD63, which is a membrane protein from exosomes (Figure 
4.21C). 
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Figure 4.21. Characterization of MSC-derived EVs. (A) Mean and mode size expressed in nm of MSC-
derived EVs at several ages by NTA analysis. (B) MSC-derived EVs from pre-pubertal group by electronic 
microscopy. Straight size is 200 µM. (C) APC signal measured by flow cytometry in MSC-EVs from adult 
group marked with 10 µM DiI using anti-CD63 beads. One representative experiment is shown. *P<0.01 
compared with dynabeads were considered statistically significant using Mann-Withney-U and Kruskal-
Wallis tests. 
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The ratio protein per particle and production of MSC derived EVs by NTA revealed that 
ratio protein/particle decreased with increasing donor age (Figure 4.22B), however with 
respect production rBM-MSC-derived EVs increased with age (26±1%) (Figures 4.22A 
and 4.22B). 
Figure 4.22. NTA study of MSC-derived EVs at several ages. (A) Number of particles per ml supernatant 
from rBM-MSCs at several ages. (B) Protein concentration per particle at different ages. (C) Particles per 
cell at several ages. One representative experiment is shown. #P<0.05 compared with previous age group 
and *P<0.01 compared with previous age group, were considered statistically significant using Mann-
Withney-U and Kruskal-Wallis tests. 
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4.13 Detection of miRs relationship with Toll-like receptor 4 in 
rBM-MSC-derived EVs at different ages 
qRT-PCR analysis of miRs associated with Toll like receptor 4: miR-146a; miR-155; 
miR-132; miR-21-5p and miR-335, determined that miR-146a, miR-155 and miR-132 
decreased their expression 93±3 % with the increase donor age (Figures 4.23A, 4.23B 
and 4.23C). Howewer, the adult group presented the highest expression of miR-335 
(P<0.05) (Figure 4.23D) and miR-21-5p increased its expression in pre-pubertal group 
when compared to other groups (P<0.05) (Figure 4.23E). 
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Figure4.23. Pro-inflammatory profile of micro-RNAs contained in MSC-derived EVs with age. (A) miR-
146a expression using qRT-PCR analysis normalized by expression miR-16 used as housekeeping. (B) 
miR-155-5p expression using qRT-PCR analysis normalized by expression miR-16 used as housekeeping. 
(C) miR-132-5p expression using qRT-PCR analysis normalized by expression miR-16 used as 
housekeeping. (D) miR-335 expression using qRT-PCR analysis normalized by expression miR-16 used as 
housekeeping. (E) miR-21-5p expression using qRT-PCR analysis normalized by expression miR-16 used 
as housekeeping. One representative experiment is shown. #P<0.05 compared with previous age group, 
*P<0.01 compared with previous age group were considered statistically significant using Mann-Withney-U 
and Kruskal-Wallis tests. A.U= arbitrary units. 
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4.14 miR-21-5p as regulator on pro-inflammatory and 
differentiation capacities of TLR4 in rBM-MSCs from pre-
pubertal group 
rBM-MSCs from pre-pubertal group were transitory transfected with miRVana miR-21-
5p and its expression was checked by qRT-PCR (Figure 4.24A), the transfected cells 
expressed levels of miR-21-5p statistical significant lower (P<0.05) than the same cells 
transfected with mimic miRNA used as control. qRT-PCR analysis of damage-associated 
molecular pattern (DAMPS) associated with TLR4 indicated that miR-21-5p inhibition 
produced a statistical significant decreased (P<0.05) of S100A4, S100A6 and HMGB1 
with respect rBM-MSCs control (Figure 4.24B). Also, it was checked Nanog gene 
expression at mRNA level and it was statistically significant higher (P<0.05) in cells 
transfected with miRVana miR-21-5p with respect to control (Figure 4.24C). 
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Figure 4.24. Effect of miR-21-5p on DAMPs and Nanog in mesenchymal stem cells from pre-pubertal 
group. (A) miR-21-5p expression using qRT-PCR analysis normalized by expression U6 used as 
housekeeping. (B) S100A4, S100A6 and HMGB1 using qRT-PCR analysis normalized by expression HPRT 
used as housekeeping. (C) Nanog gene expression using qRT-PCR analysis normalized by expression 
HPRT used as housekeeping. One representative experiment is shown. #P<0.05 compared with control, 
was considered statistically significant using Mann-Withney-U and Kruskal-Wallis tests. A.U= arbitrary units; 
Control= without inhibition miR-21-5p; anti-miR-21-5p= with inhibition miR-21-5p. 
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Western blot analysis of rBM-MSCs from pre-pubertal group where miR-21-5p was 
inhibited revealed than lamin A/C, mTOR, HMGB1, TLR4 and p-Akt were statistically 
significant (P<0.05) down-regulated in the inhibited cells with respect to control cells 
(Figures 4.25 and 4.26). On the other way Wnt5a and Akt were over-expressed 
statistically significant (P<0.05) when compared to control cells (Figures 4.25 and 4.26). 
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Figure 4.25. Effect of miR-21-5p on senescence and pro-inflammatory phenotype in rBM-MSCs from 
pre-pubertal group. (A) Western blot analysis of LMNA/C and Wnt5a in pre-pubertal rBM-MSCs from pre-
pubertal group with or without inhibition of miR-21-5p and their densitometry analysis normalized with 
respect to tubulin using Image Quant 5.2. (B) Western blot analysis of TLR4, mTOR and HMGB1 in rBM-
MSCs from pre-pubertal group with or without inhibition of miR-2-5p and their  densitometry analysis 
normalized with respect to tubulin using Image Quant 5.2. The molecular weight of each protein is shown in 
the left. One representative experiment is shown. #P<0.05 compared with control, was considered 
statistically significant using Mann-Withney-U and Kruskal-Wallis tests.-= without inhibition miR-21-5p; += 
with inhibition miR-21-5p. 
  
  4. RESULTS 
- 83 - 
 
 
Figure 4.26. Effect of miR-21-5p on PI3K/Akt in rBM-MSCs from pre-pubertal group. Western blot 
analysis of p-Akt and Akt in pre-pubertal rBM-MSCs group with or without inhibition of miR-21 and their 
densitometry analysis normalized with respect to tubulin using Image Quant 5.2. The molecular weight of 
each protein is shown in the left. One representative experiment is shown. #P<0.05 compared with control 
was considered statistically significant using Mann-Withney-U and Kruskal-Wallis tests.-= without inhibition 
miR-21-5p; += with inhibition miR-21-5p. 
 
 
Also, rBM-MSCs from pre-pubertal where miR-21-5p were inhibited when treated with 
10 ng/ml LPS for 4 hours, and it was observed an increased expression statistically 
significant (P<0.05) at proteomic level of TLR4 and ratio pAkt/Akt in comparison with 
rBM-MSCs which presented miR-21-5p inhibited without the treatment of LPS (Figure 
4.27). 
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Figure 4.27. Effect of miR-21-5p on immune response in rBM-MSCs from pre-pubertal group. (A) 
Western blot analysis of p-Akt and Akt pathway and in pre-pubertal MSCs group miR-21-5p inhibited with or  
without LPS treatment and their densitometry analysis normalized with respect to  tubulin using Image Quant 
5.2. (B) Western-blot analysis of TLR4 in pre-pubertal MSCs group miR-21-5p inhibited with or  without LPS 
treatment and their densitometry analysis normalized with respect to tubulin using Image Quant 5.2. The 
molecular weight of each protein is shown in the left. One representative experiment is shown. #P<0.05 
compared with cells without treatment of 10 ng/ml LPS, was considered statistically significant using Mann-
Withney-U and Kruskal-Wallis tests.-= without; += with. 
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4.15 Variation on rBM-MSC-derived EVs characteristic during 
aging 
Using fluorescence microscopy, it was observed internalizing of MSC-derived EVs from 
adult group (aEVs) in rBM-MSCs from young group (yMSCs) at 2 days and increase of 
EVs inside of rBM-MSCs along the time (Figure 4.28), the similar profile it was observed 
in aMSCs co-cultured with yEVs (Figure 4.28). Additionally, some MSC-derived EVs 
labelled with DiI were observed in the perinuclear region (Figure 4.28). 
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Figure 4.28. Observation of our in vitro model using fluorescence microscopy. Images of fluorescence 
microscopy (40X) of nucleus of MSCs were stained with DAPI and EV-derived MSCs were stained with DiI. 
(A) yMSCs cultured with aEVs at 2, 3 and 6 days. (B) aMSCs cultured with yEVs at 2, 3 and 6 days. (C) 
Control yMSCs and aMSCs without EVs. One representative experiment is shown. aMSCs= MSCs from 
adult group; yMSCs= MSCs from young group; aEVs= MSC-derived EVs from young group; yEVs= EV-
derived MSCs from young group.  
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Expression of Nanog, a pluripotency marker, was statistically significant decreased 
(P<0.05) in yMSCs with aEVs in comparison with yMSCs without aEVs used as control 
at 2 days. Instead aMSCs with yEVs presented increased expression (P<0.05) with 
respect to control at 6 days (Figure 4.29A) and it was observed an increased expression 
of Oct4 gene in aMSCs with yEVs with respect to the control after 3 days. However, Oct4 
expression in yMSCs with aEVs had a lower statistically significance (P<0.05) after 3 
days than the control (Figure 4.29B). 
Vinculin presented a statistically significant (P<0.05) increased expression at 2 days in 
yBM-MSCs with aEVs with respect to the control (Figure 4.29C). aMSCs with yEVs 
present a statistically significant (P<0.05) decreased expression with respect to controls 
at 6 days (Figure 4.29C). 
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Figure 4.29. Nanog, Oct4 and Vinculin expression at genetic level in our in vitro model. (A) Histograms 
represent gene expression of Nanog normalized by HPRT expression gene used as housekeeping in MSCs 
with or without EVs. (B) Histograms represent gene expression of Oct4 normalized by HPRT gene used as 
housekeeping in MSCs with or without EVs. (C) Histograms represent gene expression of Vinculin 
normalized by HPRT gene used as housekeeping in MSCs with or without EVs. One representative 
experiment is shown. #P<0.05 compared with control was considered statistically significant using Mann-
Withney-U and Kruskal-Wallis tests. Control= MSCs cultured with growth medium without EVs; aMSCs= 
MSCs from adult group; yMSCs= MSCs from young group; aEVs= EVs from adult group; yEVs= MSC-
derived EVs from young group. 
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Also, yMSCs with aEVs showed statistically significant (P<0.01) higher expression with 
respect to the control (Figure 4.30) and aMSCs with yEVs presented a statistically 
significant (P<0.01) decreased in expression of three isoforms of Lamin A/C with respect 
to control at 6 days (Figure 4.31). 
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Figure 4.30. Analysis of isoforms of Lamin A using western-blot in our in vitro model. (A) Western-
blot analysis of prelamin A, Lamin A/C yMSCs with or  without aEVs at different times (1, 2, 3 and 6 days). 
(B) Densitometry analysis of three isoforms of Lamin A normalized with respect to tubulin using Image Quant 
5.2. The molecular weight of each protein is shown in the left. One representative experiment is shown. 
*P<0.01 compared with control was considered statistically significant using Mann-Withney-U and Kruskal-
Wallis tests. Control= MSCs cultured with growth medium without yMSCs= MSCs from young group; aEVs= 
MSC-derived EVs from adult group. 
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Figure 4.31. Analysis of isoforms of Lamin A using western blot in our in vitro model. (A) Western 
blot analysis of prelamin A, Lamin A/C aMSCs with or  without yEVs at different times (1, 2, 3 and 6 days). 
(B) Densitometry analysis of three isoforms of Lamin A normalized with respect to tubulin using Image Quant 
5.2. The molecular weight of each protein is shown in the left. One representative experiment is shown. 
*P<0.01 compared with control was considered statistically significant using Mann-Withney-U and Kruskal-
Wallis tests aMSCs= MSCs from adult group; yEVs= MSC-derived EVs from young group. 
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It is well known that long-term in vitro culture alters the morphology, susceptibility to 
senescence and mitochondrial function of the cells. Thus, independently from donor age, 
in vitro aging of MSCs seems to result in complete loss of their progenitor 
characteristics214. Accordingly, functional analysis demonstrated altered mitochondrial 
morphology, decreased antioxidant capacities and elevated ROS levels in long-term 
cultivated cells independently of the aged of the donor215.  
Our study is focused to know how aging could be influencing some kind of changes in 
the properties of rBM-MSCs using a direct comparison among chronological aged MSCs 
both at cellular and molecular levels to advance in the knowledge of MSCs and their 
clinical use. 
BM-MSCs from Wistar rats at six different ages (newborn, infant, young, pre-pubertal, 
pubertal and adult) were used in this study, following the Sengupta´s review to stablish  
the aging groups, verifying the phase in days of the animals216.  
rBM-MSCs from different aging groups were characterized by flow cytometry. We didn´t 
observe statistical significant differences among the mesenchymal and hematopoietic 
markers into the different rBM-MSCs aging groups studied (Figure 4.1). These results 
were coincident with results published by Jin et al.28 indicating that rBM-MSCs have 
similar markers but were not as abundant as published by Harting et al.217. These cells 
were able to adhere to the plastic culture plate which is an intrinsic characteristic of 
mesenchymal stem cells.  
One of the aims of our study was to establish the differences into proliferation processes 
relating them to the chronological donor age. Our results indicated that chronological age 
is directly influencing the expression of proliferation marker Ki67218 because the lowest 
levels of Ki67 corresponded with less cells present in proliferation assays in infant and 
pre-pubertal groups. On the other hand high levels of CD117, a self-renewal marker in 
MSCs as indicated by Blazquez-Martinez et al.13 were corresponding to higher cell in 
proliferation assays of young and adult groups respect to the other groups (Figure 4.2). 
All of the groups were able to differentiate towards several mesoderm lineages (Figure 
4.3) and together with the expression of pluripotency markers by qRT-PCR (Figure 4.4) 
indicated these MSCs keep their pluripotency capacity. 
iTRAQ analysis is an adequate technique to study complex samples like we have used in 
this work219. Our results by iTRAQ analysis allowed the identification of 1072 proteins, 
201 of them were statistically significant modulated among the groups (Figure 4.6 and 
Table 8.6). Our study represented a step further from a previous iTRAQ-based study220 
where 156 differentially expressed proteins were detected.  
60 modulated proteins found in our iTRAQ analysis were involved in proliferation as 60S 
ribosomal proteins with different sedimentation speed like 60S RP L10, 60S RP L9, 60S 
RP L23, 60S RP L24, 60S RP L4, 60S RP L6 and 60S RP L7, which were over-expressed 
in young group when compared to other groups. That could explain the highest expression 
of proliferation markers CD117 and Ki67 by flow cytometry (Figure 4.2) in this group. 
Maulik et al.221 also found over expression of these proteins relationship with 
proliferation process. Our results indicated that expression of vinculin gene (Figure 4.7B) 
was very low in newborn and young, actually the most proliferative groups (Figure 4.2). 
On the contrary, pre-pubertal group presented high vinculin gene expression coincidently 
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with less proliferative potential. Toma-Jonik et al.222 published recently that great 
mobilization and proliferation potential related with vinculin in melanoma cells and at the 
same time Piltti et al.223 published that Rho kinase inhibitor (ROCKi) treatment increased 
the cellular proliferation in human foreskin fibroblast cells. It is known that significantly 
less Vinculin-associated focal adhesions were present in ROCKi-treated cells224. 11-β-
hydroxysteroid dehydrogenase type 1 (11-β-HSD1), an enzyme which generates 
glucorticoids in cells, was found in our iTRAQ analysis significantly increased in pre-
pubertal group. This fact could explain the decrease proliferation potential and increased 
capacity of differentiation in pre-pubertal group. All this is agreement with Bujalska et 
al.225 who published that 11-β-HSD1 activity in uncommitted adipose stromal cells may 
facility proliferation rather than differentiation. Transforming growth factor β1 (TGF-β1) 
induces senescence in BM-MSCs via an increased production of mitochondrial ROS and 
the production of ROS intracellular is associated with a decreased potential of 
mitochondrial membranes, DNA damage and cellular senescence226,227. This fact could 
explain that the statistically significant (P<0.05) decrease of total ROS in the pre-pubertal 
group because TGF-β1 was found statistically significantly (P<0.05) lower with respect 
to other groups in the iTRAQ analysis (Figure 4.8B and Table 8.6). 
86 modulated proteins found in our iTRAQ analysis were involved in the pluripotency 
process. Terme et al.228 showed that pluripotent cells had decreased level of H1.0 and 
increased levels of H1.1, H1.3 and H1.5 when they were compared with differentiated 
cells. Differentiation of embryonic stem cells is accompanied by a global reduction of 
panacetylation of histones H3 and H4 suggesting that histone acetylation plays an 
important role the maintenance of embryonic stem cells pluripotency229.Our results 
indicated that H4 was statistically significant decreased in the adult group. It could point 
towards their lowest pluripotency with respect to the other groups. Results published by 
Bermeo et al.230 indicated that MSCs over-expressing Lamin A had higher osteogenic and 
lower adipogenic differentiation potential. Their studies demonstrated that Lamin A/C 
played a significant role in differentiation towards both osteoblast and adipocyte lines by 
regulating some of the elements of Wnt/β-catenin signalling during early MSCs 
differentiation. We also found high levels of Lamin A/C by western-blot analysis in rBM-
MSCs from adult group which we could link to the lowest adipogenic potential with the 
statistically significant (P<0.05) lowest levels of oil red staining during its directed 
differentiation (Figures 4.3 and 4.7A). We considered the role of Lamin A, a senescence 
marker, and its relationship with the increase of ROS, which is associated with an increase 
of thioredoxin. We found increased Lamin A and SOD-2 (Figure 4.7A), producing a 
oxidative damage, in adult group which could indicate the influence of age231 on 
impairment of MSCs functions in a  similar way that results published by Stolzing et 
al.232.  
The decision to exit pluripotency and undergo differentiation is of singular importance 
for pluripotent cells, including MSCs. The molecular mechanisms for these decisions to 
differentiate, as well as reversing those during induced pluripotency have focused largely 
on transcriptomic controls. Easly et al.233 explored the role of translational control for the 
maintenance of pluripotency and the decisions to differentiate. ATP-citrate synthase is 
profoundly linked to the pentose phosphate route and its inhibition has been recently 
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linked to a decrease in the proliferation rate234. Also it has been reported by Pattapa et 
al.235 that MSCs resided under hypoxic conditions, which were associated with the 
inherent metabolism of the cells. However, MSCs under normoxia growth conditions 
derived a significant proportion of ATP from oxidative phosphorylation in addition to 
glycolysis. From the list of modulated proteins, 55 of them are involved in the energy 
metabolism process. We observed increase of LDH from adult group (Figure 4.9A), it 
could be explained by the fact that this group presented an increase in glycolysis. Pre-
pubertal group showed decrease of LDH and decreased in glycolysis. All these resuts 
couls be explained through pentose phosphate pathways because of we found a significant 
decrease G6PDH in the pre-pubertal group and a significant increase in the adult group 
(Figure 4.9B). mTOR is a Ser/Thr protein kinase that functions as an ATP and amino 
acid sensor to balance nutrient availability and cell growth236. mTOR regulates cellular 
senescence and drives bioenergetic infrastructure237, also it restrains proliferation 
potential of stem cells mediating their self-renewal loss, which is an effect that can be 
suppressed by mTOR-inhibitors, such as rapamycin, antagonizing senescence238. mTOR 
plays an important role in the regulation of hematopoietic stem cell self-renewal in vitro 
and inhibition of mTOR hyperactivation with rapamycin may represent a novel approach 
to promote ex vivo expansion and their long-term hematopoietic reconstitution of 
hematopoietic stem cells239. Our results from mTOR family by western blot analysis 
indicated that mTOR (Figure 4.10) was statistically significant increased in adult group 
when compared to other groups studied. It could be due BM-MSCs from the adult group 
were more senescence than BM-MSCs from young group. We corroborated that date 
checking expression of Lamin A/C in all groups. We observed that adult group had the 
highest expression of Lamin A (Figure 4.7A) together with less dye accumulation of 
TMRM (Figure 4.8C). 
We found correlation between inhibition of mTOR and decrease of CD117 and Ki67 
which are proliferation markers in the literature240,241 and we wonder if this relationship 
between the mTOR pathway on proliferation was present when the proliferation markers 
were inhibited by specific reagents. IM decreases CD117 expression in gastrointestinal 
stromal tumors242 and JK184, a compound designed to antagonize Hh signalling, reduces 
expression of CD31, Ki67 and VEGF in tumour tissues243, respectively (Figure 4.11B). 
We also found these drugs arrested cells in transition from G2 phase to M phase in the 
cell cycle (Figure 4.11C). 
We modified mTOR pathway through modification of proliferation markers for first time. 
We used two inhibitors of proliferation IM or JK184 at two physiological doses which 
did not affect the cell viability (Figure 4.11A). The expression of mTORC1 complex was 
modified (Figures 4.12, 4.13, 4.14 and 4.15) with both treatments. mTORC1 complex 
has been linked with cell growth50, proliferation244, survival245, protein translation233 and 
other cellular metabolic processes246. Additionally, we confirmed the relationship 
between mTORC1 and proliferation markers when BM-MSCs from adult group were 
treated with rapamycin, an inhibitor of the mTOR signalling pathway, with potent 
immunosuppressive properties247,248. The adult group presented a decrease of 
proliferation markers expression by flow cytometry (Figure 4.16). Our results were 
coincident with Gu Z et al. who reported that rapamycin decelerated senescence of BM-
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MSCs from systemic lupus erythematosus patients by inhibiting excessive cellular growth 
caused by the mTOR pathway72. This discovery helped to advance the knowledge of the 
mTOR pathway in aging used in pharmacological approaches to treat human pathologies 
linked to mTOR deregulation. 
We decided to study in depth the influence of aging on mesenchymal stem cells and we 
carried out a transcriptome analysis using RNA-sequencing which is an adequate 
technique to study complex samples such as we have used in our study249. Our results by 
RNA-seq analysis allowed the identification of 9628 genes that were statistically 
significant modulated among groups (Figure 4.17A). This analysis represented a step 
further from a previous iTRAQ-based study250. We used the R/Bioconductor package 
RamiGO which is an R interface for AmiGO that enables visualization of Gene Ontology 
(GO) trees211. RamiGO provides easy customization of annotation, highlighting of 
specific GO terms, using of terms by P-value. We showed RamiGO functionalities in a 
genome-wide gene set analysis of genes differently expressed comparing BM-MSCs from 
six chronologically different groups (Figure 4.17B). But, we focused on genes involved 
into inflammation mediated by chemokine and cytokine signalling pathways (PO00031), 
which were modulated in infant, young and pubertal groups (Figures 4.18 and 4.19). 
Within this pathway until 250 markers of extracellular vesicles were found using 
bioinformatics platforms: Vesiclepedia (www.microvesicles.org/)108, EVpedia 
(www.evpedia.info)109 and ExoCarta (www.exocarta.org)110, which are relevant 
software resources to extracellular vesicles research, also based on our iTRAQ results 
(Table 8.6). Micro-RNAs involved into extracellular vesicles and their relationship with 
inflammation mediated by chemokine and cytokine signalling pathways were obtained 
by open-source software for target predictions miRanda and TargetScan which are 
available at http://www.microrna.org212 and http://www.targetscan.org213 
respectively. Thus, we studied the influence of aging on the profile of micro-RNAs pro-
inflammatory containing in MSC-derived EVs to advance in compression of 
immunosuppressive capacity of MSCs to use as future safe therapeutic approaches.  
MSC-derived EVs present advantages over cell-based therapy as it eliminates the safety 
concerns associated with injection of MSC in patients and particularly useful for 
enhancing recovery from various diseases like as graft-versus-host disease 12,101. Hence it 
is necessary to advance our knowledge on the chronological age of MSC-derived EVs to 
maximize clinical utility. Firstly, we isolated MSC-derived EVs using the protocol of 
ultracentrifugation by Del Fattore et al.251. Then they were characterized by size by NTA, 
which calculates the size of the total concentration of the vesicles in solution252. Also, we 
followed the technique used by Gercel-Taylor et al.253 who reported their optimized 
method to measure the size distribution of cell-derived vesicles comparable to other 
instrumentation analysis. Additionally, we found an increase in the production of MSC-
derived EVs from adult group when compared to other groups (Figure 4.22). This could 
be explained by the deregulation in intracellular and extracellular calcium level. Calcium 
balance plays a role in plasma membrane fusion events by small GTPase Rab11 and the 
citron kinase19. We found statistically significant high levels of calcium/calmodulin-
dependent protein kinase type II, caldesmon, calponin-1, caluminen and calreticulin in 
adult group with respect to the other ages in iTRAQ analysis (Table 8.6) will be 
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corroborating this hypothesis. Our EVs had a similar diameter size as reported by 
Vallabhaneni et al.254 (Figure 4.21A). We confirmed that at least 30% from EVs were 
exosomes because they were CD63 positive (Figure 4.21C) as indicated by the 
International Society for Extracellular Vesicles (ISEV)105.  
Age-related changes of immune system functions are complex phenomena incompletely 
understood. The acquired immune system shows a functional decline in ability to respond 
to new pathogens during aging, whereas serum levels of inflammatory cytokines are 
increased with age51. “Inflammaging” is a prominent aging-associated alteration in 
intercellular communication and one of the major driving diseases associated with age. 
We observed CD200 levels in our age groups because Pietila et al.255 proposed CD200 is 
a good immunosuppressive marker in hMSCs, it is involved in the capacity of MSCs 
mediated immune behaviour of THP-1 macrophage-like cells. We found a decrease of 
CD200 in the adult group (Figure 4.20A) with respect to other groups, which could be 
explained by the loss of immunosuppressive capacity similar to results obtained by 
Kilpinen L et al. 215. who have published that aging affects immunological functions due 
the altered membrane glycerophospholipid composition 
We checked TLR4, a receptor recognizing “danger” signals and its activation leads to 
cellular and systemic responses that regulate innate and adaptive immune cells256, 
therefore it is associated in pro-inflammatory signature of MSCs257. We found high levels 
of TLR4 in the pre-pubertal group (Figure 4.20B).  
DAMPs are involved in regulation of proliferation258, differentiation, apoptosis258, Ca2+ 
homeostasis, energy metabolism, inflammation and migration259, and HMBG1 protein 
described as a DNA-binding protein that stabilizes nucleosomes and facilitates 
transcription and enhanced expression of pro-inflammatory cytokines260 (Figure 4.20B 
and Table 8.6). Pre-pubertal group showed a decreased capacity of self-renewal besides 
an increased expression of DAMPs261 at protein level such as S100 proteins (S100A4, 
S100A6) (Table 8.6). All of these could be explained due to the deregulated in 
gonadotropin realising hormone pathway and inflammation mediated by chemokine and 
cytokine signalling pathways obtained by transcriptome analysis (Figures 4.18 and 4.19).  
There is a controversy on the role of TLR4 in pro-inflammatory and differentiation 
capacities9 in MSCs and this study thereby provides helpful tools for regenerative 
medicine. We checked miRs associated with TLR4 contained in MSC-derived EVs. miR-
146a, known as one of key TLR-induced miRNAs, inhibits the TLR-signalling pathway 
by targeting IRAK1 kinase and TRAF6 ligase. miR-132 which is a target of IL1R 
associated kinase IRAK 4, regulator of production inflammatory cytokines23. miR-155 
which is induced via TLR in macrophages and dendritic cells and exerts profound effect 
on the activity of immune cells24-26. Xu et al262 reported that miR-155 regulates the 
immunosuppressive capacity of MSCs by TAK1-binding protein 2 (TAB2). In our study 
we observed a decrease of these miRs contained in EVs with increasing age groups 
(Figures 4.23A. 4.23B and 4.23C) and it could be associated with the decrease of MSC-
derived EVs immunologically activity and loss of capacity to activate the immune system 
through the induction of anti-inflammatory cytokines and T cells. Additionally, MSC-
derived EVs from adult group contained the highest level of miR-335 (Figure 4.23D).  It 
could be associated with cellular senescence and the loss of therapeutic capacity because 
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it was linked to reduced capacity to activate protein kinase D1 (PRKD1) which in turn 
reduces the activity of AP-1 transcription factor263,264 in vitro aging corresponding with 
chronological in vivo aging. miR-21-5p regulates negatively LPS-induced lipid 
accumulation and inflammatory response in macrophages by the TLR4-NF-kB 
pathway265 which is involved in human mesenchymal stem cells during differentiation by 
regulating SPRY229. We found the highest level of miR-21-5p in MSC-derived EVs 
from pre-pubertal group and the lowest level in adult group (Figure 4.23E) hence it could 
be a target to understand role of TLR4 in differentiation of pro-inflammatory capacity 
aging-depending. To understand in depth the role of aging on TLR4 we studied 
AKT/mTOR and non-canonical pathways on pre-pubertal group. TLR4 regulates 
proliferation and osteogenic differentiation through Wnt3a and Wnt5a signaling266 while 
its activation into MSCs from umbilical cord increased this differentiation to a certain 
extent267. Gharibi et al.268 published that the chemically inhibition of the Akt/mTOR 
pathway affected TLR4. Our results indicated that TLR4 trend to increase with age and 
the treatment with LPS did not affect (Figure 4.20B) their immunological response 
within 4 hours. So we focused on Wnt5a protein which, through TLR4, is induced by 
inflammatory mediators, like LPS, in several stem cells types and regulated by cytokine 
and chemokine production269,270. The inhibition of miR-21-5p resulted in the 
overexpression of Wnt5a accompanied by a decrease of Lamin A/C, a senescence 
marker231 (Figure 4.25A). It looks like a decrease of miR-21 increased the self-renewal 
and pluripotent capacities in the pre-pubertal group, as demonstrated by the high 
expression of Nanog (Figure 4.24C). The inhibition of miR-21-5p affected also 
Akt/mTOR pathway because mTOR and pAkt were downregulated (Figures 4.25B and 
4.26). The immunological response of pre-pubertal BM-MSCs group was not statistically 
significant modulated (Figure 4.27). These data might suggest that miR-21-5p could be 
a regulator of TLR4 signalling without affecting the immune response. All results provide 
an insight into mechanisms involved in BM-MSC aging and suggest possible 
interventions on micro-RNAs to maintain quiescence and function of MSCs and their 
derived extracellular vesicles a priori to in vivo transplantation or pharmacological agents 
in disease. 
There are many studies about the mechanisms of EVs uptake in target cells such as 
clathrin-mediated endocytosis117,162,163 , caveolin-dependent endocytosis165–167 , 
macropinocytosis100,271, phagocytosis160, involvement of lipid rafts174,272 and cell surface 
membrane fusion273,171. Furthermore, we demonstrated the internalization of MSC-
derived EVs, labelled with DiI, was independent of the individual’s age by fluorescence 
microscopy (Figure 4.28). These results were similar to other studies using other cellular 
types such as dendritic cells274 melanoma cells171. Moreover, we studied the influence of 
aging through MSC-derived EVs in self-renewal capacity of BM-MSCs. Therefore, we 
performed genetic studies to evaluate the expressions of pluripotency markers such as 
Nanog and Oct4, which are important transcription factors to control expression of 
multiples genes associated with pluripotency pathways of MSCs. Their expression is 
reduced in vitro culture under normoxia275 as a result an inactivation of these genes which 
reduce proliferation and pluripotency capacities276. 
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It is known epigenetic mechanisms for placing global chromatin dynamics are central to 
tracking pluripotency and lineage progression of hESCs and the deacetylation histone is 
necessary to expression of Oct4 and Nanog in hESCs277. We observed in our model that 
expression of these pluripotency markers changed when we cultured cells at medium with 
MSC-derived EVs. Adult group increased expression of Nanog and Oct4 when they were 
cultured at medium with yEVs by contrast, young group co-cultured with aEVs decreased 
expression of these transcription factors (Figures 4.29A and 4.29B). In this way, we 
confirmed that EVs influenced the self-renewal capacity of MSCs at genetic levels. 
Additionally, we studied vinculin expression (Figure 4.29C) which is involved in 
proliferation through contractility and cellular adhesion278 and Lamin A/C (Figures 4.30 
and 4.31). Additionally, we observed the greatest effectivity of aEVs in comparison with 
yEVs because of the changes at proteomic and genetic levels observed as soon as 2 days 
(Figures 4.29, 4.30 and 4.31). All these results suggest that aEVs could contained “age-
promoting” factors term used by Randon et al.279, which may be responsible for the age-
associated decline of stem cells functionality. All of this provides an important key to the 
understanding of the aging process and the development of EV-based therapies254,280.  
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1. Aging was affecting on the proliferation profile of bone marrow mesenchymal 
stem cells. Bone marrow mesenchymal stem cells from young group (14 days) 
had the most proliferative capacity. Conversely, the pre-pubertal (35-38 days) 
group was the less proliferative. Besides, mTORC1complex modulated 
proliferation markers (CD117 and Ki67) in bone marrow mesenchymal stem cells 
from the oldest group. 
2. Aging was affecting on the pluripotent profile of bone marrow mesenchymal stem 
cells because they had different expression of pluripotency marker (Nanog). Bone 
marrow mesenchymal stem cells from young group (14 days) are the most 
pluripotent and the oldest group have less capacity. 
3. Proteomic analysis revealed 201 statistically significant modulated proteins 
among groups. Functional clustering revealed alterations in pathways related to 
proliferation, pluripotency and energy metabolism. NGS study found out 9628 
genes statistically modulated among age groups and they are involved with 
glycolysis, gonadotropin realising hormone pathway, integrin signalling pathway, 
PDGF pathway and inflammation mediated by chemokine and cytokine 
signalling. 
4. Aging influences on the pro-inflammatory phenotype of bone marrow 
mesenchymal stem cells, through the expression of pro-inflammatory markers 
such as CD200 and TLR4. 
5. Bone marrow mesenchymal stem cells produced extracellular vesicles with 
different content of miRs inside them and their production age-dependent. 
6. The miRNAs contained in EVs change in an age-dependent manner and these 
changes influence and determinate the therapeutic potential of the EVs through 
modulation of the innate immune response. 
7. miR-21-5p was a regulator on pro-inflammatory and pluripotent capacities from 
TL4 signalling pathway through pAkt/Akt in bone marrow mesenchymal stem 
cells from pre-pubertal group (35-38 days). 
8. Bone marrow mesenchymal stem cell-derived extracellular vesicles and their self-
renewal was influenced by age, as revealed by changes in the expression of self-
renewal markers such as Nanog, Oct4, Vinculin and Lamin A/C. 
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Table 8.1. List of antibodies to flow cytometry. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Antibody Reference Dilution Company, City, Country 
 
Alexa Fluor 647 hamster anti-rat 
CD29 
 
RU0-562153 
 
1:1000 
 
BD PharmigenTM, Haryana, India 
PE mouse anti-human CD34 RUO-
5558222 
1:1000 BD PharmigenTM, Haryana, India 
FITC mouse anti-rat CD45RA  RUO-561886 1:1000 BD PharmigenTM, Haryana, India 
PE mouse anti-rat CD90 RUO-551401 1:1000 BD PharmigenTM, Haryana, India 
APC anti-human CD117 117A-10T 1:1000 Immunostep, Salamanca, Spain 
FITC anti-rat CD200 1399990143 1:1000 Immunostep, Salamanca, Spain 
FITC mouse anti-Ki67 RUO-556026 1:1000 BD PharmigenTM, Haryana, India 
Alexa Fluor 647 mouse IgG1 k 
isotype control 
RUO-557783 1:1000 BD PharmigenTM, Haryana, India 
Rabbit anti-goat IgG-FITC sc-2777 1:1000 St.Cruz Biotechnology, St.Cruz, 
United States 
Rabbit anti-goat IgG-PE sc-3755 1:1000 St.Cruz Biotechnology, St.Cruz, 
United States 
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Primary Antibodies  Reference Dilution Company, City, Country 
    
Mouse monoclonal to Lamin-A/C (LMNA)-
purified 
BM6000P 1:1000 Acris, Schillerstr, Germany 
Rabbit polyclonal to p70S6K ab47511 1:1000 Abcam, Cambridge, United 
Kindgom 
Rabbit monocolonal to mTOR (7C10) #2983 1:1000 Cell Signaling, Barcelona, 
Spain  
Rabbit monoclonal to Raptor (24C12) #2280 1:1000 Cell Signaling, Barcelona, 
Spain 
Rabbit monoclonal to Rictor (53A2) #2114 1:1000 Cell Signaling, Barcelona, 
Spain 
Rabbit monoclonal to Gβl (86b8) #3274 1:1000 Cell Signaling, Barcelona, 
Spain  
Rabbit monoclonal to Phospho-mTOR 
(Ser2448)  
#5536 1:1000 Cell Signaling, Barcelona, 
Spain  
Mouse anti-rat TLR4-purified 1399990142 1:1000 Immunostep, Salamanca, 
Spain 
Rabbit monoclonal to AMPKα (23A3) #2603 1:1000 Cell Signaling, Barcelona, 
Spain 
Mouse monoclonal to Wnt5a ab86720 1:1000 Abcam, Cambridge, United 
Kindgom 
Rabbit monoclonal to Akt #9272 1:500 Cell Signaling, Barcelona, 
Spain 
Rabbit monoclonal to phospho-Akt (Ser473) #9271 1:500 Cell Signaling, Barcelona, 
Spain 
Mouse monoclonal to Vimentin ab8069 1:1000 Abcam, Cambridge, United 
Kingdom 
Mouse monoclonal to manganese superoxide 
dismutase (SOD-2) 
611580 1:1000 BD PharmigenTM, Haryana, 
India 
Rabbit polyclonal to HMGB1 ab18256 1:1000 Abcam, Cambridge, United 
Kindgom 
Rabbit monoclonal to α-tubulin (11H10) #2125 1:5000 Cell Signaling, Barcelona, 
Spain 
Mouse monoclonal to β-actin  A5441 1:5000 Sigma-Aldrich,  
Anti-rabbit immunoglobulins, HRP-linked 
antibody 
#7074 1:1000 Cell Signaling, Barcelona, 
Spain 
Anti-mouse immunoglobulins, HRP-linked 
antibody 
11689 1:1000 Dako, Glosturp, Denmark 
Table 8.2. List of antibodies to western-blot. 
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Gene Number acces Forward primer (5´-3´) Reverse primer (5´-3´) T /ºC 
 
Nanog 
 
NM_005103.4 
 
atgcctcacacggagactgt 
 
aagtgggttgtttgcctttg 
 
61 
Oct4 NM_00510 ctcctggagggccaggaatc atatacacaggccgatgtgg 61 
Rex1 NM_005106.4 gtgcatcacacctcagactgt cgttggttgaaggccaactg 61 
Sox2 NM_001109181.1 ctccgggacatgatcagc ggtagtgctgggacatgtgaa 61 
Vinculin NM_012583.2 aggagaccttgcgaagacagg gcggttgccacttgtttag 61 
S100A4 NM_012618.1 agctactgaccagggagctg ctggaatgcagcttcgtct 59 
S100A6 NM_053485.2 tgatccagaaggagctcacc agatcatccatcagccttgc 60 
HMGB1 NM_012963.2 ccggatgcttctgtcaactt ttgatttttgggcggtactc 60 
HPRT NM_012583.2 agccgaccggttctgtcat agccgaccggttctgtca 61 
Table 8.3. Specific primers of different rat genes for qRT-PCR. 
 
 
Target Number acces Sequence ( 5’-3’) 
 
hsa-miR-16 
 
MIMAT0000069 
 
tagcagcacgtaaatattggcg 
rno-miR-21-5p MIMAT0000790 tagcttatcagactgatgttga 
hsa-miR-132-5p MIMAT0004594 accgtggctttcgattgttact 
hsa-miR-146a MIMAT0000449 tgagaactgaattccatgggtt 
rno-miR-155-5p MIMAT0030409 ttaatgctaattgtgataggggt 
rno-miR-335 MIMAT0000575 tcaagagcaataacgaaaaatgt 
Table 8.4. Specific primers of miRNAs for qRT-PCR. 
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Buffer Composition Company, City, Country 
 
Fixative 
 
10% (v/v) acetic acid 
40% (v/v) ethanol 
 
All from PANREAC, Barcelona, Spain 
Sensitizer 0.02 % (w/v) sodium thiosulfate All from Sigma-Aldrich, St.Louis, United 
States 
Silver 0.075% (v/v) formaldehyde 
0.2% (w/v) silver nitrate 
All from Sigma-Aldrich, St.Louis, United 
States 
Revealing 0.025% (v/v) formaldehyde 
3% (w/v) sodium carbonate 
12.5 mg/l sodium thiosulfate 
All from Sigma-Aldrich, St.Louis, United 
States 
 
Stop 10% (v/v) acetic acid 
3% (w/v) Tris-base 
All from Sigma-Aldrich, St.Louis, United 
States 
 
Table 8.5. List of buffer to silver-stainning. 
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Energy metabolism            
Accession Name 
Peptides 
(95%) I/ N PVal I/N Y/I PVal Y/I PP/Y PVal PP/Y P/PP PVal P/PP A/P PVal A/P 
Q6P783 6-phosphofructokinase  5 0.7228 0.1496 1.0497 0.7085 1.1027 0.3079 1.4117 0.0388 1.2082 0.2192 
Q7TP11 
6-phosphogluconate dehydrogenase. 
decarboxylating  5 0.8664 0.0404 0.9404 0.345 1.1936 0.1035 1.2877 0.0026 0.6857 0.0099 
P06761 78 kDa glucose-regulated protein  35 0.9172 0.0089 0.9677 0.334 1.1997 0 0.8295 0.002 1.4611 0 
M0RDC5 
Acyl-CoA-binding protein 
(Fragment)  1 0.9923 0.9393 1.0172 0.8471 1.0129 0.8865 1.1744 0.4947 1.408 0.0299 
F1LN88 
Aldehyde dehydrogenase. 
mitochondrial  9 0.915 0.2981 0.9521 0.605 1.0255 0.8092 0.8105 0.1287 1.249 0.0303 
P07943 Aldose reductase  9 1.0984 0.3717 0.8893 0.186 0.9549 0.5728 0.9715 0.7164 1.2055 0.0389 
Q91W30 Aldose reductase-like protein  10 1.6948 0.0054 0.5021 0.0183 1.2079 0.2492 1.0106 0.9424 1.2476 0.0229 
D3ZUM4 Beta-galactosidase  5 1.0315 0.7835 1.3171 0.0441 1.0942 0.385 1.1471 0.1506 0.9005 0.1892 
O35567 
Bifunctional purine biosynthesis 
protein PURH  13 0.9914 0.9389 0.8798 0.2663 1.1514 0.3918 0.8194 0.0166 1.1312 0.0362 
Q99JD5 
Branched-chain-amino-acid 
aminotransferase  5 1.0463 0.7187 0.842 0.0756 1.3485 0.0127 0.9146 0.4169 0.9297 0.5047 
P15791 
Calcium/calmodulin-dependent 
protein kinase type II subunit delta  5 0.9646 0.825 0.9676 0.8106 1.3814 0.0071 0.7966 0.044 1.0233 0.8049 
G3V9E3 Caldesmon 1. isoform CRA_b  18 1.0648 0.1599 0.9241 0.1919 1.4728 0 0.7388 0.0002 1.6353 0 
Q08290 Calponin-1  9 0.8714 0.0531 1.3003 0.0464 0.8214 0.2876 0.723 0.0013 1.2572 0.0412 
P37397 Calponin-3  10 1.3337 0.0378 0.8281 0.0224 1.0857 0.2275 0.7288 0.0035 1.1632 0.1397 
P18418 Calreticulin  12 1.1514 0.0446 0.8607 0.0394 1.3403 0.0004 0.7119 0.0002 1.4109 0.0004 
G3V6S3 Calumenin  5 1.0591 0.4369 1.0768 0.3271 0.9833 0.8456 0.7673 0.2524 1.5598 0.0141 
Q6P6T6 Cathepsin D  7 0.8801 0.1287 1.0622 0.3991 1.5419 0.0105 0.9111 0.1808 1.3326 0.0234 
             
Table 8.6. List of modulated proteins (P < 0.05) in rBM-MSCs at different ages classified according to their principal biological process using iTRAQ-8plex. I/N= 
infant vs newborn; Y/I=young vs infant; PP/Y= pre-pubertal vs young; P/PP= pubertal vs pre-pubertal; A/P= adult vs pubertal. 
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Accession Name 
Peptides 
(95%) I/ N PVal I/N Y/I PVal Y/I PP/Y PVal PP/Y P/PP PVal P/PP A/P PVal A/P 
             
P97601 Chaperonin 10  3 1.0204 0.7796 1.0011 0.9902 0.9415 0.5177 0.939 0.4419 1.4235 0.0087 
G3V936 Citrate synthase  3 0.7934 0.0267 1.167 0.0848 0.7904 0.0267 1.1452 0.2405 0.857 0.2318 
F1M779 Clathrin heavy chain  9 1.2157 0.0137 1 0.9994 0.9612 0.7295 1.1343 0.2338 0.8853 0.3235 
Q6TUH9 
Corticosteroid 11-beta-
dehydrogenase isozyme 1  3 0.7341 0.2686 1.3756 0.2277 1.6421 0.0328 1.9857 0.0672 0.7338 0.0642 
P47875 Cysteine and glycine-rich protein 1  7 1.0015 0.9815 1.0448 0.5131 1.2576 0.0488 0.6896 0.0389 1.2501 0.0705 
O08651 
D-3-phosphoglycerate 
dehydrogenase  3 0.8786 0.1902 0.7465 0.0308 1.1981 0.1105 1.1565 0.1448 1.0565 0.5069 
Q5BJ93 Enolase 1. (Alpha)  23 1.0226 0.655 1.026 0.5722 1.054 0.2406 0.7412 0 1.2752 0.0123 
Q8R4A1 ERO1-like protein alpha  5 0.8236 0.0936 1.0042 0.9607 1.1541 0.1632 1.0604 0.6296 1.4685 0.0439 
P05065 Fructose-bisphosphate aldolase A  7 0.7852 0.0001 0.9961 0.9275 1.1519 0.0055 1.17 0.0228 1.1494 0.0589 
P11762 Galectin-1 13 0.8947 0.1869 1.0817 0.3224 0.9378 0.4491 0.738 0.0127 1.2891 0.0226 
Q8CJG5 Gene  3 0.9562 0.7992 0.6552 0.233 1.5338 0.0488 1.0942 0.6762 0.9227 0.7939 
P05370 
Glucose-6-phosphate 1-
dehydrogenase  16 1.0157 0.847 1.0285 0.7414 0.9947 0.9314 1.0827 0.1708 1.2136 0.0003 
Q6P6V0 Glucose-6-phosphate isomerase  13 0.859 0.1021 0.9669 0.5321 1.1179 0.0929 1.1489 0.1394 1.2446 0.0072 
P04797 
Glyceraldehyde-3-phosphate 
dehydrogenase  28 1.0559 0.3012 1.2268 0.0077 0.8176 0.0404 1.0972 0.4988 0.8495 0.1048 
P56574 
Isocitrate dehydrogenase [NADP]. 
mitochondrial  3 1.0223 0.8926 1.0131 0.8828 0.8721 0.3389 1.3609 0.025 0.8545 0.1231 
B5DEN4 L-lactate dehydrogenase  14 0.7058 0.0001 1.146 0.00197 1.1828 0.0191 1.2617 0 1.416 0 
Q6P7A9 Lysosomal alpha-glucosidase  4 0.9754 0.7869 1.0694 0.6226 1.4268 0.048 0.8687 0.254 1 1 
Q6AYC4 Macrophage-capping protein  2 1.1578 0.3404 1.3646 0.0086 0.8334 0.049 0.7546 0.0948 1.3655 0.0617 
F1LP60 Moesin (Fragment)  40 1.0168 0.6741 0.8227 0.0003 1.4257 0 0.9895 0.8299 0.9461 0.1782 
P20070 NADH-cytochrome b5 reductase 3  2 0.7339 0.0716 1.4911 0.0447 0.9088 0.5256 0.9743 0.903 0.8315 0.169 
Q6XD99 Non-erythroid spectrin beta  2 1.3375 0.0053 1.0624 0.4554 1.1109 0.3101 0.7568 0.0122 1.5134 0.0041 
P16617 Phosphoglycerate kinase 1  29 0.775 0 1.0397 0.3579 1.0241 0.6829 1.1179 0.0446 1.3076 0 
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P25113 Phosphoglycerate mutase 1  9 0.7559 0.0052 1.1081 0.1211 1.1188 0.142 1.105 0.1848 1.3205 0.0024 
P54001 Prolyl 4-hydroxylase subunit alpha-1  15 0.9432 0.3007 0.923 0.1417 1.26 0.0005 0.779 0.0002 0.9234 0.2253 
M0R9D5 Protein Ahnak  60 1.4134 0 0.9734 0.2788 1.2761 0 0.8082 0 2.1551 0 
D3ZIE9 Protein Aldh18a1  5 1.2134 0.1403 1.038 0.7002 0.5751 0.0236 0.8643 0.2248 0.7301 0.0622 
M0R3X6 Protein LOC100912203  6 0.8645 0.163 1.0325 0.6321 1.1276 0.2248 0.9918 0.9068 1.2992 0.0104 
D4A5L9 Protein LOC679794  4 0.6761 0.0039 1.6157 0.0178 0.7517 0.0082 0.9865 0.8661 1.0755 0.375 
Q6P9U0 Protein Serpinb6  8 0.9886 0.8679 1.0239 0.6691 1.3013 0.0066 0.8823 0.2774 1.1196 0.16 
D3ZF39 Protein Uap1  10 1.0277 0.7709 1.0072 0.947 1.6544 0.0038 0.9744 0.7756 1.6238 0.0005 
B0BMT0 RCG47746. isoform CRA_a  90 1.0669 0.6161 0.7141 0.0061 1.4858 0.0047 0.5813 0.0012 0.7691 0.1418 
Q6IRL3 Reticulon  7 1.0111 0.8671 0.8818 0.3109 1.3224 0.0677 0.7406 0.0052 0.9133 0.4439 
B2GVB1 S100 calcium binding protein A6 3 1.0605 0.5609 1.2045 0.2186 1.7118 0.0122 0.3918 0.0244 1.665 0.037 
Q5U3Z7 Serine hydroxymethyltransferase  3 0.7739 0.0051 0.9472 0.5152 1.0085 0.9511 1.1442 0.2328 1.0402 0.831 
F1M953 Stress-70 protein. mitochondrial  12 0.9377 0.2437 0.7924 0.0057 1.174 0.0025 0.8961 0.1199 1.5666 0 
P48500 Triosephosphate isomerase  16 0.6753 0.0004 1.174 0.0315 1.0854 0.3958 1.2639 0.1091 1.4017 0.0001 
Q9Z1A6 Vigilin  3 1.1784 0.0874 0.8426 0.0918 1.0244 0.862 0.9978 0.9727 1.2104 0.0345 
P81155 
Voltage-dependent anion-selective 
channel protein 2  6 1.0012 0.9931 1.0633 0.4458 1.2708 0.0343 0.8377 0.1616 0.992 0.9444 
Pluripotency 
            
P63102 14-3-3 protein zeta/delta  24 0.9971 0.9573 0.9743 0.6297 1.0748 0.2065 0.8947 0.1104 1.1562 0.0250 
Q7TP91 Ab1-205  3 0.9802 0.8434 1.2607 0.1387 0.9026 0.3795 1.0629 0.7975 0.6232 0.0302 
Q64640 Adenosine kinase  2 0.9609 0.8197 1.1207 0.3134 1.1155 0.346 1.0828 0.4536 0.6855 0.0454 
P39069 Adenylate kinase isoenzyme 1  4 0.7781 0.0775 1.2606 0.053 1.0747 0.7679 0.9795 0.8759 1.6777 0.029 
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P23928 Alpha-crystallin B chain  5 1.207 0.0573 1.8689 0.0119 2.2257 0.0003 0.2931 0.0035 1.5629 0.0723 
Q6IMZ3 Annexin A6 24 1.2484 0.0001 1.1079 0.0199 0.9791 0.5623 1.0031 0.9354 1.0187 0.5863 
Q07936 Annexin A2  22 1.2928 0 1.0234 0.6825 1.368 0.0001 0.8172 0.003 1.072 0.1567 
Q05175 Brain acid soluble protein 1  3 0.9481 0.8617 1.209 0.454 1.3727 0.148 0.4584 0.0445 1.6462 0.1009 
Q6T487 
Brain-specific alpha actinin 1 
isoform  48 0.7786 0.0007 1.1584 0.0465 1.0249 0.6506 0.8259 0.0018 1.1052 0.2188 
Q8R4A2 Caveolin 1 (Fragment)  4 0.9676 0.8582 1.8465 0.0328 1.0661 0.7396 0.7326 0.1573 1.0726 0.6061 
P02454 Collagen alpha-1(I) chain  21 1.9314 0.0008 0.4642 0 1.3783 0 1.1251 0.0342 1.123 0.1023 
F1LS40 Collagen alpha-2(I) chain  19 1.486 0.0008 0.6971 0 1.1467 0.0083 0.9555 0.2908 1.3211 0.0003 
F1LMA7 C-type mannose receptor 2  5 1.1259 0.191 0.8731 0.3184 0.8322 0.3836 0.8408 0.3689 1.7697 0.0009 
P47875 Cysteine and glycine-rich protein 1  5 1.0995 0.2349 0.9264 0.4028 1.275 0.0227 0.7329 0.0396 1.2025 0.1773 
Q6AYI1 
DEAD (Asp-Glu-Ala-Asp) box 
polypeptide 5  9 0.9335 0.2865 0.9937 0.9257 0.8965 0.0659 1.2504 0.0032 0.9596 0.434 
Q62952 
Dihydropyrimidinase-related protein 
3  8 1.2443 0.0364 1.5656 0.0028 0.858 0.2853 0.8247 0.0165 1.0088 0.9184 
Q4V8H8 EH domain-containing protein 2  0 0.9656 0.7399 1.3396 0.2041 0.8004 0.248 1.6703 0.0471 0.7495 0.491 
Q68FR6 Elongation factor 1-gamma  9 1.0087 0.8562 0.9072 0.4157 1.2134 0.0011 0.9535 0.5667 0.8485 0.0109 
C0JPT7 Filamin alpha  100 1.2134 0 1.3022 0 0.8202 0 0.9147 0.0068 1.386 0 
D4A8D5 Filamin. beta (Predicted)  19 1.0951 0.0867 1.2541 0.0012 0.8193 0.0061 0.7937 0.0124 1.329 0.0009 
B6DYQ7 Glutathione S-transferase pi  4 1.0946 0.3206 1.1008 0.6055 1.5111 0.0241 3.1507 0.0004 0.3406 0.0033 
G3V913 Heat shock 27kDa protein 1  5 1.6407 0.0562 0.9647 0.8462 1.5674 0.0118 0.636 0.038 1.3145 0.0077 
Table 8.6. List of modulated proteins (P < 0.05) in rBM-MSCs at different ages classified according to their principal biological process using iTRAQ-8plex. I/N= 
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P63018 Heat shock cognate 71 kDa protein  30 0.9815 0.6625 1.2334 0.0221 0.8841 0.0143 1.0164 0.8526 1.1903 0.0184 
F1M3D3 
Heterogeneous nuclear 
ribonucleoprotein M  3 0.6983 0.0017 1.0334 0.5966 0.9158 0.4502 1.1725 0.1239 1.0388 0.7714 
Q6IMY8 
Heterogeneous nuclear 
ribonucleoprotein U  8 0.7965 0.0032 1.0228 0.7409 0.9994 0.9956 1.1924 0.0262 0.8534 0.1414 
P15865 Histone H1.4  8 0.7411 0.0048 2.4013 0.0005 1.0711 0.2301 0.5016 0.0007 0.6377 0.007 
D3ZBN0 Histone H1.5  4 1.911 0.0166 0.4907 0.0135 0.9905 0.9189 1.4031 0.0552 0.8838 0.2767 
G3V9C7 Histone H2B  20 1.2535 0.0051 0.9957 0.9764 0.8311 0.1792 1.4957 0.0005 0.7706 0.0027 
M0RBX6 Histone H3  6 1.1323 0.058 1.4413 0.0125 1.201 0.0272 0.5991 0.0004 0.494 0.0002 
P62804 Histone H4  13 1.4819 0.0057 0.5999 0.0004 1.1515 0.0641 1.7155 0.0008 0.6785 0.002 
Q6P6G9 Hnrpa1 protein   8 0.6091 0.0304 0.9626 0.6587 0.943 0.663 1.1142 0.7189 0.969 0.7865 
P50503 Hsc70-interacting protein   4 0.9785 0.7614 1.0509 0.7519 1.1426 0.4415 0.8392 0.2581 1.5699 0.0074 
P49134 Integrin beta-1  6 1.5471 0.0002 0.9023 0.1179 1.5398 0.0098 0.7217 0.0064 1.311 0.0037 
G3V7Q7 
IQ motif containing GTPase 
activating protein 1 (Predicted). 
isoform CRA_b  29 0.9058 0.0331 0.8665 0.0016 1.2223 0 1.0398 0.2744 0.8961 0.0032 
G3V8L3 Lamin A. isoform CRA_b  26 0.9048 0.0029 0.968 0.4478 1.1812 0.0001 1.0126 0.746 1.2067 0 
Q6TXE9 LRRGT00050  4 0.8206 0.0425 0.8878 0.4999 1.0972 0.6832 1.5 0.0036 0.8044 0.129 
Q6TUD1 LRRGT00113  2 0.7362 0.0289 1.0159 0.9238 1.0387 0.7991 1.0836 0.5779 0.9606 0.8364 
Q5M7W5 Microtubule-associated protein 4  2 1.6111 0.1601 0.845 0.5023 1.0907 0.433 0.6693 0.1236 1.6243 0.0414 
B2GV99 Myl6 protein  11 1.0049 0.9535 1.1269 0.1948 1.0655 0.29 0.9193 0.1676 1.3394 0.0011 
Table 8.6. List of modulated proteins (P < 0.05) in rBM-MSCs at different ages classified according to their principal biological process using iTRAQ-8plex. I/N= 
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G3V9Y1 
Myosin. heavy polypeptide 10. non-
muscle. isoform CRA_b  51 0.9356 0.0771 1.0793 0.1827 0.8786 0.0186 0.8988 0.0205 0.792 0.0018 
G3V6P7 
Myosin. heavy polypeptide 9. non-
muscle  98 0.9405 0.0071 1.1877 0 1.0117 0.6464 0.957 0.2338 1.3299 0 
P05982 
NAD(P)H dehydrogenase [quinone] 
1  8 1.3454 0.0036 0.7746 0.0108 1.2457 0.0611 0.817 0.2198 1.7303 0.0017 
G3V8R1 Nucleobindin 2. isoform CRA_b  3 0.7234 0.0259 2.0743 0.0023 0.5945 0.0061 0.8133 0.1039 1.5101 0.0176 
F1M4W3 Palladin (Fragment)  6 1.0033 0.9633 0.8726 0.1096 1.0418 0.6509 0.6823 0.0117 1.0929 0.2707 
P52944 PDZ and LIM domain protein 1  8 1.0741 0.3026 1.0802 0.1599 1.3743 0.0005 0.9648 0.7456 1.2349 0.03 
Q62920 PDZ and LIM domain protein 5  17 0.9467 0.5156 0.6947 0.0022 1.4784 0.0057 0.6885 0.0358 0.8014 0.071 
Q6AYQ9 Peptidyl-prolyl cis-trans isomerase  6 0.9218 0.2069 0.9782 0.6989 1.2033 0.0649 0.7408 0.0209 0.837 0.0475 
Q62658 
Peptidyl-prolyl cis-trans isomerase 
FKBP1A  2 1.254 0.0638 1.1087 0.2151 1.0291 0.6981 0.8516 0.0786 1.38 0.0149 
D3ZAF5 
Periostin. osteoblast specific factor 
(Predicted). isoform CRA_a    4 0.5315 0.1266 1.4489 0.0583 0.7663 0.0352 1.3251 0.0507 0.8907 0.4068 
Q63716 Peroxiredoxin-1  13 0.8935 0.0404 1.0622 0.5224 1.083 0.5586 0.884 0.3841 1.2919 0.0335 
P35704 Peroxiredoxin-2 5 0.9438 0.6729 1.3399 0.0331 0.9268 0.3898 0.8375 0.2252 1.1003 0.4352 
Q9R063 Peroxiredoxin-5. mitochondrial  5 1.0571 0.6808 0.7826 0.0577 1.2214 0.0908 0.8798 0.195 1.4277 0.0498 
F1LPK7 Phospholipid scramblase 3  5 1.3539 0.015 0.7564 0.0206 1.2564 0.0285 0.9783 0.8008 1.0061 0.9704 
G3V8L9 
Polymerase I and transcript release 
factor  10 1.0181 0.7755 1.5741 0.0001 1.2442 0.0026 0.6574 0.0001 1.2032 0.1746 
Table 8.6. List of modulated proteins (P < 0.05) in rBM-MSCs at different ages classified according to their principal biological process using iTRAQ-8plex. I/N= 
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G3V9I0 
Procollagen-lysine.2-oxoglutarate 5-
dioxygenase 2  15 0.6772 0.0001 1.3393 0.0139 0.8435 0.0459 1.1106 0.2824 1.033 0.765 
D3ZRX9 Protein Cnn2  9 0.9803 0.7232 0.9782 0.6955 1.1542 0.0382 0.7727 0.0037 1.1053 0.1116 
G3V6T7 
Protein disulfide isomerase 
associated 4  4 1.094 0.3778 1.5291 0.0042 0.7583 0.087 0.8527 0.0368 1.1596 0.0466 
P04785 Protein disulfide-isomerase  18 0.9524 0.2161 0.9019 0.0205 1.1449 0.002 0.91 0.0672 1.3562 0 
P11598 Protein disulfide-isomerase A3  23 1.0044 0.9331 1.1813 0.0003 1.0096 0.899 0.888 0.1863 1.151 0.1114 
Q63081 Protein disulfide-isomerase A6 9 0.7832 0.0043 1.1044 0.262 1.2788 0.0234 0.9335 0.4195 1.0394 0.5727 
D3ZHA0 Protein Flnc  28 0.9537 0.2739 1.6131 0 0.8375 0.0128 0.9354 0.1802 1.1796 0.0125 
E2RUH2 Protein LOC100360501  3 0.8715 0.4837 1.2547 0.0379 0.7763 0.024 1.2418 0.1487 0.7978 0.0359 
M0R7B4 Protein LOC684828 6 1.9171 0.003 0.4959 0.0035 1.0813 0.3542 1.3227 0.0305 0.8447 0.1021 
F1MA29 Protein LOC685520  5 0.7506 0.0026 1.15 0.0892 0.9181 0.414 1.0561 0.438 1.066 0.4416 
D3ZUB0 Protein Rcn1  2 1.0185 0.8167 0.8941 0.2217 1.1262 0.2053 0.8607 0.297 1.3273 0.0313 
I6L9G5 Protein Rcn3  2 1.0873 0.4834 0.5646 0.023 1.147 0.2936 0.9716 0.7715 1.3833 0.2381 
D4A1P2 Protein Rpl10l  7 1.0101 0.8587 0.8912 0.0814 0.8855 0.0554 1.4153 0.0002 0.6894 0.0001 
F1M853 Protein Rrbp1 12 0.9865 0.8266 0.9487 0.2254 1.4058 0.0002 0.6416 0.0002 1.4396 0 
P05942 Protein S100-A4  8 1.3344 0.0883 0.8596 0.3432 2.371 0.0005 0.6816 0.0449 1.6256 0.0034 
B0BMT9 Protein Sqrdl  5 0.8772 0.1123 0.8745 0.2138 1.3482 0.0318 0.672 0.0272 1.1637 0.2917 
P50399 Rab GDP dissociation inhibitor beta  5 0.6527 0 1.1226 0.1842 0.8087 0.0191 1.2167 0.0909 0.8327 0.0497 
Q5FVG5 
Similar to tropomyosin 1. embryonic 
fibroblast-rat. isoform CRA_c  21 0.8189 0.0635 0.8236 0.0664 1.5332 0.0055 0.4284 0.0029 0.9622 0.622 
Table 8.6. List of modulated proteins (P < 0.05) in rBM-MSCs at different ages classified according to their principal biological process using iTRAQ-8plex. I/N= 
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Q6IRH6 Slc25a3 protein  5 0.6221 0.0046 1.2418 0.0813 0.9018 0.3869 1.2937 0.0271 0.7334 0.0095 
P06685 
Sodium/potassium-transporting 
ATPase subunit alpha-1  6 1.0612 0.5229 0.847 0.0206 0.9521 0.6531 1.1204 0.4092 0.8973 0.1495 
P16975 SPARC  5 1.2574 0.0585 0.8963 0.1879 1.0501 0.5303 0.9358 0.5629 1.2361 0.0437 
Q63413 Spliceosome RNA helicase Ddx39b  4 0.7567 0.0206 1.0276 0.7991 0.904 0.431 1.3219 0.0189 0.679 0.0523 
Q6IRK8 Spna2 protein  9 1.3867 0 1.211 0.003 1.0232 0.7136 0.7877 0.0016 1.7205 0 
D4A8Y5 
Staphylococcal nuclease domain-
containing protein 1  3 0.919 0.451 1.2908 0.0445 0.8256 0.0815 1.2376 0.0644 0.7802 0.1202 
Q71SA3 Thrombospondin 1  7 0.8058 0.0398 0.7166 0.0007 1.3192 0.0007 0.9713 0.6767 1.4974 0.0023 
P31232 Transgelin 39 1.2096 0.0003 1.2967 0.0743 1.133 0.0136 0.5637 0.0001 1.7372 0 
Q5XFX0 Transgelin-2  17 0.9888 0.8414 1.0039 0.955 1.3666 0.0009 0.9786 0.7678 1.1396 0.048 
Q6AYT3 tRNA-splicing ligase RtcB homolog  4 0.6896 0.019 0.9867 0.8815 0.8815 0.1894 1.1372 0.1808 0.8525 0.4565 
Q63610 Tropomyosin alpha-3 chain 9 0.9843 0.838 1.4987 0.0199 1.2255 0.0709 0.6776 0.0538 1.8819 0.0153 
P09495 Tropomyosin alpha-4 chain  12 0.9739 0.7802 1.356 0.0682 1.0117 0.925 0.8335 0.1905 1.5771 0.0401 
G3V6C4 UDP-glucose 6-dehydrogenase  8 1.0597 0.478 0.9444 0.6809 1.256 0.011 1.0009 0.9911 1.4008 0.0135 
Q63355 Unconventional myosin-Ic  10 1.2333 0.0007 0.8095 0.0071 1.2252 0.0431 1.0652 0.3451 0.8854 0.0253 
P31000 Vimentin  110 1.0703 0.0545 1.0991 0.0394 1.1756 0.0018 0.76 0 0.9955 0.9047 
Proliferation 
           
 
           
P62268 40S ribosomal protein S23  3 1.0729 0.3955 0.7949 0.0312 1.0116 0.8769 0.9447 0.6609 1.0981 0.4568 
Table 8.6. List of modulated proteins (P < 0.05) in rBM-MSCs at different ages classified according to their principal biological process using iTRAQ-8plex. I/N= 
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M0RD75 40S ribosomal protein S6 (Fragment)  5 1.213 0.0348 0.7478 0.0343 1.0648 0.6105 0.8839 0.3222 1.2172 0.0637 
B2RYR8 40S ribosomal protein S8  5 1.156 0.0743 0.7651 0.0113 0.9563 0.6408 1.1034 0.3318 1.0474 0.6037 
P29314 40S ribosomal protein S9  10 1.2232 0.0078 0.7297 0.0002 1.1604 0.014 1.0442 0.4378 1.0231 0.6427 
P38983 40S ribosomal protein SA  7 1.0045 0.948 0.8267 0.0864 1.0707 0.3666 1.3083 0.0159 0.8177 0.0379 
P63039 
60 kDa heat shock protein. 
mitochondrial  14 1.0284 0.7397 1.0424 0.6331 1.0209 0.827 0.7502 0.0126 1.1048 0.3793 
Q6PDV7 60S ribosomal protein L10  8 1.2944 0.0232 0.7476 0.0503 1.0811 0.4911 0.9186 0.3735 1.079 0.2893 
P41123 60S ribosomal protein L13  4 1.2788 0.1225 0.8351 0.0607 1.0613 0.7175 1.269 0.0179 0.8472 0.0781 
P61314 60S ribosomal protein L15  2 1.0608 0.6431 0.9332 0.5211 0.8939 0.228 1.6856 0.0065 0.7429 0.0338 
Q0QEW8 
60S ribosomal protein L18 
(Fragment)  3 0.8899 0.3903 1.0505 0.6391 0.9184 0.5621 1.4963 0.0365 0.7225 0.0735 
P62718 60S ribosomal protein L18a  4 1.0118 0.8521 0.8707 0.2832 1.0157 0.9288 1.3147 0.032 0.8694 0.1711 
P62832 60S ribosomal protein L23  6 1.2256 0.0212 0.838 0.0334 0.9969 0.9615 0.9723 0.8064 1.1553 0.1309 
P83732 60S ribosomal protein L24  7 1.5524 0.0024 0.5064 0.0004 1.2108 0.0391 0.8698 0.2155 1.2834 0.0175 
P25886 60S ribosomal protein L29  3 1.5331 0.0443 0.9651 0.7362 1.0984 0.4167 0.8404 0.5923 0.7419 0.2733 
P21531 60S ribosomal protein L3  5 1.0552 0.6436 0.8494 0.0879 0.932 0.5476 1.463 0.0213 0.7223 0.0148 
Q6P3V9 60S ribosomal protein L4  9 1.419 0.0021 0.627 0.0002 1.0227 0.7849 0.9688 0.6057 1.139 0.0543 
P09895 60S ribosomal protein L5  6 0.9424 0.3628 0.9732 0.6933 0.9466 0.5073 1.2345 0.0225 0.8597 0.1305 
H7C5Y5 60S ribosomal protein L6  7 1.3496 0.0261 0.6716 0.0068 1.0461 0.66 1.0542 0.451 1.0501 0.6358 
Q6P790 60S ribosomal protein L6 (Fragment)  7 1.2191 0.0025 1.0302 0.7281 1.0286 0.6572 0.8965 0.2512 0.987 0.8763 
Table 8.6. List of modulated proteins (P < 0.05) in rBM-MSCs at different ages classified according to their principal biological process using iTRAQ-8plex. I/N= 
infant vs newborn; Y/I=young vs infant; PP/Y= pre-pubertal vs young; P/PP= pubertal vs pre-pubertal; A/P= adult vs pubertal. 
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Accession Name 
Peptides 
(95%) I/ N PVal I/N Y/I PVal Y/I PP/Y PVal PP/Y P/PP PVal P/PP A/P PVal A/P 
             
P05426 60S ribosomal protein L7  5 1.3498 0.0462 0.6788 0.065 1.1405 0.3092 0.9309 0.3885 1.0532 0.5387 
P85970 
Actin-related protein 2/3 complex 
subunit 2  11 0.9564 0.6557 0.9226 0.2715 1.3327 0.0061 1.0044 0.938 1.0774 0.3839 
Q9Z1P2 Alpha-actinin-1  77 0.8727 0.0028 0.8694 0.0002 1.3424 0.0013 0.8164 0.0001 0.9543 0.1358 
Q9QXQ0 Alpha-actinin-4  50 1.2074 0.0004 1.1204 0.037 1.0349 0.3567 0.9069 0.2105 1.1419 0.036 
Q66HH8 Annexin 5 9 0.9925 0.8998 1.0383 0.7603 0.9707 0.811 0.9909 0.8915 1.4149 0.0034 
P45592 Cofilin-1  12 1.2442 0.0041 1.0603 0.5475 1.0804 0.2025 0.9203 0.5481 1.2685 0.011 
D3ZH41 
Cytoskeleton-associated protein 4 
(Predicted)  12 0.7853 0.0004 1.107 0.0513 0.9476 0.3458 0.7919 0.0005 1.2344 0.0033 
Q6AYH5 Dynactin subunit 2  3 1.151 0.2739 0.8845 0.3112 1.1661 0.2508 0.8114 0.3778 1.3787 0.0248 
P52555 
Endoplasmic reticulum resident 
protein 29  2 1.0186 0.8459 1.3064 0.1141 1.2519 0.2488 0.8626 0.2226 1.5742 0.0319 
Q6P3V8 
Eukaryotic translation initiation 
factor 4A1  13 1.0465 0.4461 0.8673 0.0328 1.055 0.416 1.0269 0.6429 0.7893 0.0001 
P04937 Fibronectin  17 1.1267 0.3104 0.7887 0.0119 1.2538 0.0001 0.6481 0.0907 2.4985 0.0056 
Q6P792 Four and a half LIM domains 1  6 0.7431 0.0006 1.7903 0.0001 1.1108 0.096 0.7768 0.0085 0.8731 0.0375 
P11762 Galectin-1 OS=Rattus norvegicus  14 0.7674 0.0204 0.7313 0.053 1.2804 0.0564 0.8213 0.4313 1.1116 0.227 
B6DYQ2 Glutathione S-transferase mu 2  5 1.1023 0.4484 1.0507 0.6202 0.8053 0.0678 0.8616 0.3082 1.2838 0.0235 
P63245 
Guanine nucleotide-binding protein 
subunit beta-2-like 1  6 1.0188 0.7481 0.8543 0.044 1.0255 0.6962 1.0046 0.963 0.9843 0.8938 
Q6P7Q4 Lactoylglutathione lyase  6 0.8942 0.2376 0.9113 0.2336 1.2099 0.0449 0.9186 0.2639 1.0132 0.8509 
Q99MZ8 LIM and SH3 domain protein 1  5 1.4773 0.0032 1.0103 0.9316 1.1251 0.1144 0.7622 0.0071 1.3922 0.0031 
Table 8.6. List of modulated proteins (P < 0.05) in rBM-MSCs at different ages classified according to their principal biological process using iTRAQ-8plex. I/N= 
infant vs newborn; Y/I=young vs infant; PP/Y= pre-pubertal vs young; P/PP= pubertal vs pre-pubertal; A/P= adult vs pubertal. 
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Accession Name 
Peptides 
(95%) I/ N PVal I/N Y/I PVal Y/I PP/Y PVal PP/Y P/PP PVal P/PP A/P PVal A/P 
             
O08557 
N(G).N(G)-dimethylarginine 
dimethylaminohydrolase 1  4 0.8682 0.4556 2.2145 0.0173 0.5358 0.0395 0.7504 0.1763 1.2909 0.0453 
Q6S3A0 Plectin 6  28 1.0437 0.2665 0.9378 0.1139 1.1564 0.0026 0.996 0.9259 1.2269 0.0027 
D4A4Z9 Protein Ktn1  7 0.9773 0.8388 0.901 0.2289 1.3423 0.0487 0.7373 0.0131 1.0952 0.3487 
D3ZPL5 Protein LOC100361311  10 1.2843 0.0356 0.683 0.017 1.0148 0.8697 0.9663 0.7274 1.1144 0.0623 
M0RCY2 Protein LOC683961  6 0.9886 0.9133 0.9596 0.6555 0.761 0.0353 1.4335 0.0202 0.591 0.0003 
D3ZN21 Protein RGD1309586  6 0.951 0.6075 0.9746 0.7735 0.957 0.6381 1.2502 0.0226 0.8539 0.0205 
D4A6W6 Protein RGD1561333  6 1.7423 0.0038 0.5049 0.0038 1.2265 0.2464 0.8945 0.5405 1.1717 0.2285 
D4A6W6 Protein RGD1561333  5 1.1352 0.1387 1.0601 0.5478 0.9173 0.2914 1.5332 0.0034 0.6202 0.0124 
F1LT35 Protein RGD1564606 (Fragment)  6 1.1172 0.1379 1.1037 0.4799 1.0681 0.4407 0.772 0.0124 1.2544 0.0157 
G3V852 Protein Tln1  38 1.2686 0 1.2229 0 0.8272 0 0.9642 0.3307 1.3768 0 
Q4QQV0 Protein Tubb6  22 1.0776 0.4062 0.8668 0.3417 1.2995 0.0298 0.946 0.6332 1.0638 0.6569 
Q6P3E1 Rps16 protein (Fragment)  7 1.6881 0.0047 0.5471 0.0061 1.508 0.0481 0.8378 0.1083 1.2384 0.0629 
Q9QZR6 Septin-9  6 1.0595 0.4348 0.9334 0.3019 1.2185 0.0277 0.8772 0.1483 1.017 0.8438 
Q6LDS4 Superoxide dismutase [Cu-Zn]  6 1.1464 0.0737 1.169 0.0483 0.8679 0.0643 1.0068 0.9549 1.3603 0.0094 
P07895 
Superoxide dismutase [Mn]. 
mitochondrial  10 0.76 0.2573 0.9976 0.9829 2.2825 0.02 1.074 0.2946 1.3438 0.0046 
P28480 T-complex protein 1 subunit alpha  6 0.7782 0.0579 1.5251 0.0086 0.9731 0.7177 1.2381 0.2501 0.9675 0.8659 
Q68FQ0 T-complex protein 1 subunit epsilon  4 0.8933 0.2273 1.0047 0.9576 0.9601 0.7021 1.1826 0.1497 0.8175 0.0229 
Q6P502 T-complex protein 1 subunit gamma  5 1.0456 0.4189 0.8549 0.0333 1.0502 0.74 1.0936 0.3134 0.9009 0.3475 
Table 8.6. List of modulated proteins (P < 0.05) in rBM-MSCs at different ages classified according to their principal biological process using iTRAQ-8plex. I/N= 
infant vs newborn; Y/I=young vs infant; PP/Y= pre-pubertal vs young; P/PP= pubertal vs pre-pubertal; A/P= adult vs pubertal. 
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Accession Name 
Peptides 
(95%) I/ N PVal I/N Y/I PVal Y/I PP/Y PVal PP/Y P/PP PVal P/PP A/P PVal A/P 
             
P11232 Thioredoxin  9 0.9519 0.7004 0.9806 0.8828 1.1098 0.4942 0.9058 0.4438 1.2619 0.0373 
Q99PD6 
Transforming growth factor beta-1-
induced transcript 1 protein  6 1.0858 0.7029 0.7535 0.8138 1.2703 0.2603 0.635 0.0115 0.8607 0.8969 
P68370 
Tubulin alpha-1A chain OS=Rattus 
norvegicus GN=Tuba1a PE=1 SV=1 19 1.1996 0.0477 1.1154 0.0721 0.7776 0.0946 0.9411 0.7092 0.7696 0.0004 
R9PXU6 Vinculin  57 1.1908 0 0.9981 0.9534 1.4169 0 0.8383 0.0001 1.1453 0 
Table 8.6. List of modulated proteins (P < 0.05) in rBM-MSCs at different ages classified according to their principal biological process using iTRAQ-8plex. I/N= 
infant vs newborn; Y/I=young vs infant; PP/Y= pre-pubertal vs young; P/PP= pubertal vs pre-pubertal; A/P= adult vs pubertal. 
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Abstract: Mesenchymal stem cells (MSCs) are undifferentiated cells with an unlimited 
capacity for self-renewal and able to differentiate towards specific lineages under 
appropriate conditions. MSCs are, a priori, a good target for cell therapy and clinical trials 
as an alternative to embryonic stem cells, avoiding ethical problems and the chance for 
malignant transformation in the host. However, regarding MSCs, several biological 
implications must be solved before their application in cell therapy, such as safe ex vivo 
expansion and manipulation to obtain an extensive cell quantity amplification number for 
use in the host without risk accumulation of genetic and epigenetic abnormalities. Cell 
surface markers for direct characterization of MSCs remain unknown, and the precise 
molecular mechanisms whereby growth factors stimulate their differentiation are still 
missing. In the last decade, quantitative proteomics has emerged as a promising set of 
techniques to address these questions, the answers to which will determine whether MSCs 
retain their potential for use in cell therapy. Proteomics provides tools to globally analyze 
cellular activity at the protein level. This proteomic profiling allows the elucidation of 
connections between broad cellular pathways and molecules that were previously 
impossible to determine using only traditional biochemical analysis. However; thus far, the 
results obtained must be orthogonally validated with other approaches. This review will 
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focus on how these techniques have been applied in the evaluation of MSCs for their future 
applications in safe therapies. 
Keywords: mesenchymal stem cell; proteomic analysis; characterization; differentiation  
 
Abbreviations:  
DIGE difference in-gel electrophoresis 
2D-PAGE two-dimensional polyacrylamide gel electrophoresis 
ESI electrospray ionization 
GELFREE gel-eluted liquid fraction entrapment electrophoresis 
IEF iso-electric focusing 
IMAC immobilized metal ion affinity chromatography 
iTRAQ isobaric tags for relative and absolute quantification 
LC liquid chromatography 
LCM laser capture micro-dissection 
MALDI-MSI matrix-assisted laser desorption ionization mass spectrometry imaging 
MSCs mesenchymal stem cells 
18O (18)O-labeling of reactive carbonyl modifications 
PCR polymerase chain reaction 
PMF peptide mass fingerprinting 
SELDI-TOF-MS surface enhanced laser desorption/ionization-time of flight-mass spectrometry 
SCX strong cation exchange 
SDS-PAGE sodium dodecyl sulfate polyacrylamide gel electrophoresis 
SID stable isotope dilution 
SILAC stable isotope labeling by/with amino acids in cell culture 
Ti20 tolerable intake 20 
1. Introduction  
Mesenchymal stem cells (MSCs) are multipotent cells with an important potential in human 
regenerative medicine because of their ability to migrate to sites of injury [1], their capability of 
suppressing the immune response [2] and their accessibility in large numbers from the patient’s own 
bone marrow or fat tissue. It has been increasingly observed that the transplanted MSCs do not 
necessarily engraft and differentiate at the site of injury, but might exert their therapeutic effects 
through secreted trophic signals [3]. MSCs secrete a variety of autocrine/paracrine factors that make 
up the secretome, which supports regenerative processes in the damaged tissue, induces angiogenesis, 
protects cells from apoptotic cell death and modulates the immune system. The MSC secretome has 
become a subject of intensive proteomic profiling in the search for and identification of released 
factors and microvesicles that might be applicable in regenerative medicine. Jointly with the methods 
for MSC isolation, expansion and differentiation, proteomic secretome analysis of MSC has been 
increased in use, mainly due to the extensive development of protein separation techniques and mass 
spectrometry, recently reviewed by Skalnikova et al. [4]. This review will focus on the study of the 
intracellular proteome. 
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The term proteomics encompasses all research methodologies aimed at qualitative and quantitative 
study of the proteins, or proteome, present in a cell type, tissue or organism at a given stage of 
development [5]. In the last decade, there has been an exponential increase in the use of these 
techniques in translational research, due in large part to the progress in state-of-the-art mass 
spectrometry. With this technique, developed in the middle of the last century [6], it is possible to 
calculate, with remarkable accuracy, the mass/charge ratio of any compound that can ionize, as well as 
the mass/charge ratio of the fragments originated by the collision of the compound with an inert gas. 
The accuracy in the measurement is so high that it is actually possible to identify the compound. In the 
case of proteomics, mass spectrometers are designed to identify and quantify peptides and proteins in a 
very sensitive and high-throughput manner. It has been widely accepted that proteomics can never 
replace, but complements, genomic information [7,8]. First, unlike what happens in genomics, 
proteomics studies lack a technique, such as polymerase chain reaction (PCR), to amplify these very 
low abundance molecules for study. This greatly complicates the study of very scarce proteins, such as 
growth factors or cytokines [9]. Unfortunately, the wide dynamic range of protein concentration causes 
the most abundant signal to mask the signal of low-abundance molecules. Finally, post-translational 
modifications, such as phosphorylation, glycosylation, etc., can completely change the function of a 
protein, but the total amount thereof does not vary. Due, at least in part, to these limitations, it is now 
required that the data obtained in individual samples be tested using proteomic techniques, including 
Western blot or enzyme-linked immuno sorbent assay (ELISA) or even genomic techniques, such as 
real-time PCR (RT-PCR).  
The protein expression profile of MSCs may reveal potential hazards associated with senescence 
and tumoral transformation that may occur during culture. Proteomic is a valuable tool for human 
MSC characterization following physiological modifications of the phenotypes of MSCs and 
identification of possible changes occurring during expansion. Mass spectrometry-based comparative 
membrane proteomics can enable the identification of novel cancer biomarkers by distinguishing 
proteins that change membrane localization between normal and malignant tissues and cells. The 
combination of analyzers and other types of available components has led in recent years to a long list 
of devices designed specifically for each type of molecule. Specifically, the range of platforms 
designed for the analysis of peptides and proteins has been adapted specifically to different qualitative 
and quantitative techniques (Table 1). This review describes proteomic techniques currently applied or 
prospectively applicable to MSC studies.  
Table 1. Studies of mesenchymal stem cells (MSCs) using quantitative proteomic techniques. 
Proteomic Technique MSC Source 
Biological 
significance 
Instrument Ref. 
2D-LC-MS/MS Bone marrow Characterization Q-TOF [10] 
2DE-MALDI-TOF/TOF MS Umbilical cord blood Characterization MALDI-TOF/TOF [11] 
2DE-MALDI-TOF-MS Amniotic fluid Characterization MALDI-TOF [12] 
2D-LC-MALDI-MS Bone marrow Characterization MALDI-TOF [13] 
2DE and combined MS and MS/MS Bone marrow Characterization MALDI-TOF/TOF [14] 
2DE and combined MS and MS/MS Umbilical cord Characterization MALDI-TOF/TOF [14] 
2DE and combined MS and MS/MS Placenta Characterization MALDI-TOF/TOF [14] 
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Table 1. Cont. 
Proteomic Technique MSC Source 
Biological 
significance 
Instrument Ref. 
DIGE-MALDI-TOF/TOF Bone marrow Characterization MALDI-TOF/TOF [15] 
2DE-PMF Bone marrow Characterization MALDI-TOF/TOF [16] 
2DE-PMF Bone marrow Characterization MALDI-TOF/TOF [17] 
GELFREE-LC-MALDI-TOF/TOF Bone marrow Characterization MALDI-TOF/TOF [18] 
2DE-MALDI-TOF-MS Bone marrow Extension culture MALDI-TOF [19] 
2DE-MALDI-TOF-MS Bone marrow Extension culture MALDI-TOF [20] 
2DE-MALDI-TOF-MS/MS Bone marrow Extension culture MALDI-TOF [21] 
2DE-MALDI-TOF-MS/MS Bone marrow Extension culture MALDI-TOF [22] 
SELDI-TOF-MS Adipose tissue Extension culture SELDI-TOF [23] 
2DE coupled MS Bone marrow Extension culture Q-TOF [24] 
2DE-MALDI-MS Bone marrow Senescence MALDI-TOF [25] 
2DE-ESI-Q-TOF-MS/MS Bone marrow Senescence Q-TOF [26] 
DIGE-MALDI-TOF-MS Bone marrow Extension culture MALDI-TOF [27] 
2DE-ESI-MS/MS Bone marrow Differentiation Q-TOF [28] 
LC-MS/MS Bone marrow Differentiation Q-TOF [29] 
DIGE-MALDI-TOF-MS Bone marrow Differentiation MALDI-TOF [30] 
2DE-MALDI-TOF-MS Bone marrow Differentiation MALDI-TOF [31] 
2DE-ESI-Q-TOF-MS/MS Umbilical cord blood Differentiation Q-TOF [32] 
DIGE-MALDI-TOF/TOF-MS/MS Adipose tissue Differentiation MALDI-TOF/TOF [33] 
2DE-MALDI-TOF/MS Umbilical cord blood Differentiation MALDI-TOF [34] 
LC-coupled MS/MS Intervertebral disc Differentiation LTQ [35] 
LC-coupled MS/MS Bone marrow Differentiation LTQ-Orbitrap [36] 
DIGE- MALDI-TOF/TOF-MS/MS Umbilical cord stroma Differentiation MALDI-TOF [37] 
SILAC-LC-MALDI-TOF/TOF-MS/MS Bone marrow Differentiation MALDI-TOF/TOF [38] 
DIGE-MALDI-TOF-MS Bone marrow Differentiation MALDI-TOF [39] 
SILAC-LC-MS/MS Bone marrow Differentiation LTQ-Orbitrap [40] 
DIGE-IEF-MALDI-MS/MS Bone marrow Cell Therapy MALDI-TOF/TOF [41] 
2DE-MALDI-TOF-MS Bone marrow Cell Therapy MALDI-TOF [42] 
DIGE-MALDI-TOF/TOF-MS/MS Bone marrow Cell Therapy MALDI-TOF/TOF [43] 
SDS-PAGE-LC coupled MS/MS Bone marrow Cell Therapy LTQ [44] 
LC-coupled MS/MS Bone marrow Cell Therapy LTQ-Orbitrap [36] 
DIGE-MALDI-TOF-MS Bone marrow Cell Therapy MALDI-TOF [45] 
2DE, two-dimensional electrophoresis; MALDI, matrix-assisted laser desorption ionization; TOF, time of 
flight; PMF, peptide mass fingerprinting; DIGE, difference in-gel electrophoresis; SELDI, surface enhanced 
laser desorption/ionization; ESI, electrospray ionization; SILAC, stable isotope labeling by/with amino  
acids in cell culture; IEF, iso-electric focusing; SDS-PAGE, sodium dodecyl sulfate polyacrylamide gel  
electrophoresis; LTQ, linear trap quadrupole. 
2. Proteomic Techniques 
Proteins extracts coming from cultured cells are highly complex protein samples that present a wide 
dynamic range of concentrations [46]. Fractionation of the sample is therefore necessary to reduce its 
complexity. Protein quantification performed by colorimetric or fluorometric assays is one of the 
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weaknesses of the entire proteome flow, because there is currently no universal method to quantify any 
sample with high accuracy and reproducibility. After fractionation by electrophoretic techniques, 
isoelectric focusing or chromatographic analysis, subsequent identification and quantification of the 
peptides allows the identification and quantification of the original proteins using certain algorithms. 
In some cases, directed digestion is initially performed in solution, followed by peptide fractionation as 
liquid chromatography (LC), strong cation exchange (SCX) or the off-gel separation of peptides. 
Alternatively, fractionation of proteins by gel size or isoelectric point is performed first as sodium 
dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE), two-dimensional polyacrylamide gel 
electrophoresis (2D-PAGE) or isoelectric focusing (IEF) followed by digestion. Sometimes, the 
digestion is performed between two successive fractionations, depending on the sample type and 
complexity. In any case, fractionation of the studied sample clearly decreases the complexity of the 
resulting fractions, but also lengthens the total time for analysis. 
It is currently accepted that a research project based on proteomics should have two phases. In the 
initial phase of shaping or profiling, the proteome or protein profile of a particular type of sample, such 
as a cell line or tissue samples at a given stage of development of MSCs, is determined. One way to do 
this is by two-dimensional electrophoresis (2DE) with subsequent identification of proteins by peptide 
mass fingerprinting using a matrix-assisted laser desorption ionization-time of flight (MALDI-TOF) 
platform. In this technique, developed in the early nineteen-nineties by Henzel et al. [47], proteins are 
separated on acrylamide gels in two dimensions, by isoelectric point and by size and can be identified 
by the pattern of tryptic peptides, i.e., from in-gel digestion with trypsin, which specifically digests 
protein in lysine and arginine residues. The combination of peptides with a specific ion m/z ratio is 
unique to each protein and depends only on their amino acid sequence and post-translational 
modifications of these; so, this is called protein finger printing. The study may simply be qualitative, 
i.e., determine which peptides and, therefore, proteins are or are not present in the sample, or 
quantitative, to determine their relative abundance between the conditions under study. Many diseases 
are not due to the presence or absence of a specific protein or group of proteins, but to changes in the 
abundance; in this case, it is necessary, as in most cases, to perform a differential metabolic or 
chemical labeling of the samples. Once differentially labeled, samples are mixed, and thereafter, it 
becomes a single process in order to reduce experimental variability and bias, assuming, of course, that 
a precise quantification of the total amount of protein in the different samples has been done previously. 
In a second discovery phase, techniques, such as the difference in-gel electrophoresis (DIGE) [48],  
a variant of the two-dimensional electrophoresis in which the proteins are labeled with a fluorophore, 
the isobaric tags for relative and absolute quantification (iTRAQ) or stable isotope labeling by/with 
amino acids in cell culture (SILAC) are used for relative quantification. The analysis is performed on a 
selected number of samples (in many cases working with sets or pools of samples) and generates a 
panel of several tens of proteins or peptides modulated between the different conditions under study 
and, therefore, to be candidates for potential targets, such as a possible drug treatment. Among the 
most popular platforms used in this phase, we find the linear trap quadrupole (LTQ)-orbitrap and the 
MALDI-TOF/TOF or LC-MALDI-TOF/TOF when combined with an off-line chromatographic 
system. At a later stage of verification, the linear trap quadrupole coupled to Fourier transform ion 
cyclotron resonance (LTQ-FT) or triple quadrupole-ion trap (QqQ-trap) platforms are used, allowing 
direct absolute quantification of a specific candidate in a large number of individual samples, which is 
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known as multiple or selected reaction monitoring or assays (MRM and SRM, respectively). This 
involves the selection of representative peptides of the candidate that must meet certain characteristics 
and also the synthesis of isotope-labeled versions of that peptides that are spiked in the sample in a 
known amount, enabling absolute quantification of the protein [49].  
In any case, the raw data generated in the analysis of any of the phases are reflected in the mass 
spectra and fragmentation of peptides, which is a dimensional graphical representation of the different 
intensities of detected ions against their m/z ratio. These data are processed and interpreted by search 
engines, equipped with powerful software, using complicated algorithms that integrate the raw data 
with existing protein databases at different sequence repositories (Uniprot, Nextprot, NCBI), allowing 
the identification and, if appropriate, quantification of the proteins present in the samples analyzed. 
The proteomic approach generates informative data on the expression and post-translational 
modifications of proteins that are useful to assess the true potential of MSCs in regenerative medicine. 
No matter which technologies are used, proteomic analysis is always a challenge, because the 
proteome is extremely diverse [50], changes with time and is highly sensitive to pre-analytical 
conditions (Figure 1).  
Figure 1. Workflows used in MSC proteomic analysis. Quantitative methods are indicated 
in red. SCX, strong cation exchange; IMAC, immobilized metal ion affinity chromatography; 
iTRAQ, isobaric tags for relative and absolute quantification.  
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3. Characterization of Mesenchymal Stem Cells  
To date, 2DE gel analysis has been the most used proteomic approach for determining cell surface 
markers of MSCs [51]. The goal is to compare cells from different origins, to follow their 
differentiation and to ultimately define a specific MSC proteomic signature. One important initial task 
is the optimization of 2DE protocols, so that they are robust enough to be used in a multisite project. 
Provansal et al. detailed several thorough protocols that can be used for MSCs in culture [50]. 
Salasznyk et al. [10] identified markers for two cell populations, analyzed the expression of human 
MSC proteins and compared them to those of human osteoblasts using 2D-LC-MS/MS. Among the 
755 different proteins identified in both cell populations, two sets of proteins, 247 found only in 
human MSCs and 158 in human osteoblast cells, were identified. Substantial differences in clusters of 
proteins responsible for calcium-based signaling and cell adhesion were found between the two cell types.  
Feldmann et al. [11] achieved protein identification using MALDI-TOF-MS and gel-matching with 
previously identified databases in their characterization of MSCs from umbilical cord blood after 2DE. 
Roughly 205 molecules were identified representing 145 different proteins and 60 isoforms or post-
translational modifications. The identified proteins could be grouped into several functional categories, 
including metabolism, folding, cytoskeleton, transcription, signal transduction, protein degradation, 
detoxification, vesicle/protein transport, cell cycle regulation, apoptosis and calcium homeostasis.  
Roubelakis et al. [12], using 2DE and the MALDI-TOF-MS approach, have generated, for the first 
time, a protein map of cultured amniotic fluid MSCs by identifying 261 proteins. They directly 
compared the amniotic fluid MSC protein map with that of cultured MSCs from bone marrow and 
found that the functional pattern of the identified proteins from both sources was similar. However, 
cultured MSCs from amniotic fluid displayed a number of unique proteins related to proliferation and 
a primitive phenotype, which may be attributable to the distinct features of the two MSC types. 
Protein profiling of MSC clonal populations was conducted by 2D-LC-MALDI-MS by  
Mareddy et al. [13]. A total of 83 proteins was identified with high confidence, of which 11 showed 
differential expressions between subpopulations, including cytoskeletal and structural proteins, calcium 
binding proteins, cytokinetic proteins and members of the intermediate filament family. This study 
generated a proteome reference map of bone marrow MSCs from the clonal populations, which will be 
valuable to better understand the underlying mechanism of MSC self-renewal and differentiation. 
Li et al. [14], using 2DE and combined MS and MS/MS analysis, identified six differentially 
expressed proteins among MSC samples derived from bone marrow, umbilical cord and placenta, with 
five of them known to be involved in cell migration as either migration enhancing or inhibiting 
proteins. Consistent with their migration capacity, the levels of migration enhancing proteins, 
including cathepsin B, cathepsin D and prohibitin, were significantly lower in MSCs from umbilical 
cord when compared with those MSCs from bone marrow and MSCs from placenta. A higher 
expression for migration inhibiting proteins, including plasminogen activator inhibitor-1 (PAI-1) and 
manganese superoxide dismutase, was found in MSCs from umbilical cord. They also showed that the 
overexpression of PAI-1 impaired the migration capacity for bone marrow and placenta MSCs, while 
silencing of PAI-1 enhanced the migration capacity of umbilical cord MSCs. Their study indicated that 
migration-related proteins are pivotal in the chain of events governing the migration capacity of MSCs. 
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Jaishankar et al. [15] reported a nuclear proteomic analysis of human embryonic and bone  
marrow-derived MSCs. Their proteomic screen highlighted a five-fold difference in the expression of 
Reptin52. They showed, using 2D-DIGE, that Reptin52 is more abundantly expressed in human 
embryonic stem cells than human MSCs. Moreover, they observed differential expression of Pontin52 
and beta-catenin-proteins known to interact with Reptin52, known regulators of beta-catenin, further 
supporting a role for Wnt signaling in stem cell self-renewal and proliferation. 
The expression of a specific set of cell surface cluster differentiation (CD) markers, (CD13, CD29, 
CD44, CD73, CD90, CD105 and CD166) and the absence of hematopoietic stem cell markers (CD34, 
CD45, CD117 [52], HLA class I and HLA-DR antigens [16,17]) strongly support the characterization 
of MSCs using 2DE-PMF. In this regard, it is worth noting that different groups reach similar 
conclusions using different proteomic platforms. 
Mindaye et al. [18] achieved the proteomic analysis of membrane proteins, which is challenging 
and notably underrepresented in proteomic studies, due to the difficulty in the extraction and isolation 
of lipophilic proteins embedded in lipidic layers. They introduced a new approach, including high 
pressure-assisted membrane protein extraction, protein fractionation by gel-eluted liquid fraction 
entrapment electrophoresis [18] and the combined use of liquid chromatography MALDI and ESI 
tandem mass spectrometry. This report presented the first comprehensive proteomic analysis of the 
membrane proteome of undifferentiated and culture-expanded human MSCs from bone marrow 
obtained from different human donors. This new workflow approach enabled them to identify at least 
two-fold more membrane proteins compared to previous published works. A total of 84 cell surface 
CDs were identified, including 14 newly-identified CDs.  
From these works, we can conclude that cellular compartment pre-fractionation drives to a better 
characterization of the stem cell populations, which may be defined in the near future by their 
proteomic profile regardless of their origin, age or stage.  
4. Ex Vivo Cultivation of Mesenchymal Stem Cells  
MSCs hold great promise for cell-based therapeutic use, because of their multipotency and the 
existence of simple methods for in vitro expansion. However, during in vitro expansion, MSCs will 
age and lose their multipotency and proliferation capability. Several studies have provided evidence 
that homogeneous MSCs preparations can be reproducibly isolated under standardized conditions; 
however, culture conditions exert a major impact on the transcriptome, proteome and cellular 
organization of MSCs. Sun et al. [19] used 2DE-MALDI-TOF-MS to perform an analysis during the 
serial subculture of human MSCs. The expression of 12 polypeptides was consistently differentially 
regulated (eight upregulated and four downregulated) during serial subculture until the seventh 
passage. The profile changes were concentrated on proteins related to cell cycle, cell morphology and 
cell proliferation. The data indicated that MSCs underwent morphological changes and a decline in 
proliferation over the course of serial cultivation. Of the differentially regulated proteins, cytoskeletal 
components, including annexin A1 and A2, were upregulated, whereas metabolic, synthetic and 
degradation pathway-related proteins, such as T-complex protein 1 alpha and T-complex protein 1 
gamma, were downregulated during the serial subculture of the isolated human MSCs. Wagner et al. [20] 
using 2DE, also identified 136 protein spots from MALDI-TOF-MS corresponding to the differential 
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protein expression of two human bone marrow populations cultured in two different conditions. 
Proteins involved in metabolism were more highly expressed in low glucose media, whereas proteins 
involved in development, morphogenesis, extracellular matrix and differentiation were more highly 
expressed in a commercial medium.  
Lazzarotto-Silva et al. [21] compared and analyzed MSCs from human bone marrow at different 
culture passages using 2DE-MALDI-TOF-MS/MS and observed similar results in all cultures at  
all passages, suggesting a high degree of similarity among them. The same result was found by  
Binato et al. [22] after image analysis demonstrated that MSCs would have similar protein expression 
patterns at the first passage. These results suggested that the protein profile of human MSC cultures 
derived from different passages and different donors were equivalent. However, changes in the proteomic 
profile of different tissue-derived MSCs during passages in culture have been evaluated using  
surface enhanced laser desorption/ionization-time of flight-mass spectrometry (SELDI-TOF-MS) by  
Capra et al. [23]. This group evaluated the presence of stable molecular markers in adipose tissue-derived 
MSCs and found changes in the proteomic phenotype following prolonged in vitro culture. The protein 
with the greatest change in expression during cell culture was identified as calcyclin. 
Lee et al. [24] used 2DE coupled to MS to identify differentially expressed proteins at the cell 
membrane level in MSCs growing in basic fibroblast growth factor (bFGF) containing medium; a total 
of 15 differentially expressed proteins were identified, of which nine of them were upregulated and six 
downregulated. The expression level of three actin-related proteins, F-actin-capping protein subunit 
alpha-1, actin-related protein 2/3 complex subunit 2 and myosin regulatory light chain 2, was 
confirmed by complementary analysis. The results indicated that the expression levels of these there 
actin-related proteins were important to the bFGF-induced morphological change of MSCs. 
Madeira et al. [25] studied the molecular mechanisms underlying cellular senescence resulting from 
extended ex vivo cultivation of bone marrow MSCs; they used 2DE-MALDI-MS to demonstrate 
significant evidence of culture-induced senescence. Proteins involved in cellular structure, the 
structure of the cytoskeleton, folding and stress response were less abundant in cells with advanced 
senescence, while proteins involved in energy metabolism, cell cycle regulation, aging and apoptosis 
were more abundant.  
Several studies have reported that caloric restriction increases the proliferation of MSCs and 
decreases apoptosis. Kim et al. [26] examined the effect of low glucose on human bone marrow MSC 
proliferation compared with that under normal glucose conditions to learn if calorie restrictions modify 
the proteomic profile of MSCs in culture. 2DE was utilized, and the results found that calorie 
restriction does not have a significant effect on cell proliferation, reactive oxygen species generation, 
glucose consumption, population doublings and adipogenic differentiation of MSCs. However, they 
identified three upregulated proteins and seven downregulated proteins. These results indicate that 
calorie restriction induced differentially expressed proteins, which may provide further information on 
the aging and differentiation of stem cells. 
A study by Kuboki et al. [27] focused on the mechanotransduction of MSCs in response to matrix 
elasticity. Proteomic profiles of MSCs cultured on tissue culture plastic and soft and stiff matrices 
were determined using DIGE. The results indicated abundance and organization changes in 
cytoskeletal proteins, as well as differential regulation of important signaling-related proteins,  
stress-responsive proteins and also proteins involved in collagen synthesis. The expressions of major 
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cytoskeletal proteins, including actin, tubulin and vimentin, of cells cultured on the gels were 
remarkably changed. Significant downregulation of α-tubulin and β-actin was observed on gel samples 
in comparison to the rigid tissue culture plates. The abundance of expression of vimentin appeared to 
be highest in MSCs cultured on hard gels. These results suggest that the substrate stiffness 
significantly affects the expression levels of the cytoskeletal proteins of MSCs, with implications for 
cellular integrity. 
The proteomic studies done on cultivated MSCs show the high plasticity of these cells, which are 
able to regulate the expression of proteins related to the generation of energy, oxidative stress, cell 
cycle and apoptosis in order to adapt to the factors and conditions of culture. Furthermore, the 
importance of the support used for the culture should be mentioned, since this affects the expression 
of, mainly, proteins related to cytoskeleton structure and cell attachment. 
5. The Mesenchymal Stem Cell Differentiation Process 
Proteomic techniques help to study changes in the human MSC signaling transduction network 
during early differentiation lineage commitment. Several works have demonstrated the value of proteomic 
tools for studying stem cell differentiation and elucidating the underlying molecular mechanisms. 
Wang et al. [28] used ESI-MS/MS to identify proteins in 2DE from human bone marrow MSCs 
cultured with transforming growth factor-β (TGF-β). They generated a proteome reference map of 
MSCs, and they identified approximately 30 proteins with an increase or decrease in the expression or 
phosphorylation in response to TGF-β. The proteins regulated by TGF-β included cytoskeletal 
proteins, matrix synthesis proteins, membrane proteins, metabolic enzymes and others. TGF-β 
increased the expression of smooth muscle alpha-actin and decreased the expression of gelsolin. 
Overexpression of gelsolin inhibited TGF-β-induced assembly of smooth muscle alpha-actin. On the 
other hand, reduction of gelsolin expression enhanced the assembly of alpha-actin and actin filaments 
without significantly affecting alpha-actin expression. These results suggest that TGF-β coordinates 
the increase of alpha-actin and the decrease of gelsolin to promote MSC differentiation. 
Foster et al. [29] used LC coupled MS/MS to characterize changes in the expression of membrane 
protein markers before and after short-term induction of osteoblast differentiation in a cell model of 
human MSCs. They identified 463 unique proteins with extremely high confidence, including all 
known markers of human MSCs, such as CD71, CD105, CD166 and CD44, among 148 integral 
membrane or membrane-anchored proteins and 159 membrane-associated proteins. Twenty-nine 
integrins and cell adhesion molecules, 20 receptors and 18 Ras-related small GTPases were also 
identified. Upon osteoblast differentiation, the expression levels of 83 proteins increased by at least  
two-fold, whereas the levels of another 21 proteins decreased by at least two-fold. 
DIGE-LC coupled with tandem MS analysis of the plasma membrane-containing fraction from 
bone marrow MSCs differentiated towards adipocytes allowed Jeong et al. [30] to identify 707 
proteins, approximately half of which could be identified as membrane-related proteins. Of particular 
interest was a subset of ectodomain-containing membrane-bound proteins, which encompasses most 
known surface markers for MSCs, but also contains a multitude of solute carriers and ATPases. Upon 
adipogenic differentiation, this proteomic profile was amended to include several proteins involved in 
lipid metabolism and trafficking, at the expense of, most noticeably, ectoenzymes. 
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Zhang et al. [31] analyzed protein expression profiles of undifferentiated, as well as osteogenic-
induced MSCs, using 2DE-MALDI-TOF-MS to investigate the early gene expression in osteoblast 
differentiation. They generated proteome maps of undifferentiated human MSCs and osteogenic-induced 
human MSCs on day 3 and day 7. One-hundred two spots with at least two-fold changes in expression 
and 52 differently expressed proteins were successfully identified. These proteins were classified into 
more than seven functional categories: metabolism, signal transduction, transcription, calcium-binding 
protein, protein degradation, protein folding, and others. 
Kim et al. [32] focused on proteins that were differentially expressed during osteogenic 
differentiation of MSCs from umbilical cord blood. They analyzed the protein expression inherent to 
osteogenic differentiation with 2DE-ESI-Q-TOF. Eleven differentially expressed spots were observed 
between the two groups, before and after differentiation; four proteins were found to be involved in the 
osteogenic process for the first time: PGAM1, VBP1, hsp27 and β-actin. β-actin might also prove 
useful as a cytosolic biomarker protein for osteogenesis and could be employed in the quality control 
of osteoblasts for cell-therapy applications. 
Proteomic analysis of human MSCs derived from adipose tissue undergoing osteoblast differentiation 
was realized by Giusta et al. [33]. Phenotypic modifications were observed during the in vitro 
osteogenic differentiation process using DIGE-MALDI-TOF/TOF-MS/MS towards osteoblast-like 
cells. A total of 51 differentially expressed proteins were identified when comparing the three 
observed conditions; 16 of these proteins were identified, five of which were overexpressed in the 
early stages of osteogenic differentiation. All five, superoxide dismutase, lamin A, filamin, heat shock 
protein-27, cathepsin D and fibulin 1, play a very important role in the formation of osteoprogenitor 
cells. The identification of these proteins opened new ways for their use as biomarkers for the 
detection of cells undergoing osteogenesis.  
Kim et al. [34] realized 2DE-MALDI-TOF-MS to study the direct differentiation of MSC from 
umbilical cord blood towards osteoblasts. They found the 308 spots that were identified during the 
differentiation process. Sixteen of these proteins were identified with a mean OD (optical density) ratio 
>30 and were acting in the extracellular region, cytosol or mitochondria, while 20 of these proteins 
with a mean OD ratio <0.1 had high catalytic activity. These results provide an initial proteomic 
database for umbilical cord blood MSCs differentiation.  
Human MSCs differentiated towards chondrocytic cells with conditioned medium derived from 
porcine notochordal cells in native tissue or in alginate beads, and compared with chondrogenic 
(TGFβ-3) or basal medium, were studied by Purmessur et al. [35]. Dried peptides subjected to  
LC-coupled MS/MS for detection indicated the highest levels of glycosaminoglycan (GAG), as well as  
the upregulation of SOX9 and Collagen II gene expression in MSCs differentiated towards 
chondrocyte cells in medium from porcine notochordal cells. 
Protein phosphorylation plays a critical role in the signaling transduction network during early 
human MSCs osteogenic lineage commitment. Human MSCs cultured in osteogenic induction medium 
were analyzed using LC-coupled MS/MS by Lo et al. [36]. They observed a dramatic loss of the 
protein phosphorylation level after one day of osteogenic induction. Pathway analysis of the resulting 
phosphoproteins revealed a high correlation with cell proliferation and protein synthesis pathways. 
During osteogenic differentiation, differentially expressed phosphoproteins demonstrated the dynamic 
alterations in cytoskeleton at early stages of differentiation.  
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De la Fuente et al. [37] followed protein profile changes during the chondrogenic differentiation 
process of MSCs from umbilical cord stroma using DIGE-MALDI-TOF/TOF-MS/MS. A total of 97 spots 
were modulated during the chondrogenesis process; 54 of these spots were identified as 39 different 
proteins and 15 isoforms. Of the 39 different proteins identified, 15 were downregulated, 21 were 
upregulated and three were up- and down-regulated at different phases of the chondrogenic process.  
Rocha et al. [38] applied the SILAC technique for the quantitative analysis of protein modulation 
during the chondrogenic differentiation process of human MSCs from bone marrow. They could 
identify 622 different proteins by LC-MALDI-TOF/TOF-MS/MS analysis and found 65 proteins 
whose abundance was significantly modulated between day 2 and day 14 of chondrogenesis. 
Fibronectin, gelsolin, vimentin, alpha-ATPase, mitochondrial superoxide dismutase and cyclophilin A 
were increased at day 14 compared to day 2 of chondrogenic induction, thus being markers of the 
enhanced extracellular matrix synthesis, cell adhesion, metabolism and response to stress processes 
that take place in the early steps of chondrogenesis.  
Herencia et al. [39] evaluated the role of Wnt/β-catenin activation during human MSC 
differentiation into hepatocytes. The differentiation to hepatocytes was achieved using two different 
conditioned media. Comparison of both differentiation protocols by DIGE revealed the differential 
expression of 11 proteins with altered expression in hepatocellular carcinoma. In one of these 
protocols, β-catenin nuclear translocation and the upregulation of genes related to the Wnt/β-catenin 
pathway, such as Lrp5 and Fzd3, as well as the oncogenes, c-myc and p53, were observed. In the other 
protocol, Wnt/β-catenin was inactivated. Hepatocytes with nuclear translocation of β-catenin also had 
abnormal cellular proliferation and expressed membrane proteins involved in hepatocellular 
carcinoma, metastatic behavior and cancer stem cells. Further, these cells had also an increased  
auto-renewal capability, as shown in a spheroid formation assay. Cathepsin B and D, adenine 
phosphoribosyltransferase, triosephosphate isomerase, inorganic pyrophosphatase, peptidyl-prolyl  
cis-trans isomerase A or lactate dehydrogenase β-chain were upregulated only with the protocol 
associated with Wnt signaling activation, while other proteins involved in tumor suppression, such as 
transgelin or tropomyosin β-chain, were downregulated in this protocol.  
Alves et al. [40] used SILAC to study the effect of activin A on the osteogenic differentiation of 
MSCs from bone marrow. They found 104 proteins changed more than 1.5-fold following activin A 
treatment. More than half of these proteins, 74 proteins, were downregulated by activin A, while only 
30 proteins were upregulated. They observed changes in the expression of collagen XII, osteonectin 
and several cytoskeleton-binding proteins. Moreover, in osteoblasts differentiated from MSCs, matrix 
vesicle production was deficient, containing a very low expression of annexin proteins. 
Proteomics provides, therefore, very valuable information in directed differentiation studies of 
MSCs. All the works above have generated new knowledge on the metabolic pathways modulated 
during the differentiation, thus permitting a better understanding of the processes. The precision and 
accuracy of the techniques allow the detection of very subtle changes in the expression of proteins or 
in their phosphorylation state. It is also remarkable that proteomics has permitted the detection in 
cultured MSCs of the activation of oncogenic factors by certain culture conditions, an undesirable 
process when it comes to the use of these cells in therapeutic treatment. 
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6. Cellular Therapy with Mesenchymal Stem Cell 
MSCs have emerged as a promising tool for treating degenerative or incurable diseases. Proteomic 
techniques provide a comprehensive basis for understanding the potential effect of MSCs on tissue 
repair and regeneration. Knowledge of the molecular mechanisms governing the different adult lineages 
differentiation process is critical to the development of therapeutic applications for human diseases. 
Seshi B et al. [41] reported a 2D-DIGE protocol in which complex protein samples from normal 
and leukemic human bone marrow mesenchymal progenitor cells were used as model samples for a 
combination of liquid-phase IEF with DIGE. Using liquid-phase IEF, the normal and leukemic cells 
were pre-fractionated into five sub-proteomes after multiplexing, but prior to DIGE. This analysis mapped 
protein identities to 128 mesenchymal progenitor cell proteins with at least one unique peptide match 
at >95% confidence. Of these proteins, 72 (56%) were expressed more than 1.25-fold higher or lower 
in leukemic cells compared with normal cells (p < 0.05). These data were used to infer gene ontology 
biological processes that may be altered in leukemic bone marrow mesenchymal progenitor cells. 
The first proteomic analysis of human MSCs after exposure to shear stress was realized by Yi et al. [42] 
using 2DE and MALDI-TOF-MS. Overall, 32 protein spots were identified with high confidence.  
Thirteen of these proteins were found to be consistently regulated by over two-fold after 3 dyn/cm
2
 
shear stress treatment for six hours; 10 were upregulated and three downregulated.  
DIGE-MALDI-TOF/TOF was utilized by Zhuang et al. [43] to analyze the differential proteome of 
bone marrow-derived MSCs from adolescent idiopathic scoliosis. A total of 41 significantly altered 
protein spots were detected, of which 34 were identified, representing 25 distinct gene products. 
Among these proteins, five related to bone growth and development, including pyruvate kinase M2, 
annexin A2, heat shock 27 kDa protein, γ-actin, and β-actin, were found to be dysregulated. At the 
protein level, the results supported the previous hypothesis that the decreased osteogenic 
differentiation ability of MSCs is one of the mechanisms leading to osteopenia in adolescent  
idiopathic scoliosis. 
Recent studies have shown that microvesicles from MSCs contribute to the recovery of damaged 
tissues in animal disease models. Kim et al. [44] profiled the MSC microvesicles proteome from bone 
marrow to investigate its therapeutic effects. Seven-hundred thirty proteins were identified by LC 
coupled MS/MS analysis of MSC microvesicles separated by SDS-PAGE. This proteome included 
five positive and two variable known markers of MSCs, but no negative markers. In addition, 43 
surface receptors and signaling molecules controlling self-renewal and differentiation of MSCs were 
identified. This analysis showed that cellular processes represented by the MSC microvesicle proteins 
include cell proliferation, adhesion, migration and morphogenesis. The integration of the self-renewal of 
MSCs and differentiation-related genes that can be associated with the therapeutic effects of MSC 
microvesicles includes: surface receptors; signaling molecules (CDC42 and VAV2; cell adhesion); and 
MSC-associated antigens (CD109, CD151, CD248 and CD276). These proteomes provide a 
comprehensive basis for understanding their potential effect on MSC microvesicle tissue repair  
and regeneration. 
Dynamic changes in the phosphoproteomic profiles of human MSCs during osteogenic differentiation 
and revealed potential candidates mediating the osteogenic commitment of human MSCs shown by 
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liquid chromatography tandem mass spectrometry [36] may shed light on the development of new 
therapeutic targets for metabolic bone diseases, such as osteoporosis and osteomalacia. 
Han S et al. [45] studied differential proteins expressed in the MSCs of patients with degenerative 
scoliosis. They compared MSCs from patients with degenerative scoliosis and patients with lumbar 
spinal stenosis. The MSC samples were analyzed by DIGE-MALDI-TOF-MS to find the differential 
proteins. They found 115 spots that were expressed differently in the MSCs of degenerative scoliosis 
patient; 44 proteins were identified. Of these proteins, PIAS2, NDUFA2 and TRIM 68 were  
upregulated in degenerative scoliosis. This information from this proteomics analysis will be useful in 
understanding the pathophysiology of degenerative scoliosis and opens further lines of investigation on 
the functional pathway, the specificity and the mechanism of action of these proteins.  
Proteomic profiling has provided a variety of novel molecular procedures that can form the basis 
for more in-depth investigations into the effects of shear stress in vitro human MSCs proliferation, 
differentiation and apoptosis; this may, in turn, significantly influence applications in stem cell therapy 
and tissue regeneration. 
7. Outlook and Perspectives 
Liquid chromatography-multiple reaction monitoring mass spectrometry of peptides using stable 
isotope dilution [53] provides a powerful tool for targeted protein quantification. However, the high 
cost of labeled peptide standards for stable isotope dilution (SID) is an obstacle to multiple reaction 
monitoring studies. Zhang et al. [53] compared SID to a labeled reference peptide (LRP) method, 
which uses a single labeled peptide as a reference standard for all measured peptides, and a label-free 
(LF) approach, in which quantification is based on the analysis of un-normalized peak areas for 
detected MRM transitions. They concluded that the LRP and LF methods provide cost-effective 
alternatives to SID for many quantitative liquid chromatography-multiple reaction monitoring mass 
spectrometry applications. These procedures have not yet been applied to study the application of 
MSCs to cell therapy, but offer this opportunity. Proteomic differential displays could help to increase 
the cell therapies with MSCs through specific adjustments based on these displays. 
Promising techniques need special mention here. Matrix assisted laser desorption ionization mass 
spectrometry imaging (MALDI-MSI) and laser micro-dissection are currently under expansion and 
development. The MALDI-MSI combines high resolution power and the ability to monitor a large 
number of proteins in a single analysis feature of the mass spectrometry and has the advantage of 
being able to apply histomorphologic techniques, including providing visual information about the 
spatial distribution of analytes. The approach is as simple as a laser ―sweep‖ with a given spatial 
resolution, 50 microns or less, of a tissue, cut with histological techniques for mass spectrometry, to 
determine the intensity at each pixel of a certain range of m/z. In practice, this involves making a  
two-dimensional map of the distribution of ions (peptides, lipids, sugars) in a histological section. 
Although, at first, it was successful only in soft tissues (brain, kidney, lung, etc.) [54,55], investigators 
have recently begun to utilize it successfully in tissues, such as cartilage [56]. The laser capture  
micro-dissection (LCM) technique identifies LCM regions corresponding to individual cells or groups 
of cells in tissue sections, using a laser coupled to a microscope. The resulting sections are deposited in 
micro-tubes for analysis, in this case, an extraction of proteins that can be further examined with 
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differential labeling to, for example, determine the differential proteome of cells or groups of adjacent 
cells in the same tissue [57]. This technique opens possibilities to study small groups of MSCs 
undergoing cell division after differentiation. 
8. Conclusions 
To summarize, applied mass spectrometry proteomics has enabled a breakthrough in resolving the 
power and speed of analysis. Few techniques have proven valid for detection, analysis and 
quantification, in a single experiment, of many analytes; mass spectrometry is one of them. Thus far, 
2D-based proteomic strategies have been primarily used to characterize MSCs. In the future, it will be 
essential to use gel-free-based strategies to delve deeper into the characteristic proteomes of different 
MSC populations. While increasingly specific and sensitive equipment is launched on the market 
every year, clinical validation by other, even more sensitive techniques, such as RT-PCR and 
immunoassays, is still needed. 
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Influence of age on rat bone-
marrow mesenchymal stem cells 
potential
J. Fafián-Labora1, P. Fernández-Pernas1, I. Fuentes1, J. De Toro1, N. Oreiro2, S. Sangiao-
Alvarellos3, J. Mateos1 & M.C. Arufe1
Mesenchymal stem cells promising role in cell-based therapies and tissue engineering appears to be 
limited due to a decline of their regenerative potential with increasing donor age. Six age groups 
from bone marrow mesenchymal stem cells of Wistar rats were studied (newborn, infant, young, 
pre-pubertal, pubertal and adult). Quantitative proteomic assay was performance by iTRAQ using 
an 8-plex iTRAQ labeling and the proteins differentially expressed were grouped in pluripotency, 
proliferative and metabolism processes. Proliferation makers, CD117 and Ki67 were measure by 
flow cytometry assay. Real time polymerase chain reaction analysis of pluripotency markers Rex1, 
Oct4, Sox2 and Nanog were done. Biological differentiation was realized using specific mediums 
for 14 days to induce osteogenesis, adipogenesis or chondrogenesis and immunostain analysis of 
differentiated cell resulting were done. Enzimoimmunoassay analysis of several enzymes as L-lactate 
dehydrogenase and glucose-6-phosphate isomerase were also done to validate iTRAQ data. Taking 
together these results indicate for the first time that mesenchymal stem cells have significant 
differences in their proliferative, pluripotency and metabolism profiles and those differences are age 
depending.
Mesenchymal Stem Cells (MSCs) have self-renewal capacity and multiple differentiation potentials, and 
a priori, could play important roles in regenerative medicine. The promising role of MSCs in cell-based 
therapies is their trophic, paracrine and immunomodulatory functions that may have the greatest ther-
apeutic impact in vivo1,2. Tissue engineering from MSCs are of highly importance for regeneration of 
mesenchymal tissues such as craniofacial bone3, cartilage4 and connective tissues5.
Since several years ago, numerous studies have shown that MSCs from different tissues have similar 
levels of surface antigen expression, immunosuppressive activity, and differentiation ability6. The ability 
of MSC to carry out normal tissue regeneration in the body and their potential for using in clinical 
applications may be impaired by loss of stem cell number and function with age7. There are different rate 
of cell proliferation and clonality between MSCs depending of source from the cells are obtained8 and 
the chronological age form the donors and also the number of the in vitro culture passages9. MSCs are 
missing their characteristics during the chronological or in vitro culture of them10 but not in the same 
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way. Various attempts have been made to address challenges associated with aging of MSC including 
culture in hypoxic conditions11 and ectopic expression of pluripotency-associated factors12. This study 
applied the 8-plex iTRAQ system to analyze MSCs from six different aging groups, as this quantitative 
proteomic technology has the capability to compare several time points in a single experiment.
The major contributor to the development of the senescent cellular phenotype is hyper activation of 
nutrient sensor and growth pathways, in particular mTOR and its derivative complexes mTORC1 and 
mTORC213,14. mTOR family regulates senescence and autophagy during reprogramming of somatic cells 
to pluripotency indicating the important role of energy metabolism to stem cell renewal and aging15. We 
studied the relationship between mTOR and the proliferation markers CD117 and Ki67 using imatinib 
mesylate, the inhibitor of tyrosine kinase receptor for CD11716 and JK184 which reduce expression of 
Ki6717. We establish a framework for future comparative and functional studies; we have analyzed the 
phenotypic, genotypic features and biological-related changes in MSCs of rat bone marrow from animals 
of different ages.
Material and Methods
Isolation and culture of cells. For isolation of MSCs, the animals were anesthetized with Fluorane 
(Izasa, A Coruña, SP) and sacrificed by cervical dislocation method. Femurs were dissected from male 
Wistar rat (Animal Service, CHUAC) at different ages: neonate (0 days old), infant (7 days old), young 
(14 days old), pre-pubertal (35–38 days old), pubertal (45 days old) and adult (2 months old). All the 
methods were carried out in “accordance” with the approved guidelines of Spanish law (32/2007). All 
experimental protocols were approved by Animal Ethical Committee of Galicia. The protocol used by 
Karaoz et al.18 was followed in this work. Briefly, the ends of the bones were cut away and a 21-gauge nee-
dle that was inserted into shaft of the bone marrow was extruded by flushing with 5 ml D-Hank’s solution 
supplemented with 100 IU/ml penicillin–100 mg/ml streptomycin (all from Life Technologies, Madrid, 
Spain). Marrow plug suspension was dispersed by pipetting, successively filtered through 70-μ m mesh 
nylon filter (BD Biosciences, Bedford, MA, USA), and centrifuged at 20000 g for 10 min. Supernatant 
containing thrombocytes and erythrocytes was discarded, and the cell pellet was resuspended in the 
medium. The cells from four rats were seeded onto 100 cm2 dish plate (TM Nunclon) and incubated 
at 37 °C with 5% humidified CO2. The MSCs were isolated on the basis of their ability to adhere to the 
culture plates. On the third day, red blood cells and other non-adherent cells were removed and fresh 
medium was added to allow further growth. The adherent cells grown to 70% confluence were defined 
as passage zero (P0) cells. After 5 min of centrifugation, 1 × 106 MSCs were seeded on two dish plates 
100 cm2 (TM Nunclon) in RPMI supplemented with 10% fetal bovine serum (FBS), 100 U/ml penicillin 
and 100 mg/ml streptomycin (all from Sigma-Aldrich, St. Louis, MO, USA). The medium was added 
and replaced every 3 or 4 days for 2 weeks. Before being used in inducing mesoderm differentiation, the 
MSCs had been expanded for 2 passages and characterized. Afterwards MSCs from adult group were 
incubated during 12 hours previously to protein extraction with imatinib mesylate or JK184 (all from 
Sigma-Aldrich).
Flow Cytometry. To characterize the different populations of MSCs from chronological different 
animals, their MSCs were washes twice in PBS (Sigma-Aldrich, St. Louis, MO, USA), then pre-blocked 
with 2% rat serum in PBS. The following direct antibodies were used: PE-conjugated mouse anti-human 
CD34 (1:20 from DakoCytomation, Barcelona, SP); FITC-conjugated mouse anti-rat CD45 (1:20 
BD Pharmingen, New Jersey, USA); PE-Cy5.5-conjugated mouse anti-rat CD90 (1:20 Immunostep, 
Salamanca, SP) and APC-conjugated mouse anti-rat CD29 (1:20 Immunostep, Salamanca, SP). The cells 
were washed with PBS after one hour of incubation with the corresponding antibody at room temper-
ature. To check proliferation profile of the different populations of MSCs from chronological different 
animals, their MSCs were incubated with APC conjugated mouse anti-rat CD117 (1:20 Immunostep, 
Salamanca, SP), mouse anti-BRDU (sigma-Aldrich) and FITC conjugated mouse anti-human Ki67 (1:20 
Immunostep, Salamanca, SP). The secondary FITC-conjugated rabbit anti-mouse antibody was used to 
link cells incubated with anti-BRDU. The stained cells were then washed twice with PBS and 2 × 105 cells 
were analyzed with a FACSAria flow cytometer (BD Science, Madrid, SP). FACS data was generated by 
DIVA software (BD Science). Negative control staining was performed using FITC-conjugated mouse 
IgG1K isotype, PE- conjugated mouse IgG1K isotype, PE-Cy5.5- conjugated mouse IgG1K isotype and 
APC- conjugated mouse IgG1K isotype (all from BD Pharmingen). For the intracellular ROS accumu-
lation was used H2DCFDA. Upon oxidation by ROS, the non-fluorescent H2DCFDA is converted to 
the highly fluorescent 2′,7′-dichlorofluorescein. MitoSOX™ Red Reagent was used to determine mito-
chondrial ROS including superoxide dismutase activity. Tetramethylrhodamine, methyl ester (TMRM) 
(from Thermo Fisher Scientific, Life Technologies, SP), the permanent dye that accumulates in active 
mitochondria with intact potentials, was used to detect functional mitochondria in the MSCs at different 
ages following functional mitochondrial staining protocol from commercial.
Proliferation assay. Different numbers of cells (0, 1000, 2000, 4000, 8000 and 16000 cells), were 
plated in triplicate in 96-well plates and allowed to adhere for 8 hours, were used to calculate the prolifer-
ation curve. The number of cells was then calculated using CellTiter 96® AQueous Non-Radioactive Cell 
Proliferation Assay (Promega, Madison, WI, USA) following manufacturer instructions. For the assay, 
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4000 cells were plated for each cell line in triplicate in 96-well plates, and the total number of cells was 
calculated at different time points (0, 1, 2, 5 and 6 days).
The cytotoxicity assay was realized using Cell Counting Kit-8 (Dojindo Molecular Technologies, Inc. 
MD 20850, USA). Briefly 100 all of cell suspension (5000 cells/well) in a 96-well plate were incubated for 
24 hours at at 37 °C, 5% CO2. After that medium with imatinib mesylate or JK184 was added to the wells 
48 hours later, 10 μ l of CCK-8 solution was added to each well of the plate. After four hours incubation 
the absorbance was measured at 450 nm using a microplate reader.
Histological and immunohistochemical analysis. MSCs following differentiation into 
chondrocyte-like or adipocyte-like cells were frozen in OCT embedding matrix (BDH Chemicals, Poole, 
UK). The cells were fixed in 4% (w/v) paraformaldehyde (Sigma-Aldrich) in PBS at pH 7.6. Some cells 
were stained with Safranin O, Modified Masson´s (Sigma-Aldrich) to evaluate the distribution of prote-
oglycan in the extracellular matrix generated by the cells differentiated towards chondrocyte-like cells. 
Other cells were stained with Alizarin red (Sigma-Aldrich) to check alkaline deposits in cells differenti-
ated towards osteocyte-like cells. Other cells were stained with Oil red (Sigma-Aldrich) to check oil drops 
in cells differentiated towards adipocyte-like cells.
Densitometry analysis. AnalySIS Image Processing (Soft Imaging system GmbH V. 5.0, Olympus, 
Münster, Germany) was used to do a densitometry quantification of the staining obtained by immuno-
histochemistry analysis shown in the plots. Three fields 200 mm2 in size from each inmunostain- safra-
nine O, oil red, modified Masson’s and alizarin red - and time studied were quantified using arbitrary 
units for immunohistochemistry values provided by the computer program. Values expressed as percent-
age of positive stain for each marker studied were used for immunohistochemistry analysis. All values 
were referenced with respect to values obtained from cells cultured in the control medium (RPMI 5% 
knockout serum, 1% penicillin and 1% streptomycin).
Real time quantitative polymerase chain reaction (qRT-PCR) analysis. Primers for amplifica-
tion of rat Rex1, Oct4, Sox2 and Nanog genes were used to determine the expression of those markers 
for pluripotency in the different populations of MSCs from chronological different animals. Details are 
shown in Table 1. The amplification program consisted of initial denaturation at 92 °C for 2 minutes fol-
lowed by 40 cycles from 92 °C for 15 seconds, annealing at 55–62 °C, depending on the gene, for 30 sec-
onds and extension at 72 °C for 15 seconds. PCR analyses were done in triplicate, with each set of assays 
repeated three times. To minimize the effects of unequal quantities of starting RNA and to eliminate 
potential sources of inconsistency, relative expression levels of each gene was normalized to ribosomal 
protein (HPRT) using the 2-Δ Δ Ct method19. Control experiments utilized no reverse transcriptase.
Protein isolation and immunoblot analysis. Immunoblot analysis was performed on 40 μ g of total 
protein extracted from MSCs, as previously described20. The blots were probed with antibodies, made 
into rabbit, directed against mTOR, raptor (Cell Signaling, Izasa, Madrid, ES), vimentin, superoxide 
dismutase (SOD-2), lamin A/C and tubulin (all form Sigma-Aldrich) was used for housekeeping. A sec-
ondary anti-goat antibody (Cell Signaling) was used to visualize proteins using an AmershamTM ECLTM 
Western Blotting Analysis System (GE Healthcare, Amersham Biotechnology, Manchester, UK). Ideal 
concentrations for each antibody were determined empirically. Working concentrations were 1:1000 of 
the recommended stock solutions.
iTRAQ labelling. Equal amounts of proteins from each group of different age cells (100 μ g) were dena-
tured with 2% sodium dodecyl sulfate (SDS) in 1 M tryethylammonium bicarbonate (TEAB) (ABSciex, 
Foster City, CA). The samples were then reduced for 1 h at 60 °C using 50 mM tris-(2-carboxyethy) phos-
phine (TCEP) (ABSciex), and cysteine-blocked with 84 mM iodoacetamide (Sigma-Aldrich) at room 
temperature in the dark for 30 min. The proteins were digested with spectrometry grade trypsin (Gold 
Mass, Promega, Madison,WI) at a concentration of 1:50 trypsin/protein for 16 h at 37 °C. Each peptide 
Gene Name Fw primer Rv primer mRNA ID A.T. (°C)
Rex1 gtgcatcacacctcagactgt cgttggttgaaggccaactg NM_005106.4 61
Oct4 ctcctggagggccaggaatc atatacacaggccgatgtgg NM_00510 61
Sox2 ctccgggacatgatcagc ggtagtgctgggacatgtgaa NM_001109181.1 61
Nanog atgcctcacacggagactgt aagtgggttgtttgcctttg NM_005103.4 61
Vinculin aggagaccttgcgaagacagg gcggttgccacttgtttag NM_001107248 61
HPRT agccgaccggttctgtcat agccgaccggttctgtca NM_012583.2 61
Table 1.  Specific primers for real-time reverse transcriptase-polymerase chain reaction (RT-PCR) 
amplification, listed with their annealing temperature (A.T.). Fw = forward; Rv = r e v er s e .
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solution was labeled for 1.5 h at room temperature using the iTRAQ reagents previously reconstituted in 
70 μ L of ethanol, following the manufacture Protocol (ABSciex). The samples were labeled with iTRAQ 
reagents as follows: newborn: 119 and 121 as a control infant: 114; young: 116; pre-pubertal: 118; puber-
tal: 115; adult: 117. The reaction was stopped by adding deionized water, and the labeled samples were 
combined. The mixture was desalted using home-made stage-tips.
iTRAQ relative quantification by 2D-LC-MALDI-TOF/TOF analysis. In a first step, the desalted 
peptides were fractionated by basic reversed phase extraction in a 1400 HPLC system (Agilent). The 
fractions were collected along a 110 minutes gradient and subjected to further acidic reversed phase 
extraction in a nanoHPLC system (Tempo, ABSciex) into a C18 silica-based column (New Objective, 
Woburn, MA) with an internal diameter of 300 Ả. The injection volume was 5 μ L, and peptides were 
eluted during a ninety minutes gradient at a constant flow rate of 0.35 μ L/min. Eluting peptides were 
automatically mixed with alpha-cyano at 4 mg/mL en 70% AcN, TFA 0.1% and deposited on a MALDI 
LC-plate using a SunCollect (SunChrom) spotter. The chromatograms, composed by 350 spots, each one 
comprising a 15 sec deposition, were then analyzed in a 4800 MALDI-TOF/TOF platform (ABSciex). 
4000 series Explorer v.4.2 software was used to generate the spectra and peak list. After manual depo-
sition of mass calibrates, plate model and default calibration of the MALDI plate was done with a laser 
voltage of 3200 kV and 1000 shots/spectrum. Samples were automatically analyzed in MS mode with 
a laser voltage of 3400 kV and 1500 shots/spectrum. Automated precursor selection was done using a 
Job-wide interpretation method (up to 12 precursors/fraction, Signal to Noise lower threshold = 50) 
excluding trypsin autolytic peptides and other background ions, with a laser voltage of 4200 and 2000 
shots/spectrum. CID collision energy range: medium. LC-MALDI-TOF/TOF data were analyzed using 
ProteinPilot 4.0 software (ABSciex). Protein Pilot Search parameters were as follows: Sample type: 
iTRAQ 8-plex; Cys-alkylation: iodoacetamide; Digestion: trypsin; ID focus: Biological modifications; 
Database: last SwissProt release; Species filtering: none; Search effort: Thorough ID and Detection Protein 
Threshold Unused ProtScore (Conf)> 1.3 (95.0%). Scoring model was defined by the Paragon algorithm. 
In the case of the high complexity samples, False Discovery Rate -FDR- was estimated in less than 1% 
by doing the searching in parallel against a decoy database using “PSPEP on” mode -data not shown-.
Bioinformatics. Biological functional analysis of different modulated proteins detected by iTRAQ 
quantification, were categorized according to their function, biological process and cellular component, 
using the String 9.0 software21. Proteins with statistically significant changes were identified by filtering 
according to these criteria: 1) they had to be present in two biological replicates; 2) changes between 
groups had to be statistically significant (P < 0.05); and 3) fold change had to be greater than 1.2 and 
lower than 0.8 (date do not shown) This approach allowed us to select 201 differentially expressed pro-
teins for further analysis.
Enzymatic Analysis. 5 × 105 cells from each group of different age were used for the assessment of 
enzyme activities. The cells were homogenized in 200 μ L of 250 mM sucrose(Sigma-Aldrich, St.Louis, 
MO), 50 mM HEPES (Sigma-Aldrich), 0,5 mM EDTA (Sigma Aldrich) and one tablet protease inhib-
itor cocktail (Roche, Mannheim, Germany ). Enzymes activities were determined using a SUNRISE 
spectrophotometer (TECAN, Mannedorf, Switzerland). Reaction rates of enzymes were determined by 
the increase or decrease in absorbance of NAD(P)H (Sigma-Aldrich, St.Louis, MO) at 340 nm at 37 °C. 
Lactate dehydrogenise (EC 1.1.1.27) was determined in BM-MSCs using 50 mM Trizma base (pH 7,4), 
0,15 mM NADH and 5 mM sodium pyruvate (omitted for control) (all Sigma Aldrich, St.Louis, MO). 
Glucose-6-phosphate 1-deshydrogenase (EC 1.1.1.49) and 6-phosphogluconate dehydrogenase, decar-
boxylating (EC 1.1.1.343) was determined in BM-MSCs using 78 mM Trizma base, 5 mM MgCl2(pH 
7,4), 0,1 mM NADP, 0,5 mM D-Glucose 6-phosphate disodium salt hydrate and 6-Phosphogluconic acid 
trisodium salt (omitted for control) ( all Sigma-Aldrich, St.Louis, MO).
Statistics. All experiments were performed in triplicate and one representative is shown. 
Non-parametric statistical analyses were performed by Mann-Whitney-U and Kruskal-Wallis tests using 
GraphPad Prism6 (GraphPad Software, La Jolla, CA). Each group was compared with previous group. A 
p value less than 0.05 or 0.01 were considered statistically significant. All the the data are presented as 
standard error of the mean.
Results
Characterization of populations of MSCs from different ageing group by flow cytometry reveled that no 
statistical significant differences exist between group respects levels of mesenchymal and hematopoietic 
markers used for that (Fig. 1A). Positive cells for CD45 and CD34 were less than 1%, positive cells for 
CD29 were 30 ± 5% and positive cells for CD90 were 75 ± 5% in all groups studied.
Proliferation Assays results indicated that MSCs from groups of newborn (17 × 103 ± 100), young 
(21 × 103 ± 200), pubertal (15 × 103 ± 300) and adult (16 × 103 ± 100) animals had a statistically sig-
nificant higher (p < 0.01) number the cells compared to infant (9 × 103 ± 500), and pre-pubertal 
(10 × 103 ± 500) (Fig. 1B).
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Flow cytometry assays to detect CD117 and Ki67 positive cells indicated that MSCs from pubertal and 
young groups had the statistical significant (p < 0.01 and p < 0.05 respectively)) higher CD117 positive 
cells percentage of MSCs (74.65 ± 0.07 and 71.95 ± 3.10 respectively) than the rest of the groups studied, 
newborn: 61.53 ± 0.37; infant: 60.50 ± 1.58; adult: 61.12 ± 6.35 and pre-pubertal: 35.25 ± 2.14. On the 
other hand, infant and pre-pubertal groups had the statistical significant (p < 0.05) lower Ki67 positive 
cells percentage (15.63 ± 0.24 and 14.65 ± 0.41 respectively) than the rest of the groups studied, newborn: 
18 ± 0.55; young: 19.33 ± 0.43; pubertal 22.68 ± 0.40 and adult: 29.02 ± 0.16 (Fig. 1C)
Differentiation capacity of the groups studied was tested through direct mesoderm induction using 
specific culture medium. It was observed that pre-pubertal group presented statistically significant 
(p < 0.05) highest stain for safranine O, modified Masson´s and oil red by histological analysis followed 
by pubertal with respect to the other groups. Young group presented the highest staining, statistically 
significant (p < 0.05) for alizarin red with respect to others groups and the adult group presented the 
lowest statistically significant (p < 0.05) differentiation potential with respect to other groups (Fig. 2A,B). 
Nanog, Oct4, Sox2 and Rex1 gene expression were tested by qRT-PCR analysis to check the pluripotency 
potential of the studied groups. The results shown the statistically significant (p < 0.05) highest expres-
sion of Nanog in young group with respect to the others groups in opposition of statistically significant 
(p < 0.01) decrease expression of this same gene, Nanog, in the pre-pubertal group respect to the others 
(Fig. 2C).
All proteins from MSCs of rat bone marrow at different ages studied were compared between them. 
Summary each group was composed of a pool from 6 animals and two different iTRAQ experiments were 
performed. The results obtained in the iTRAQ study indicated that 1.072 proteins were identified, 201 of 
Figure 1. Proliferation profile from rat mesenchymal stem cells at different age. (A) Characterization 
by flow cytometry assay of percentage of positives mesenchymal stem cells markers (CD29 and CD73) 
and negative hematopoietic markers (CD34 and CD45). (B) Proliferation assay of studied aging groups 
for 6 days. (C) Percentage of proliferation markers, DC117 and Ki67, from studied aging groups by flow 
cytometry assay. One representative experiment is shown. #p value less than 0.05 compared with previous 
group and *p value less than 0.01 compared with previous group, were considered statistically significant 
using Mann-Whitney-U tests.
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Figure 2. Pluripotency profile from rats mesenchymal stem cells at different age. (A) Representative 
pictures of mesenchymal stem cell from bone marrow of studied age group after 14 days with specific 
differentiation medium. On the top specific medium is indicated; OS= osteogenic medium; AD = adipogenic 
medium; CH = chondrogenic medium. Differentiation medium are indicated in Material and methods. On the 
bottom stain is indicated; Ar = alizarin red; Or = oil red; Saf O = safranine O and MM = Modified Masson’s 
stain. Straight size is 200 μ M. (B) Densitometry study of mesenchymal stem cell from bone marrow of studied 
aging group after 14 days with specific differentiation medium after immunostaining assay. AnalySIS Image 
Processing computer was used to quantify the signal of different stain obtained. #p value less than 0.01 was 
considered statistically significant using Mann-Whitney-U tests. (C) Histogram represents gene expression of 
pluripotency markers, Rex1, Nanog, Sox2 and Oct4. Real-time reverse transcriptase PCR (qRT-PCR) analysis 
normalized by expression of HPRT gene used as housekeeping. #p value less than 0.01 compared with previous 
group was considered statistically significant using Mann-Whitney-U tests. Three replicates were made.
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them statistically significant modulated between groups (Table 2). These proteins have been grouped by 
three processes attending String 9.0 software; those groups were proliferation (60 proteins), pluripotency 
(86 proteins) and energy metabolism (55 proteins) (Table 2). Significant activates pathways obtained by 
comparing modulated proteins obtained by iTRAQ analysis employing functional annotations according 
to the String 9.0 software and classified in three biological process for better comprehension were shown 
in Fig. 3. A. Several proteins found in our analysis associated with proliferation were 60Sribosomal pro-
teins with different sedimentation speed like 60S RP L10, 60S RP L9, 60S RP L23, 60S RP L24, 60S RP 
L4, 60S RP L6 and 60S RP L7; also Vinculin which gene expression was validated by qRT-PCR analysis 
(Fig. 3D), all of them were statistically significant (p < 0.05) higher in newborn and adults with respect 
to the others groups. Superoxide dismutase-2 (SOD2) and Lamin A were increasing through the increas-
ing age group like occurred in the iTRAQ analysis; all of them were validated by western blot (Fig. 3B). 
Mitosox and total ROS were studied by flow cytometry to explain SOD2 results in our iTRAQ study, ROS 
and mitosox were statistically significant (p < 0.05) lower in infant and pre-pubertal groups with respect 
to the others groups respectively (Fig. 4A,B). A fluorescence-based assay to detect functional mitochon-
dria indicated that adult group had their functional mitochondria statistically significant decreased with 
respect to others groups of study (Fig. 5B). Proteins found in our iTRAQ analysis were associated with 
pluripotency like histones H1.5; H2B; H4 and protein disulfide-isomerase A1 (PDIA1) which were sta-
tistically significant (p < 0.05) high-regulated in infant and pubertal groups with respect to the others 
(Table 2). Several proteins found in our iTRAQ analysis associated whit energy metabolism were lactate 
dehydrogenase (LDH), glucose 6 phosphate dehydrogenase (G6PDH) and 6-phosphogluconate dehydro-
genase (6PGDH), which were validated through analysis of their activity by enzimoimmunoassay (GPI). 
Lactate dehydrogenase (LDH) activity was increased in young group in front to infant and newborn 
group, decreased in pre-pubertal group in a statistically significant way (p < 0.01) and come back to 
increase its activity in pubertal and adult groups (Fig. 4C), glucose 6 phosphate dehydrogenase (G6PDH) 
and 6-phosphogluconate dehydrogenase (6PGDH) were statistically significant increased (p < 0.01) in 
pubertal and adult groups in front to others (Fig. 4D).
Immunoblot analysis indicated that mTOR and Raptor were statistically significant (p < 0.05) lower 
in pre-pubertal and pubertal groups with respect to the other groups studied. Adult group presented the 
statistically significant (p < 0.05) most increased level of mTOR and Raptor (Fig.  5A), the permanent 
dye TMRM analysis indicated a decrease in functional mitochondria which was statistically significant 
(p < 0.01) in infant and adult groups with respect to newborn and pubertal groups respectively (Fig. 5B). 
Viability assay using two physiological concentrations of Imatinib mesylate or JK184 did not affect the 
cells in culture (Fig.  5C). JK184 decreased statistically significant (p < 0.01) the expression of KI67 at 
1mg/ml dose in culture (Fig.  5D). mTOR decreased dramatically in adult group when the cells were 
incubated with Imatinib mesylate or JK184 (Fig. 5E).
Discussion
It is good known that long-term in vitro culture, but not chronological aging, alters their morphology, 
susceptibility to senescence and mitochondrial function. Thus, independent from donor animal age, 
in vitro aging of MSCs seems to result in complete loss of their progenitor characteristics9. Accordingly, 
functional analysis demonstrated altered mitochondrial morphology, decreased antioxidant capacities 
and elevated ROS levels in long-term cultivated independently the aged of the donor. Our present study 
is limited to the usage of rat MSCs instead can be able to apply on human MSCs; it provides direct 
comparison between chronological aged MSC not only at the cellular but also at the molecular level.
MSCs populations from different ageing groups were characterized by flow cytometry to check per-
centage of positive cells for mesenchymal markers, CD29 and CD90, and to check that were negative 
for hematopoietic markers (CD34, CD45) (Fig. 1A). We did not observe statistical significant differences 
between the mesenchymal markers into the different MSCs aging group studied (Fig.  2C). These were 
coincident with results published by Jin et al.6 indicating that MSCs have similar levels of surface anti-
gen expression included MSCs from different tissues. Although the mesenchymal markers were not as 
abundant as published by Harting et al.22 these cells were able to adhere to the plastic plate and this is an 
intrinsic characteristic of mesenchymal stem cells and all of the groups were able to differentiate towards 
several mesoderm lineages (Fig. 2A,B). iTRAQ analysis is an adequate technique to study complex sam-
ples like we have used in this work23. Our results by iTRAQ analysis allowed the identification of 1.072 
proteins. 201 of them were statistically significant modulated between groups (Table 2). Our study rep-
resents a step further from a previous iTRAQ-based study24 where 156 differentially expressed proteins 
were detected. Furthermore we compared six chronologically different groups, giving more strength to 
our study. To generate the quantitative proteome using iTRAQ labeling, it was first determined the labe-
ling efficiency, which exceeded 99% (data not shown). Next, the cut-off for significant fold-change was 
determined based on the 2 biological replicates of two iTRAQ experiments which were chosen based 
on the following criteria: it contained more than 3 unique peptides (> 95%) and p value < 0.05 for the 
114/119 reporter ions. Accordingly, 90% of the commonly observed in the biological replicates fell within 
25% of the respective experimental variation (Data don´t shown). The fold-change thresholds of > 1.20 
or < 0.80 was set to identify true differences between expression of reporter ions.
One of the aims of our study was to establish the differences into proliferation process relating them 
to chronological donor age. Our results indicated that chronological age is directly influencing the 
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Accession Name Peptides (95%) I/N PVal I/N Y/I PVal Y/I PP/Y Pval PP/Y P/PP PVal P/PP A/P PVal A/P
Metabolism
 Q6P783 6-phosphofruc-tokinase 5 0,7228 0,1496 1,0497 0,7085 1,1027 0,3079 1,4117 0,0388 1,2082 0,2192
 Q7TP11
6-phospho-
gluconate 
dehydrogenase, 
decarboxylating
5 0,8664 0,0404 0,9404 0,345 1,1936 0,1035 1,2877 0,0026 0,6857 0,0099
 P06761
78 kDa glu-
cose-regulated 
protein
35 0,9172 0,0089 0,9677 0,334 1,1997 0 0,8295 0,002 1,4611 0
 M0RDC5
Acyl-CoA-
binding protein 
(Fragment)
1 0,9923 0,9393 1,0172 0,8471 1,0129 0,8865 1,1744 0,4947 1,408 0,0299
 F1LN88
Aldehyde 
dehydrogenase, 
mitochondrial
9 0,915 0,2981 0,9521 0,605 1,0255 0,8092 0,8105 0,1287 1,249 0,0303
 P07943 Aldose reduc-tase 9 1,0984 0,3717 0,8893 0,186 0,9549 0,5728 0,9715 0,7164 1,2055 0,0389
 Q91W30
Aldose 
reductase-like 
protein
10 1,6948 0,0054 0,5021 0,0183 1,2079 0,2492 1,0106 0,9424 1,2476 0,0229
 D3ZUM4 Beta-galacto-sidase 5 1,0315 0,7835 1,3171 0,0441 1,0942 0,385 1,1471 0,1506 0,9005 0,1892
 O35567
Bifunctional 
purine biosyn-
thesis protein 
PURH
13 0,9914 0,9389 0,8798 0,2663 1,1514 0,3918 0,8194 0,0166 1,1312 0,0362
 Q99JD5
Branched-
chain-ami-
no-acid ami-
notransferase
5 1,0463 0,7187 0,842 0,0756 1,3485 0,0127 0,9146 0,4169 0,9297 0,5047
 P15791
Calcium/
calmodulin-de-
pendent protein 
kinase type II 
subunit delta
5 0,9646 0,825 0,9676 0,8106 1,3814 0,0071 0,7966 0,044 1,0233 0,8049
 G3V9E3 Caldesmon 1, isoform CRA_b 18 1,0648 0,1599 0,9241 0,1919 1,4728 0 0,7388 0,0002 1,6353 0
 Q08290 Calponin-1 9 0,8714 0,0531 1,3003 0,0464 0,8214 0,2876 0,723 0,0013 1,2572 0,0412
 P37397 Calponin-3 10 1,3337 0,0378 0,8281 0,0224 1,0857 0,2275 0,7288 0,0035 1,1632 0,1397
 P18418 Calreticulin 12 1,1514 0,0446 0,8607 0,0394 1,3403 0,0004 0,7119 0,0002 1,4109 0,0004
 G3V6S3 Calumenin 5 1,0591 0,4369 1,0768 0,3271 0,9833 0,8456 0,7673 0,2524 1,5598 0,0141
 Q6P6T6 Cathepsin D 7 0,8801 0,1287 1,0622 0,3991 1,5419 0,0105 0,9111 0,1808 1,3326 0,0234
 P97601 Chaperonin 10 3 1,0204 0,7796 1,0011 0,9902 0,9415 0,5177 0,939 0,4419 1,4235 0,0087
 G3V936 Citrate synthase 3 0,7934 0,0267 1,167 0,0848 0,7904 0,0267 1,1452 0,2405 0,857 0,2318
 F1M779 Clathrin heavy chain 9 1,2157 0,0137 1 0,9994 0,9612 0,7295 1,1343 0,2338 0,8853 0,3235
 Q6TUH9
Corticosteroid 
11-beta-de-
hydrogenase 
isozyme 1
3 0,7341 0,2686 1,3756 0,2277 1,6421 0,0328 1,9857 0,0672 0,7338 0,0642
 P47875
Cysteine and 
glycine-rich 
protein 1
7 1,0015 0,9815 1,0448 0,5131 1,2576 0,0488 0,6896 0,0389 1,2501 0,0705
 O08651
D-3-phos-
phoglycerate 
dehydrogenase
3 0,8786 0,1902 0,7465 0,0308 1,1981 0,1105 1,1565 0,1448 1,0565 0,5069
 Q5BJ93 Enolase 1, (Alpha) 23 1,0226 0,655 1,026 0,5722 1,054 0,2406 0,7412 0 1,2752 0,0123
 Q8R4A1 ERO1-like protein alpha 5 0,8236 0,0936 1,0042 0,9607 1,1541 0,1632 1,0604 0,6296 1,4685 0,0439
 P05065
Fructose-bi-
sphosphate 
aldolase A
7 0,7852 0,0001 0,9961 0,9275 1,1519 0,0055 1,17 0,0228 1,1494 0,0589
Continued
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Accession Name Peptides (95%) I/N PVal I/N Y/I PVal Y/I PP/Y Pval PP/Y P/PP PVal P/PP A/P PVal A/P
 P11762 Galectin-1 13 0,8947 0,1869 1,0817 0,3224 0,9378 0,4491 0,738 0,0127 1,2891 0,0226
 Q8CJG5 Gene 3 0,9562 0,7992 0,6552 0,233 1,5338 0,0488 1,0942 0,6762 0,9227 0,7939
 P05370
Glu-
cose-6-phos-
phate 1-dehy-
drogenase
16 1,0157 0,847 1,0285 0,7414 0,9947 0,9314 1,0827 0,1708 1,2136 0,0003
 Q6P6V0
Glu-
cose-6-phos-
phate isomerase
13 0,859 0,1021 0,9669 0,5321 1,1179 0,0929 1,1489 0,1394 1,2446 0,0072
 P04797
Glyceralde-
hyde-3-phos-
phate dehydro-
genase
28 1,0559 0,3012 1,2268 0,0077 0,8176 0,0404 1,0972 0,4988 0,8495 0,1048
 P56574
Isocitrate 
dehydrogenase 
[NADP], mito-
chondrial
3 1,0223 0,8926 1,0131 0,8828 0,8721 0,3389 1,3609 0,025 0,8545 0,1231
 B5DEN4 L-lactate dehy-drogenase 14 0,7058 0,0001 1.146 0,00197 1.1828 0,0191 1.2617 0 1.416 0
 Q6P7A9
Lysosomal 
alpha-gluco-
sidase
4 0,9754 0,7869 1,0694 0,6226 1,4268 0,048 0,8687 0,254 1 1
 Q6AYC4
Mac-
rophage-cap-
ping protein
2 1,1578 0,3404 1,3646 0,0086 0,8334 0,049 0,7546 0,0948 1,3655 0,0617
 F1LP60 Moesin (Frag-ment) 40 1,0168 0,6741 0,8227 0,0003 1,4257 0 0,9895 0,8299 0,9461 0,1782
 P20070
NADH-cy-
tochrome b5 
reductase 3
2 0,7339 0,0716 1,4911 0,0447 0,9088 0,5256 0,9743 0,903 0,8315 0,169
 Q6XD99 Non-erythroid spectrin beta 2 1,3375 0,0053 1,0624 0,4554 1,1109 0,3101 0,7568 0,0122 1,5134 0,0041
 P16617 Phosphoglycer-ate kinase 1 29 0,775 0 1,0397 0,3579 1,0241 0,6829 1,1179 0,0446 1,3076 0
 P25113 Phosphoglycer-ate mutase 1 9 0,7559 0,0052 1,1081 0,1211 1,1188 0,142 1,105 0,1848 1,3205 0,0024
 P54001
Prolyl 4-hy-
droxylase subu-
nit alpha-1
15 0,9432 0,3007 0,923 0,1417 1,26 0,0005 0,779 0,0002 0,9234 0,2253
 M0R9D5 Protein Ahnak 60 1,4134 0 0,9734 0,2788 1,2761 0 0,8082 0 2,1551 0
 D3ZIE9 Protein Ald-h18a1 5 1,2134 0,1403 1,038 0,7002 0,5751 0,0236 0,8643 0,2248 0,7301 0,0622
 M0R3 × 6 Protein LOC100912203 6 0,8645 0,163 1,0325 0,6321 1,1276 0,2248 0,9918 0,9068 1,2992 0,0104
 D4A5L9 Protein LOC679794 4 0,6761 0,0039 1,6157 0,0178 0,7517 0,0082 0,9865 0,8661 1,0755 0,375
 Q6P9U0 Protein Ser-pinb6 8 0,9886 0,8679 1,0239 0,6691 1,3013 0,0066 0,8823 0,2774 1,1196 0,16
 D3ZF39 Protein Uap1 10 1,0277 0,7709 1,0072 0,947 1,6544 0,0038 0,9744 0,7756 1,6238 0,0005
 B0BMT0 RCG47746, iso-form CRA_a 90 1,0669 0,6161 0,7141 0,0061 1,4858 0,0047 0,5813 0,0012 0,7691 0,1418
 Q6IRL3 Reticulon 7 1,0111 0,8671 0,8818 0,3109 1,3224 0,0677 0,7406 0,0052 0,9133 0,4439
 B2GVB1
S100 calcium 
binding protein 
A6
3 1,0605 0,5609 1,2045 0,2186 1,7118 0,0122 0,3918 0,0244 1,665 0,037
 Q5U3Z7
Serine hydrox-
ymethyltrans-
ferase
3 0,7739 0,0051 0,9472 0,5152 1,0085 0,9511 1,1442 0,2328 1,0402 0,831
 F1M953
Stress-70 
protein, mito-
chondrial
12 0,9377 0,2437 0,7924 0,0057 1,174 0,0025 0,8961 0,1199 1,5666 0
 P48500 Triosephos-phate isomerase 16 0,6753 0,0004 1,174 0,0315 1,0854 0,3958 1,2639 0,1091 1,4017 0,0001
 Q9Z1A6 Vigilin 3 1,1784 0,0874 0,8426 0,0918 1,0244 0,862 0,9978 0,9727 1,2104 0,0345
Continued
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Accession Name Peptides (95%) I/N PVal I/N Y/I PVal Y/I PP/Y Pval PP/Y P/PP PVal P/PP A/P PVal A/P
 P81155
Voltage-de-
pendent 
anion-selective 
channel pro-
tein 2
6 1,0012 0,9931 1,0633 0,4458 1,2708 0,0343 0,8377 0,1616 0,992 0,9444
Pluripotency
 P63102 14-3-3 protein zeta/delta 24 0,9971 0,9573 0,9743 0,6297 1,0748 0,2065 0,8947 0,1104 1,1562 0,0250
 Q7TP91 Ab1-205 3 0,9802 0,8434 1,2607 0,1387 0,9026 0,3795 1,0629 0,7975 0,6232 0,0302
 Q64640 Adenosine kinase 2 0,9609 0,8197 1,1207 0,3134 1,1155 0,346 1,0828 0,4536 0,6855 0,0454
 P39069
Adenylate 
kinase isoen-
zyme 1
4 0,7781 0,0775 1,2606 0,053 1,0747 0,7679 0,9795 0,8759 1,6777 0,029
 P23928 Alpha-crystallin B chain 5 1,207 0,0573 1,8689 0,0119 2,2257 0,0003 0,2931 0,0035 1,5629 0,0723
 Q6IMZ3 Annexin A6 24 1,2484 0,0001 1,1079 0,0199 0,9791 0,5623 1,0031 0,9354 1,0187 0,5863
 Q07936 Annexin A2 22 1,2928 0 1,0234 0,6825 1,368 0,0001 0,8172 0,003 1,072 0,1567
 Q05175 Brain acid solu-ble protein 1 3 0,9481 0,8617 1,209 0,454 1,3727 0,148 0,4584 0,0445 1,6462 0,1009
 Q6T487
Brain-specific 
alpha actinin 1 
isoform
48 0,7786 0,0007 1,1584 0,0465 1,0249 0,6506 0,8259 0,0018 1,1052 0,2188
 Q8R4A2 Caveolin 1 (Fragment) 4 0,9676 0,8582 1,8465 0,0328 1,0661 0,7396 0,7326 0,1573 1,0726 0,6061
 P02454 Collagen al-pha-1(I) chain 21 1,9314 0,0008 0,4642 0 1,3783 0 1,1251 0,0342 1,123 0,1023
 F1LS40 Collagen al-pha-2(I) chain 19 1,486 0,0008 0,6971 0 1,1467 0,0083 0,9555 0,2908 1,3211 0,0003
 P07335 Creatine kinase B-type 3 0,7036 0,0109 1,1785 0,2497 1,4259 0,0546 0,8379 0,2386 1,2443 0,3604
 F1LMA7 C-type man-nose receptor 2 5 1,1259 0,191 0,8731 0,3184 0,8322 0,3836 0,8408 0,3689 1,7697 0,0009
 P47875
Cysteine and 
glycine-rich 
protein 1
5 1,0995 0,2349 0,9264 0,4028 1,275 0,0227 0,7329 0,0396 1,2025 0,1773
 Q6AYI1
DEAD (Asp-
Glu-Ala-Asp) 
box polypep-
tide 5
9 0,9335 0,2865 0,9937 0,9257 0,8965 0,0659 1,2504 0,0032 0,9596 0,434
 Q62952
Dihydropy-
rimidinase-re-
lated protein 3
8 1,2443 0,0364 1,5656 0,0028 0,858 0,2853 0,8247 0,0165 1,0088 0,9184
 Q4V8H8
EH do-
main-contain-
ing protein 2
0 0,9656 0,7399 1,3396 0,2041 0,8004 0,248 1,6703 0,0471 0,7495 0,491
 Q68FR6 Elongation fac-tor 1-gamma 9 1,0087 0,8562 0,9072 0,4157 1,2134 0,0011 0,9535 0,5667 0,8485 0,0109
 C0JPT7 Filamin alpha 100 1,2134 0 1,3022 0 0,8202 0 0,9147 0,0068 1,386 0
 D4A8D5 Filamin, beta (Predicted) 19 1,0951 0,0867 1,2541 0,0012 0,8193 0,0061 0,7937 0,0124 1,329 0,0009
 B6DYQ7 Glutathione S-transferase pi 4 1,0946 0,3206 1,1008 0,6055 1,5111 0,0241 3,1507 0,0004 0,3406 0,0033
 G3V913
Heat shock 
27kDa pro-
tein 1
5 1,6407 0,0562 0,9647 0,8462 1,5674 0,0118 0,636 0,038 1,3145 0,0077
 P63018
Heat shock 
cognate 71 kDa 
protein
30 0,9815 0,6625 1,2334 0,0221 0,8841 0,0143 1,0164 0,8526 1,1903 0,0184
 F1M3D3
Heterogeneous 
nuclear ribonu-
cleoprotein M
3 0,6983 0,0017 1,0334 0,5966 0,9158 0,4502 1,1725 0,1239 1,0388 0,7714
Continued
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Accession Name Peptides (95%) I/N PVal I/N Y/I PVal Y/I PP/Y Pval PP/Y P/PP PVal P/PP A/P PVal A/P
 Q6IMY8
Heterogeneous 
nuclear ribonu-
cleoprotein U
8 0,7965 0,0032 1,0228 0,7409 0,9994 0,9956 1,1924 0,0262 0,8534 0,1414
 P15865 Histone H1.4 8 0,7411 0,0048 2,4013 0,0005 1,0711 0,2301 0,5016 0,0007 0,6377 0,007
 D3ZBN0 Histone H1.5 4 1,911 0,0166 0,4907 0,0135 0,9905 0,9189 1,4031 0,0552 0,8838 0,2767
 G3V9C7 Histone H2B 20 1,2535 0,0051 0,9957 0,9764 0,8311 0,1792 1,4957 0,0005 0,7706 0,0027
 M0RBX6 Histone H3 6 1,1323 0,058 1,4413 0,0125 1,201 0,0272 0,5991 0,0004 0,494 0,0002
 P62804 Histone H4 13 1,4819 0,0057 0,5999 0,0004 1,1515 0,0641 1,7155 0,0008 0,6785 0,002
 Q6P6G9 Hnrpa1 protein 8 0,6091 0,0304 0,9626 0,6587 0,943 0,663 1,1142 0,7189 0,969 0,7865
 P50503 Hsc70-interact-ing protein 4 0,9785 0,7614 1,0509 0,7519 1,1426 0,4415 0,8392 0,2581 1,5699 0,0074
 P49134 Integrin beta-1 6 1,5471 0,0002 0,9023 0,1179 1,5398 0,0098 0,7217 0,0064 1,311 0,0037
 G3V7Q7
IQ motif con-
taining GTPase 
activating 
protein 1 (Pre-
dicted), isoform 
CRA_b
29 0,9058 0,0331 0,8665 0,0016 1,2223 0 1,0398 0,2744 0,8961 0,0032
 Q6TXE9 LRRGT00050 4 0,8206 0,0425 0,8878 0,4999 1,0972 0,6832 1,5 0,0036 0,8044 0,129
 Q6TUD1 LRRGT00113 2 0,7362 0,0289 1,0159 0,9238 1,0387 0,7991 1,0836 0,5779 0,9606 0,8364
 Q5M7W5
Microtu-
bule-associated 
protein 4
2 1,6111 0,1601 0,845 0,5023 1,0907 0,433 0,6693 0,1236 1,6243 0,0414
 B2GV99 Myl6 protein 11 1,0049 0,9535 1,1269 0,1948 1,0655 0,29 0,9193 0,1676 1,3394 0,0011
 G3V9Y1
Myosin, heavy 
polypeptide 10, 
non-muscle, 
isoform CRA_b
51 0,9356 0,0771 1,0793 0,1827 0,8786 0,0186 0,8988 0,0205 0,792 0,0018
 G3V6P7
Myosin, heavy 
polypeptide 9, 
non-muscle
98 0,9405 0,0071 1,1877 0 1,0117 0,6464 0,957 0,2338 1,3299 0
 P05982
NAD(P)H 
dehydrogenase 
[quinone] 1
8 1,3454 0,0036 0,7746 0,0108 1,2457 0,0611 0,817 0,2198 1,7303 0,0017
 G3V8R1 Nucleobindin 2, isoform CRA_b 3 0,7234 0,0259 2,0743 0,0023 0,5945 0,0061 0,8133 0,1039 1,5101 0,0176
 F1M4W3 Palladin (Frag-ment) 6 1,0033 0,9633 0,8726 0,1096 1,0418 0,6509 0,6823 0,0117 1,0929 0,2707
 P52944
PDZ and 
LIM domain 
protein 1
8 1,0741 0,3026 1,0802 0,1599 1,3743 0,0005 0,9648 0,7456 1,2349 0,03
 Q62920
PDZ and 
LIM domain 
protein 5
17 0,9467 0,5156 0,6947 0,0022 1,4784 0,0057 0,6885 0,0358 0,8014 0,071
 Q6AYQ9
Peptidyl-pro-
lyl cis-trans 
isomerase
6 0,9218 0,2069 0,9782 0,6989 1,2033 0,0649 0,7408 0,0209 0,837 0,0475
 Q62658
Peptidyl-pro-
lyl cis-trans 
isomerase 
FKBP1A
2 1,254 0,0638 1,1087 0,2151 1,0291 0,6981 0,8516 0,0786 1,38 0,0149
 D3ZAF5
Periostin, oste-
oblast specific 
factor (Predict-
ed), isoform 
CRA_a
4 0,5315 0,1266 1,4489 0,0583 0,7663 0,0352 1,3251 0,0507 0,8907 0,4068
 Q63716 Peroxiredoxin-1 13 0,8935 0,0404 1,0622 0,5224 1,083 0,5586 0,884 0,3841 1,2919 0,0335
 P35704 Peroxiredoxin-2 5 0,9438 0,6729 1,3399 0,0331 0,9268 0,3898 0,8375 0,2252 1,1003 0,4352
 Q9R063
Peroxiredox-
in-5, mitochon-
drial
5 1,0571 0,6808 0,7826 0,0577 1,2214 0,0908 0,8798 0,195 1,4277 0,0498
 F1LPK7 Phospholipid scramblase 3 5 1,3539 0,015 0,7564 0,0206 1,2564 0,0285 0,9783 0,8008 1,0061 0,9704
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Accession Name Peptides (95%) I/N PVal I/N Y/I PVal Y/I PP/Y Pval PP/Y P/PP PVal P/PP A/P PVal A/P
 G3V8L9
Polymerase I 
and transcript 
release factor
10 1,0181 0,7755 1,5741 0,0001 1,2442 0,0026 0,6574 0,0001 1,2032 0,1746
 G3V9I0
Procollagen-ly-
sine,2-ox-
oglutarate 
5-dioxygenase 2
15 0,6772 0,0001 1,3393 0,0139 0,8435 0,0459 1,1106 0,2824 1,033 0,765
 D3ZRX9 Protein Cnn2 9 0,9803 0,7232 0,9782 0,6955 1,1542 0,0382 0,7727 0,0037 1,1053 0,1116
 G3V6T7
Protein 
disulfide 
isomerase 
associated 4
4 1,094 0,3778 1,5291 0,0042 0,7583 0,087 0,8527 0,0368 1,1596 0,0466
 P04785
Protein di-
sulfide-isomer-
ase
18 0,9524 0,2161 0,9019 0,0205 1,1449 0,002 0,91 0,0672 1,3562 0
 P11598
Protein di-
sulfide-isomer-
ase A3
23 1,0044 0,9331 1,1813 0,0003 1,0096 0,899 0,888 0,1863 1,151 0,1114
 Q63081
Protein di-
sulfide-isomer-
ase A6
9 0,7832 0,0043 1,1044 0,262 1,2788 0,0234 0,9335 0,4195 1,0394 0,5727
 D3ZHA0 Protein Flnc 28 0,9537 0,2739 1,6131 0 0,8375 0,0128 0,9354 0,1802 1,1796 0,0125
 E2RUH2 Protein LOC100360501 3 0,8715 0,4837 1,2547 0,0379 0,7763 0,024 1,2418 0,1487 0,7978 0,0359
 M0R7B4 Protein LOC684828 6 1,9171 0,003 0,4959 0,0035 1,0813 0,3542 1,3227 0,0305 0,8447 0,1021
 F1MA29 Protein LOC685520 5 0,7506 0,0026 1,15 0,0892 0,9181 0,414 1,0561 0,438 1,066 0,4416
 D3ZUB0 Protein Rcn1 2 1,0185 0,8167 0,8941 0,2217 1,1262 0,2053 0,8607 0,297 1,3273 0,0313
 I6L9G5 Protein Rcn3 2 1,0873 0,4834 0,5646 0,023 1,147 0,2936 0,9716 0,7715 1,3833 0,2381
 D4A1P2 Protein Rpl10l 7 1,0101 0,8587 0,8912 0,0814 0,8855 0,0554 1,4153 0,0002 0,6894 0,0001
 F1M853 Protein Rrbp1 12 0,9865 0,8266 0,9487 0,2254 1,4058 0,0002 0,6416 0,0002 1,4396 0
 P05942 Protein S100-A4 8 1,3344 0,0883 0,8596 0,3432 2,371 0,0005 0,6816 0,0449 1,6256 0,0034
 B0BMT9 Protein Sqrdl 5 0,8772 0,1123 0,8745 0,2138 1,3482 0,0318 0,672 0,0272 1,1637 0,2917
 P50399
Rab GDP 
dissociation 
inhibitor beta
5 0,6527 0 1,1226 0,1842 0,8087 0,0191 1,2167 0,0909 0,8327 0,0497
 Q5FVG5
Similar to 
tropomyosin 
1, embryonic 
fibroblast-rat, 
isoform CRA_c
21 0,8189 0,0635 0,8236 0,0664 1,5332 0,0055 0,4284 0,0029 0,9622 0,622
 Q6IRH6 Slc25a3 protein 5 0,6221 0,0046 1,2418 0,0813 0,9018 0,3869 1,2937 0,0271 0,7334 0,0095
 P06685
Sodium/po-
tassium-trans-
porting ATPase 
subunit alpha-1
6 1,0612 0,5229 0,847 0,0206 0,9521 0,6531 1,1204 0,4092 0,8973 0,1495
 P16975 SPARC 5 1,2574 0,0585 0,8963 0,1879 1,0501 0,5303 0,9358 0,5629 1,2361 0,0437
 Q63413
Spliceosome 
RNA helicase 
Ddx39b
4 0,7567 0,0206 1,0276 0,7991 0,904 0,431 1,3219 0,0189 0,679 0,0523
 Q6IRK8 Spna2 protein 9 1,3867 0 1,211 0,003 1,0232 0,7136 0,7877 0,0016 1,7205 0
 D4A8Y5
Staphylococcal 
nuclease do-
main-contain-
ing protein 1
3 0,919 0,451 1,2908 0,0445 0,8256 0,0815 1,2376 0,0644 0,7802 0,1202
 Q71SA3 Thrombospon-din 1 7 0,8058 0,0398 0,7166 0,0007 1,3192 0,0007 0,9713 0,6767 1,4974 0,0023
 P31232 Transgelin 39 1,2096 0,0003 1,2967 0,0743 1,133 0,0136 0,5637 0,0001 1,7372 0
 Q5XFX0 Transgelin-2 17 0,9888 0,8414 1,0039 0,955 1,3666 0,0009 0,9786 0,7678 1,1396 0,048
 Q6AYT3
tRNA-splicing 
ligase RtcB 
homolog
4 0,6896 0,019 0,9867 0,8815 0,8815 0,1894 1,1372 0,1808 0,8525 0,4565
Continued
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Accession Name Peptides (95%) I/N PVal I/N Y/I PVal Y/I PP/Y Pval PP/Y P/PP PVal P/PP A/P PVal A/P
 Q63610 Tropomyosin alpha-3 chain 9 0,9843 0,838 1,4987 0,0199 1,2255 0,0709 0,6776 0,0538 1,8819 0,0153
 P09495 Tropomyosin alpha-4 chain 12 0,9739 0,7802 1,356 0,0682 1,0117 0,925 0,8335 0,1905 1,5771 0,0401
 G3V6C4
UDP-glucose 
6-dehydroge-
nase
8 1,0597 0,478 0,9444 0,6809 1,256 0,011 1,0009 0,9911 1,4008 0,0135
 Q63355 Unconventional myosin-Ic 10 1,2333 0,0007 0,8095 0,0071 1,2252 0,0431 1,0652 0,3451 0,8854 0,0253
 P31000 Vimentin 110 1,0703 0,0545 1,0991 0,0394 1,1756 0,0018 0,76 0 0,9955 0,9047
Proliferation
 P62268 40S ribosomal protein S23 3 1,0729 0,3955 0,7949 0,0312 1,0116 0,8769 0,9447 0,6609 1,0981 0,4568
 M0RD75
40S ribosomal 
protein S6 
(Fragment)
5 1,213 0,0348 0,7478 0,0343 1,0648 0,6105 0,8839 0,3222 1,2172 0,0637
 B2RYR8 40S ribosomal protein S8 5 1,156 0,0743 0,7651 0,0113 0,9563 0,6408 1,1034 0,3318 1,0474 0,6037
 P29314 40S ribosomal protein S9 10 1,2232 0,0078 0,7297 0,0002 1,1604 0,014 1,0442 0,4378 1,0231 0,6427
 P38983 40S ribosomal protein SA 7 1,0045 0,948 0,8267 0,0864 1,0707 0,3666 1,3083 0,0159 0,8177 0,0379
 P63039
60 kDa heat 
shock protein, 
mitochondrial
14 1,0284 0,7397 1,0424 0,6331 1,0209 0,827 0,7502 0,0126 1,1048 0,3793
 Q6PDV7 60S ribosomal protein L10 8 1,2944 0,0232 0,7476 0,0503 1,0811 0,4911 0,9186 0,3735 1,079 0,2893
 P41123 60S ribosomal protein L13 4 1,2788 0,1225 0,8351 0,0607 1,0613 0,7175 1,269 0,0179 0,8472 0,0781
 P61314 60S ribosomal protein L15 2 1,0608 0,6431 0,9332 0,5211 0,8939 0,228 1,6856 0,0065 0,7429 0,0338
 Q0QEW8
60S ribosomal 
protein L18 
(Fragment)
3 0,8899 0,3903 1,0505 0,6391 0,9184 0,5621 1,4963 0,0365 0,7225 0,0735
 P62718 60S ribosomal protein L18a 4 1,0118 0,8521 0,8707 0,2832 1,0157 0,9288 1,3147 0,032 0,8694 0,1711
 P62832 60S ribosomal protein L23 6 1,2256 0,0212 0,838 0,0334 0,9969 0,9615 0,9723 0,8064 1,1553 0,1309
 P83732 60S ribosomal protein L24 7 1,5524 0,0024 0,5064 0,0004 1,2108 0,0391 0,8698 0,2155 1,2834 0,0175
 P25886 60S ribosomal protein L29 3 1,5331 0,0443 0,9651 0,7362 1,0984 0,4167 0,8404 0,5923 0,7419 0,2733
 P21531 60S ribosomal protein L3 5 1,0552 0,6436 0,8494 0,0879 0,932 0,5476 1,463 0,0213 0,7223 0,0148
 Q6P3V9 60S ribosomal protein L4 9 1,419 0,0021 0,627 0,0002 1,0227 0,7849 0,9688 0,6057 1,139 0,0543
 P09895 60S ribosomal protein L5 6 0,9424 0,3628 0,9732 0,6933 0,9466 0,5073 1,2345 0,0225 0,8597 0,1305
 H7C5Y5 60S ribosomal protein L6 7 1,3496 0,0261 0,6716 0,0068 1,0461 0,66 1,0542 0,451 1,0501 0,6358
 Q6P790
60S ribosomal 
protein L6 
(Fragment)
7 1,2191 0,0025 1,0302 0,7281 1,0286 0,6572 0,8965 0,2512 0,987 0,8763
 P05426 60S ribosomal protein L7 5 1,3498 0,0462 0,6788 0,065 1,1405 0,3092 0,9309 0,3885 1,0532 0,5387
 P85970
Actin-related 
protein 2/3 
complex sub-
unit 2
11 0,9564 0,6557 0,9226 0,2715 1,3327 0,0061 1,0044 0,938 1,0774 0,3839
 Q9Z1P2 Alpha-actinin-1 77 0,8727 0,0028 0,8694 0,0002 1,3424 0,0013 0,8164 0,0001 0,9543 0,1358
 Q9QXQ0 Alpha-actinin-4 50 1,2074 0,0004 1,1204 0,037 1,0349 0,3567 0,9069 0,2105 1,1419 0,036
 Q66HH8 Annexin 5 9 0,9925 0,8998 1,0383 0,7603 0,9707 0,811 0,9909 0,8915 1,4149 0,0034
Continued
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Accession Name Peptides (95%) I/N PVal I/N Y/I PVal Y/I PP/Y Pval PP/Y P/PP PVal P/PP A/P PVal A/P
 P45592 Cofilin-1 12 1,2442 0,0041 1,0603 0,5475 1,0804 0,2025 0,9203 0,5481 1,2685 0,011
 D3ZH41
Cytoskele-
ton-associated 
protein 4 
(Predicted)
12 0,7853 0,0004 1,107 0,0513 0,9476 0,3458 0,7919 0,0005 1,2344 0,0033
 Q6AYH5 Dynactin subunit 2 3 1,151 0,2739 0,8845 0,3112 1,1661 0,2508 0,8114 0,3778 1,3787 0,0248
 P52555
Endoplasmic 
reticu-
lum  resident 
protein 29
2 1,0186 0,8459 1,3064 0,1141 1,2519 0,2488 0,8626 0,2226 1,5742 0,0319
 Q6P3V8
Eukaryotic 
translation 
initiation factor 
4A1
13 1,0465 0,4461 0,8673 0,0328 1,055 0,416 1,0269 0,6429 0,7893 0,0001
 P04937 Fibronectin 17 1,1267 0,3104 0,7887 0,0119 1,2538 0,0001 0,6481 0,0907 2,4985 0,0056
 Q6P792 Four and a half LIM domains 1 6 0,7431 0,0006 1,7903 0,0001 1,1108 0,096 0,7768 0,0085 0,8731 0,0375
 P11762
Galectin-1 
OS= Rattus 
norvegicus
14 0,7674 0,0204 0,7313 0,053 1,2804 0,0564 0,8213 0,4313 1,1116 0,227
 B6DYQ2
Glutathione 
S-transferase 
mu 2
5 1,1023 0,4484 1,0507 0,6202 0,8053 0,0678 0,8616 0,3082 1,2838 0,0235
 P63245
Guanine nucle-
otide-binding 
protein subunit 
beta-2-like 1
6 1,0188 0,7481 0,8543 0,044 1,0255 0,6962 1,0046 0,963 0,9843 0,8938
 Q6P7Q4 Lactoylglu-tathione lyase 6 0,8942 0,2376 0,9113 0,2336 1,2099 0,0449 0,9186 0,2639 1,0132 0,8509
 G3V8L3 Lamin A, iso-form CRA_b 26 0,9048 0,0029 0,968 0,4478 1,1812 0,0001 1,0126 0,746 1,2067 0
 Q99MZ8
LIM and SH3 
domain pro-
tein 1
5 1,4773 0,0032 1,0103 0,9316 1,1251 0,1144 0,7622 0,0071 1,3922 0,0031
 O08557
N(G), N(G)-di-
methylarginine 
dimethylamino-
hydrolase 1
4 0,8682 0,4556 2,2145 0,0173 0,5358 0,0395 0,7504 0,1763 1,2909 0,0453
 Q6S3A0 Plectin 6 28 1,0437 0,2665 0,9378 0,1139 1,1564 0,0026 0,996 0,9259 1,2269 0,0027
 D4A4Z9 Protein Ktn1 7 0,9773 0,8388 0,901 0,2289 1,3423 0,0487 0,7373 0,0131 1,0952 0,3487
 D3ZPL5 Protein LOC100361311 10 1,2843 0,0356 0,683 0,017 1,0148 0,8697 0,9663 0,7274 1,1144 0,0623
 M0RCY2 Protein LOC683961 6 0,9886 0,9133 0,9596 0,6555 0,761 0,0353 1,4335 0,0202 0,591 0,0003
 D3ZN21 Protein RGD1309586 6 0,951 0,6075 0,9746 0,7735 0,957 0,6381 1,2502 0,0226 0,8539 0,0205
 D4A6W6 Protein RGD1561333 6 1,7423 0,0038 0,5049 0,0038 1,2265 0,2464 0,8945 0,5405 1,1717 0,2285
 D4A6W6 Protein RGD1561333 5 1,1352 0,1387 1,0601 0,5478 0,9173 0,2914 1,5332 0,0034 0,6202 0,0124
 F1LT35
Protein 
RGD1564606 
(Fragment)
6 1,1172 0,1379 1,1037 0,4799 1,0681 0,4407 0,772 0,0124 1,2544 0,0157
 G3V852 Protein Tln1 38 1,2686 0 1,2229 0 0,8272 0 0,9642 0,3307 1,3768 0
 Q4QQV0 Protein Tubb6 22 1,0776 0,4062 0,8668 0,3417 1,2995 0,0298 0,946 0,6332 1,0638 0,6569
 Q6P3E1 Rps16 protein (Fragment) 7 1,6881 0,0047 0,5471 0,0061 1,508 0,0481 0,8378 0,1083 1,2384 0,0629
 Q9QZR6 Septin-9 6 1,0595 0,4348 0,9334 0,3019 1,2185 0,0277 0,8772 0,1483 1,017 0,8438
 Q6LDS4
Superoxide 
dismutase 
[Cu-Zn]
6 1,1464 0,0737 1,169 0,0483 0,8679 0,0643 1,0068 0,9549 1,3603 0,0094
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Accession Name Peptides (95%) I/N PVal I/N Y/I PVal Y/I PP/Y Pval PP/Y P/PP PVal P/PP A/P PVal A/P
 P07895
Superoxide dis-
mutase [Mn], 
mitochondrial
10 0,76 0,2573 0,9976 0,9829 2,2825 0,02 1,074 0,2946 1,3438 0,0046
 P28480
T-complex pro-
tein 1 subunit 
alpha
6 0,7782 0,0579 1,5251 0,0086 0,9731 0,7177 1,2381 0,2501 0,9675 0,8659
 Q68FQ0
T-complex pro-
tein 1 subunit 
epsilon
4 0,8933 0,2273 1,0047 0,9576 0,9601 0,7021 1,1826 0,1497 0,8175 0,0229
 Q6P502
T-complex pro-
tein 1 subunit 
gamma
5 1,0456 0,4189 0,8549 0,0333 1,0502 0,74 1,0936 0,3134 0,9009 0,3475
 P11232 Thioredoxin 9 0,9519 0,7004 0,9806 0,8828 1,1098 0,4942 0,9058 0,4438 1,2619 0,0373
 Q99PD6
Transforming 
growth factor 
beta-1-induced 
transcript 1 
protein
6 1,0858 0,7029 0,7535 0,8138 1,2703 0,2603 0,635 0,0115 0,8607 0,8969
 P68370
Tubulin 
alpha-1A chain 
OS= Rattus 
norvegicus 
GN= Tuba1a 
PE= 1 SV= 1
19 1,1996 0,0477 1,1154 0,0721 0,7776 0,0946 0,9411 0,7092 0,7696 0,0004
 R9PXU6 Vinculin 57 1,1908 0 0,9981 0,9534 1,4169 0 0,8383 0,0001 1,1453 0
Table 2.  List of modulated proteins in mesenchymal stem cells at different ages classified according to 
their principal biological process using iTRAQ analysis.
expression of proliferation marker Ki6725 because of the lowest levels of Ki67 corresponded with less 
cells number in proliferation assays in infant and pre-pubertal groups. On the other way high levels 
of CD117, a self-renewal marker in MSCs as indicated Blazquez-Martinez et al.26 were corresponding 
to higher cells number in proliferation assay of pubertal and adult groups of animal respect to the rest 
groups (Fig. 1B,C).
60 modulated proteins found in our iTRAQ analysis were involved in proliferation as 60S ribo-
somal proteins with different sedimentation speed like 60S RP L10, 60S RP L9, 60S RP L23, 60S 
RP L24, 60S RP L4, 60S RP L6 and 60S RP L7 were over-expressed in young group respect to the 
others indicating their increased potential of pluripotency which would be in concordance with its 
low expression of Nanog gene by RT-PCR analysis (Fig. 2C) in this group as also Das et al.27 found 
over-expressed these proteins in different animal model process. Our results indicated that expression 
of Vinculin gene (Fig.  3C) was very low in newborn and young which were the most proliferative 
groups (Fig.  1B) on the opposite way pre-pubertal and adult presented high Vinculin gene expres-
sion coincidently with less proliferative potential. Toma-Jonik et al.28 published very recently that 
Vinculin, which is a protein involved in cell motility and adherence, was down-regulated in cells 
with great mobilization and proliferation potential like melanoma cells and at the same time Piltti 
et al.29 published that Rho kinase inhibitor (ROCKi) treatment increased the cellular proliferation 
up, in human foreskin fibroblast cells and, significantly less Vinculin-associated focal adhesions were 
present in these ROCKi-treated cells30. 11β -hydroxysteroid dehydrogenase type 1 (11β -HSD1), is an 
enzyme which generates glucocorticoids in intact cells, was found in our iTRAQ analysis signifi-
cant increased in prepubertal group, this fact could explain the decrease proliferation potential and 
increase adypogenic differentiation in prepubertal group. All this is coincident with Bujalska et al.31 
who published that 11β -HSD1 activity is uncommitted adipose stromal cells may facilitate prolif-
eration rather than differentiation. Transforming growth factor β 1 (TGF-β 1) induces senescence in 
BM-MSCs via increases the mitochondrial reactive oxygen species production and also the ROS intra-
cellular production is associated with decreasing mitochondrial membrane potential, DNA damage 
and cell senescence32,33, this fact could explain that statistically significant (p < 0.05) decreasing of 
total ROS in pre-pubertal group because TGF-β 1 was found statistically significant (p < 0.05) low 
with respect to other groups in the iTRAQ analysis.
86 modulated proteins found in our iTRAQ analysis were involved in pluripotency process. Terme 
et al.34 showed that pluripotent cells had decreased levels of H1.0 and increased levels of H1.1, H1.3, 
and H1.5 compared with differentiated cells. Our results also indicated that H4 was statistically sig-
nificant decrease in adult group which could point towards their less pluripotency with respect to 
the other groups, differentiation of embryonic stem cells is accompanied by a global reduction of 
panacetylation of histones H3 and H4 suggesting that histone acetylation plays an important role in 
maintenance of embryonic stem cells pluripotency35. Results published by Bermeo et al.36 indicate 
that MSCs over-expressing Lamin A had higher oestrogenic and lower radiogenic differentiation 
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Figure 3. Validation of iTRAQ analysis. (A) Significant activates pathways obtained by comparing 
modulated proteins obtained by iTRAQ analysis employing functional annotations according to the String 
9.0 software. Small numbers on the right of each bar are the modulated protein involved in each process.  
(B) Western blot analysis of Lamin A/C, Vimentin and Superoxide dismutase 2 (SOD-2). Tubulin was used 
as housekeeping. On the left molecular weight of each protein is shown. On the bottom the group’s source of 
mesenchymal stem cells used. The gels have been run under the same experimental conditions. (C) Vinculin 
gene expression using real-time reverse transcriptase PCR (qRT-PCR) analysis normalized by expression of 
HPRT gene used as housekeeping.
potential. Their studies demonstrated that lamin A/C played a significant role in the differentiation 
towards both osteoblast and adipocyte lines by regulating some of the elements of Wnt/β -catenin sig-
naling during early MSCs differentiation, indicating that MSC over expressing Lamina A have higher 
osteogenic and lower adipogenic differentiation potential. Our results were coincident with Bermeo’s 
results, because of we found high levels of Lamina A/C by western in MSCs from adult group which 
we could link to lowest adipogenic potential with the statistically significant (p < 0.05) lowest levels 
of oil red staining during its directed differentiation (Fig. 2A,B). Also we consider the role of Lamin 
A like a senescence marker and its relationship whit increase of ROS37 together with increase of 
Thioredoxin found in our iTRAQ study in adult group could indicate the loss of functionality with 
age, it might be due to the accumulation of oxidative damage also induce because decrease of SOD2 
in this adult group. Stolzing et al.38 demonstrated that age influences impairment of mesenchymal 
progenitor cells function.
55 modulated proteins found were involved in energetic metabolism process. The decision to exit 
pluripotency and undergo differentiation is of singular importance for pluripotent cells, including MSCs. 
The molecular mechanisms for these decisions to differentiate, as well as reversing those decisions during 
induced pluripotency have focused largely on transcriptomic controls. Easley et al.39 explored the role of 
translational control for the maintenance of pluripotency and the decisions to differentiate. ATP-citrate 
synthase is deep linked to pentose phosphate route and its inhibition has been recently linked to a 
decrease in proliferation rate40. Also it has been reported by Pattapa et cols.41 that MSCs resided under 
hypoxic conditions which were associated with the inherent metabolism of the cells. However MSCs 
under normoxia growth conditions derived a significant proportion of ATP from oxidative phosphoryl-
ation in addition to glycolysis. The observed increase of LDH in MSCs from adult group (Fig. 4C) could 
be explained because this group also had the glycolysis increased, on the other way glycolysis decreased 
in pre-pubertal group. All these results have been supported with our results through pentose phosphate 
www.nature.com/scientificreports/
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pathway activity because of were significantly decreased G6PDH in pre-pubertal group and significantly 
increased in adult group (Fig. 4D).
Global protein translation is significantly reduced in hESCs compared to their differentiated progeny. 
mTOR is a Ser/Thr protein kinase that functions as an ATP and amino acid sensor to balance nutrient 
availability and cell growth42. mTOR regulates cellular senescence and drives bioenergetic infrastruc-
ture12. mTOR restrains proliferation potential of stem cells mediating their self-renewal loss, which is an 
effect that can be suppressed by mTOR-inhibitors, such as rapamicyn, antagonizing senescence43. mTOR 
plays an important role in the regulation of hematopoietic stem cell self-renewal in vitro and inhibition 
of mTOR hyperactivation with rapamycin may represent a novel approach to promote ex vivo expansion 
and their long-term hematopoietic reconstitution of hematopoietic stem cells44. Our results of mTOR 
family by western blot analysis indicated that mTOR (Fig.  5A,B) was statistically significant increased 
in adult group versus the other groups studied it could mean that MSCs from adult group were more 
Figure 4. Metabolism profile from rats mesenchymal stem cells at different age. (A) 2′ ,7′ - 
dichlorofluorescein signal measured by flow cytometry to check ROS intracellular (B) Mitosox signal 
measured by flow cytometry to check ROS mitochondrial. (C) Lactate-dehydrogenase (LDH) activity 
measured by spectrophotometer analysis. (D) Pentose phosphate pathway activity measured by spectrometer 
analysis. G6PDH = Glucose-6-phosphate 1-dehydrogenase; 6GPDH = 6-phosphogluconate-dehydrogenase. 
*p value less than 0.01 compared with previous group and #p value less than 0.05 compared with previous 
group, were considered statistically significant using Mann-Whitney-U tests.
www.nature.com/scientificreports/
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Figure 5. mTOR pathway profile from rat mesenchymal stem cells at different age (A) Western blot of 
mTOR pathway, mTOR and raptor, Tubulin was used as housekeeping. (B) Densitometry analysis of westerns 
of mTOR normalized with respect to Tubulin. *p value less than 0.01 compared with previous group. (C) 
Tetramethylrhodamine, methyl ester (TMRM) dye accumulated in active mitochondria with intact potentials, 
was used to detect functional mitochondria in the MSCs at different ages following functional mitochondrial 
staining protocol from commercial. (D) Viability assay of mesenchymal stem cells from adult group incubated 
with 10 μ M or 5 μ M of imatinib mesylate or 1 ng/ml or 0.1 ng/ml of JK184. (E) Flow cytometry of Ki67 from 
mesenchymal stem cells of adult group incubated with 1 ng/ml or 0.1 ng/ml of JK184 in the medium. F) Western 
blot of mTOR and Tubulin of mesenchymal stem cells from adult group after incubating with 10 μ M or 5 μ M of 
imatinib mesylate or 1 ng/ml or 0.1 ng/ml of JK184 in the medium. Control = mesenchymal stem cells incubated 
with growth medium alone. The gels have been run under the same experimental conditions. *p value less than 
0.01 compared with control group was considered statistically significant using Mann-Whitney-U tests.
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senescence than MSCs from younger groups and this result was corroborated by expression of Lamin 
A/C in adult group in front at no expression of Lamin A in the other groups (Fig. 3B) together with less 
expression of TMRM (Fig. 5C) in adult group.
We found correlation between inhibition of mTOR and decrease of CD117 and Ki67 which are pro-
liferation markers in the literature45,46 and we wonder if this relationship between mTOR pathway and 
proliferation was present when the proliferation markers were inhibited by specific reagents. Our results 
using inhibitors of CD117 and Ki67, imatinib mesylate and JK184 respectively, indicated that mTOR 
pathway can be modified through modification of proliferation markers, because the MSCs from adult 
group was treated with the Ki67 inhibitor at two physiological dose which do not affected their viability 
(Fig.  5D) but the expression of mTOR was modified when the proliferation marker Ki67 and CD117 
were diminished (Fig. 5F).
Conclusions
The importance of our study lies in the fact that age from the MSCs source directly influences their dif-
ferentiation, proliferative and metabolism profiles and also it is the first time where is shown the direct 
influence of proliferative markers CD117 and Ki67 on activation of mTOR pathway. Summary we affirm 
that young group of rats has the most proliferative and pluripotent MSCs be able to future functional 
studies.
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ABSTRACT (195 words)  
Stem cells possess significant age-depending differences in their immune-response 
profile. To deeply study these differences we have analyzed by Next Generation 
Sequencing six age groups from bone marrow mesenchymal stem cells. A total of 9628 
genes presented differences of expression between age groups and those genes were 
grouped into metabolic pathways. We focused our research in young, pre-pubertal and 
adult groups which presented the highest amount of genes differentially expressed 
related with inflammation mediated by chemokine and cytokine signaling pathway 
compared with newborn group which was used as a control. Afterwards, extracellular 
vesicles from those groups were extracted and characterized by nanoparticle tracking 
and flow cytometry analysis and several micro-RNAs were checked by quantitative real 
time polymerase chain reaction because of their relationship with the pathway of 
interest. Since miR21-5p was statistically significant highest in extracellular vesicles 
from mesenchymal stem cells of pre-pubertal group, we realized a functional 
experiment inhibiting its expression and investigating the modulation of Toll-Like 
Receptor 4 and their link to damage-associated molecular patterns. Taking together 
these results indicate for the first time that mesenchymal stem cells extracellular 
vesicles-derived have significant differences in their immune profile and those 
differences are age depending.  
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INTRODUCTION 
The promising role of mesenchymal stem cells (MSCs), whose mechanism of action is 
predominantly paracrine, in cell-bases therapies and tissue engineering appears to be 
limited due to a declination of their regenerative potential with increasing donor age 1. 
Next Generation Sequencing (NGS) is a versatile technology which allows cataloguing 
cellular constituents at a steady state and functional interactions when combined with 
system perturbation and differential analysis 2 and together with novel methods of 
pattern recognition and network analyses 3, has revolutionized the field of Systems 
Biology. NGS from newborn, infant, young, pre-pubertal, pubertal and adult MSCs-
bone marrow derived have been studied to evaluate the modified expressed genes 
during ageing. Recently, it has been reported the role of micro-RNAs in ageing and 
immunosenescence and their relevant on extracellular vesicles from MSCs affecting 
their therapeutic potential. Extracellular vesicles (EVs), such as exosomes or micro-
vesicles are released by cells into environment as sub-micrometer particles enclosed by 
a phospholipid bilayer 4. EVs have been found to mediate interaction between cells, 
mediate non-classical protein secretion, facilitating processes such as antigen 
presentation, in trans signalling to neighbouring cells and transfer of RNAs and proteins 
5. The detection of low copy numbers of mRNA and small RNAs, including micro-
RNAs (miRNA), in EVs from mouse and human mast cell lines (MC/9 and HMC-1, 
respectively) has added much research interest impetus to the field 6. While mRNA and 
miRNA in EVs are inactive, they have the potential to be active when EVs are 
transfected into nearby cells. Studies indicate that EV miRNA expression profile may 
be of diagnostic/therapeutic potential 7. The Toll-like receptors (TLRs), an important 
component of innate and adaptive immune responses 8 , are expressed in MSCs and 
their derived EVs during ageing. Damage-associated molecular patterns (DAMPs) are 
molecules that have a physiological role inside but acquire additional functions when 
exposed to the extracellular environment and they can be secreted or displayed by living 
cells undergoing a life-threatening stress 9. Thus, we studied the changes in activation of 
Toll-Like receptor 4 (TLR4) together with expression changes in the DAMP; S-100A4, 
S100A6 and HMGB1 and its relationship with miRNA21-5p into pre-pubertal MSCs.  
 
MATERIAL AND METHODS 
Isolation and culture of cells 
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For isolation of MSCs, the animals were anesthetized with Fluorane (Izasa, A Coruña, 
SP) and euthanized by cervical dislocation method.  Femurs from male Wistar rat were 
dissected (Animal Service, CHUAC) at different ages: neonate (0 days old), infant (7 
days old), young (14 days old), pre-pubertal (35-38 days old), pubertal (45 days old) 
and adult (more than 3 months old). All the methods were carried out in "accordance" 
with the approved guidelines of Spanish law (32/2007). All experimental protocols were 
approved by Animal Ethical Committee of Galicia. The protocol used by Karaoz et al. 
18 was followed in this work. Briefly, the ends of the bones were cut away and a 21-
gauge needle that was inserted into shaft of the bone marrow was extruded by flushing 
with 5 ml D-Hank’s solution supplemented with 100 IU/ml penicillin–100 mg/ml 
streptomycin (all from Life Technologies, Madrid, Spain). Marrow plug suspension was 
dispersed by pipetting it up and down, successively filtered through 70-µm mesh nylon 
filter (BD Biosciences, Bedford, MA, USA), and centrifuged at 20000 g for 10 min. 
Supernatant containing platelets and erythrocytes was discarded, and the cell pellet was 
resuspended in the medium. The cells from four animals were seeded into 100 cm2 dish 
plate (TM Nunclon) and incubated at 37 ⁰C with 5% humidified CO2. The MSCs were 
isolated on the basis of their ability to adhere to the culture plates. On the third day, red 
blood cells and other non-adherent cells were removed by pre-plating technique and 
fresh medium was added to allow further growth. The adherent cells grown to 70% 
confluence were defined as passage zero (P0) cells.  After 5 min of centrifugation,  1x 
106 MSCs were seeded on two dish plates 100 cm2 (TM Nunclon)  in RPMI 
supplemented with 10% fetal bovine serum (FBS), 100 U/ml penicillin and 100 mg/ml 
streptomycin (all from Life Technologies, Madrid, SP). The medium was added and 
replaced every 3 or 4 days. The MSCs were expanded for 2 passages and characterized 
by flow cytometry. 
 
RNA-Seq protocol 
The study was designed to screen the complete transcriptome sequence per age group of 
Wistar rat. Sample preparation was carried out as recommended by Agilent SureSelect 
Strand-Specific RNA Library Prep for Illumina multiplexed sequencing method 10. 1 µg 
of total RNA per sample was performed. The Sequencing data was generated on Hiseq 
1500 on a rapid mode flow cell from Illumina. Sample prep and sequencing was 
prepared in duplicate.  
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Real time quantitative polymerase chain reaction (qRT-PCR) analysis 
RNA isolation was done using the TRIzol® extraction method. The quality of 1µL of 
each RNA samples was checked using as Agilent Bioanalyzer 2100 to determine the 
RIN (RNA Integrity) score using the Agilent 6000 Nanochip and reagents (Agilent, St. 
Clara, USA). Samples with a RIN score >7 were retained and converted to cDNA by 
SureSelet Strand Specific RNA library (Agilent, St. Clara, USA).   
For miRNA detection, cDNA was generated from DNaseI-treated RNA, using a 
QuantiMir RT Kit (System Biosciences, CA, USA) according to the manufacturer’s 
instructions. PCR products were amplified using specific primers for miRNAs: rno-
miR-335 (MIMAT0000575; 5´-TCAAGAGCAATAACGAAAAATGT); rno-miR-155-
5p (MIMAT0030409; 5´-TTAATGCTAATTGTGATAGGGGT); hsa-miR-132-5p 
(MIMAT0004594, 5¨-ACCGTGGCTTTCGATTGTTACT); hsa-miR-146a 
(MIMAT0000449, 5¨-TGAGAACTGAATTCCATGGGTT); rno-miR-21-5p 
(MIMAT0000790, 5´-TAGCTTATCAGACTGATGTTGA) and hsa-miR-16 
(MIMAT0000069, 5´- TAGCAGCACGTAAATATTGGCG). The amplification 
program consisted of initial denaturation at 50 °C for 2 minutes followed from 95 °C for 
10 minutes and 50 cycles annealing at 95°C, depending on the gene, for 15 seconds and 
extension at 60°C for 1 minute. Primers for amplification of rat genes are described in 
detail in Table I. The amplification program consisted of initial denaturation at 92ºC for 
2 minutes followed by 40 cycles from 92ºC for 15 seconds, annealing at 55-62ºC, 
depending on the gene, for 30 seconds and extension at 72ºC for 15 seconds. PCR 
analysis were done in triplicate, with each set of assays repeated three times. To 
minimize the effects of unequal quantities of starting RNA and to eliminate potential 
sources of inconsistency, relative expression levels of each gene was normalized to 
ribosomal protein (HPRT) or miR-16 using the 2-ΔΔ Ct method 11. Control experiments 
utilized no reverse transcriptase. 
 
Isolation extracellular vesicles 
Bone marrow mesenchymal stem cells from newborn (0 days), young (14 days), pre-
pubertal (35-38 days) and adult (3 months) were cultured in RPMI 1640 Medium with 
GlutaMAXTM supplement and 10 % FBS-free exosomes (all Thermo Fisher Scientific, 
Massachusetts, USA), 100 U/ml penicillin and 100 mg/ml streptomycin (Sigma-
Aldrich, St.Louis, USA). Cells were cultured with 80% confluence and supernatants 
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were collected after 48 hours. We isolated MSC-derived EVs using ultra centrifugation 
following the protocol published by Del Fattore et al. 12. In detail, supernatants were 
centrifugated at 1500 rpm for 10 min at 4 C and filtered using 0,22 µm filter sterilized 
(GE Healthcare Life Sciences, Maidstone, UK) to eliminate debris. Supernatants were 
transferred to ultracentrifugation tubes and centrifuged at 100000 x g for 2 hours at 4 C 
in Optimal-90K with 60 Ti rotor (Beckman Coulter, Mississauga, Canada). Supernatant 
containing exosomes-free media were removed and pellets were resuspended at 200 µl 
PBS.   
 
Nanoparticle Tracking Analysis   
EVs size distribution was estimated by the Brownian motion of the particles in a 
NanoSight LM12 using Nanoparticle Tracking Analysis 2.3 software (Nanosight Ltd, 
Amesbury, UK). EVs were diluted in PBS until a suitable concentration for analysis 
was reached. Particle concentration was evaluated for particles range between 30–
150nm in diameter.  
 
Electronic microscopy    
EVs were concentrated using Vivaspin concentrators (Sartorius, Gottingen, Germany). 
EVs were taken up in small volumes of deionized water, which were placed on nickel 
grids and allowed to dry for 45 minutes at 37 C. The grids with EVs were then washed 
by transferring them onto several drops of deionized water. Negative contrast staining 
was performed by incubating the grids on top of drops of 6% uranyl acetate. Excess 
fluid was removed and the grids were allowed to dry before examination on a Jeol 
JEM1400 Transmission Electron Microscope (Jeol, Tokyo, Japan).  
 
Flow Cytometry 
To characterize the different populations of MSCs from chronological different animals, 
their MSCs were washes twice in PBS, then pre-blocked with 2% rat serum in PBS. The 
following direct antibodies were used: PE-conjugated mouse anti-rat CD34 (1:20 from 
DakoCytomation, Barcelona, SP); FITC-conjugated mouse anti-rat CD45 (1:20 BD 
Pharmingen, New Jersey, USA); PE-Cy5.5-conjugated mouse anti-rat CD90 (1:20 
Immunostep, Salamanca, SP) and APC-conjugated mouse anti-rat CD29 (1:20 
Immunostep, Salamanca, SP). The cells were washed with PBS after one hour of 
incubation with the corresponding antibody at room temperature. The stained cells were 
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then washed twice with PBS and 2x105 cells were analyzed with a FACSAria flow 
cytometer (BD Science, Madrid, SP). FACS data was generated by DIVA software (BD 
Science). Negative control staining was performed using FITC-conjugated mouse 
IgG1K isotype, PE- conjugated mouse IgG1K isotype, PE-Cy5.5- conjugated mouse 
IgG1K isotype and APC- conjugated mouse IgG1K isotype (all from BD Pharmingen).  
 
miRNA transitory transfections 
MSCs were incubated with 40 nM hsa-miR-21-5p miRVana™ miRNA inhibitor or 
40nM control negative miRVana™ using the expression system following manufacturer 
indications. Validation by RT-PCR was done using Taqman®MicroRNA Assay 
following commercial instructions (all from Ambion, Applied Biosystem, Madrid, SP) 
 
Protein isolation and immunoblot analysis  
The protein content into EVs was measured with a Micro-BCA kit (Thermo Scientific, 
Pierce, Rockford, USA) following manufacturer instructions. Immunoblot analysis was 
performed on 40 µg of total protein extracted from MSCs, as previously described 13 . 
The blots were probed with antibodies directed against: LMNA/C (Acrix); Wnt5a 
(Acrix); TLR4 (Immnunostep); mTOR (Cell Signaling); HMGB1 (Abcam); pAKT; 
AKT and tubulin (all from Cell Signaling) or B-actin (Sigma-Aldrich) were used for 
housekeeping. A secondary anti-rabbit (Cell Signalling) or anti-mouse (DAKO) 
antibodies was used to visualize proteins using an Amersham ECL Western Blotting 
Analysis System (GE Healthcare, Amersham Biotechnology, Manchester, UK). Ideal 
concentrations for each antibody were determined empirically. Working concentrations 
were 1:1000 of the recommended stock solutions.  
 
Bioinformatic analysis 
An average of 25 million paired-end 100bp reads was obtained per sample. The raw 
RNA-seq reads for each sample were aligned to the reference rat genome browser (rn6 
assembly) using Bowtie2 (bowtie-bio.sourceforge.net/index.shtml/) and Tophat2 
(http://tophat.cbcb.umd.edu/). After alignment, raw sequence read depths was converted 
to estimate transcript abundance measures as fragments per kilo base of exons per 
million (FPKM) values Cufflinks (http;//cufflinks.cbcb.umd.edu/) differentially 
expressed genes and transcripts were calculate with Cuffdidd. Each group was 
compared with previous age group. The fold-change thresholds had to be greater than 
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1.2 and lower than 0.8. Identified genes with statistically significant changes were 
categorized according to their function, biological process and cellular component, 
using the R/Bioconductor package RamiGO 
(http://bioconductor.org/packages/release/bioc/html/RamiGO.html )14. 
MicroRNA.org (http://www.microrna.org) was a resource of microRNA target 
predictions and expression profiles used in this work. Target predictions were based on 
a development of the miRanda algorithm 15  and TargetScan 16. 
 
Statistical analysis 
All experiments were realized in triplicate and one representative is shown. Statistical 
non-parametric analysis (Mann-Whitney U and Kruskal-Wallis tests) was performed 
using GraphPad Prism6 (GraphPad Software, La Jolla, CA). Each group was compared 
with previous group. A p value less than 0.05 or 0.01 was considered statistically 
significant. All the the data are presented as standard error of the mean. 
 
RESULTS 
Characterization of populations of MSCs from different age groups by flow cytometry 
indicated these populations presented less than 1% of positive cells for CD45 and CD34 
hematopoietic markers and more than 60±5% positive cells for CD29 and more than 
85±5% positive cells for CD90 (Fig. 1A). 
NGS analysis indicated that a total of 9628 genes presented differences of expression 
between age groups as is shown in figure 1B. Modulated genes are indicated as up-
regulated in red and down-regulated in blue, comparing age groups chronologically 
continuous. The results indicated that the expression pattern of 4741 genes change 
between newborn and infant groups; 4939 genes change their expression pattern 
between infant and young groups; 6339 genes change their expression pattern between 
young and pre-pubertal groups; 6568 genes change their expression pattern between 
pre-pubertal and pubertal groups and 6849 genes change their expression pattern 
between pubertal and adult groups. Figure 1C shows the hierarchical clustering of genes 
involved into five pathways common between the six age groups studied, using the 
R/Bioconductor package RamiGO with a signification >1.5-fold. Genes modulated 
between newborn and infant groups were grouped into eight metabolism pathways, 
while genes modulated from infant until adult groups were grouped into up to 15 
metabolism pathways. The number of modulated genes involved into hormonal changes 
  
 
 
9 
 
as gonadotropin-releasing hormone pathway (PO6664) increased from infant age group 
until adult age group (76, 89, 116, 112 and 121 genes respectively). Genes involved into 
programmed death as apoptosis signaling pathway (PO00006) were observed modulated 
between young, pre-pubertal and adult groups (46, 57, 66 respectively). Genes involved 
into inflammation mediated by chemokine and cytokine signaling pathway (PO00031) 
was modulated in infant, young and pubertal groups (78, 82 and 103 genes respectively) 
(Fig. 2). NTA revealed out that the ratio protein/particle and the production of MSC-
derived EVs decreased with increasing donor age (40±2%) (Fig. 3A), however MSC-
derived-EVs production was increased with donor age (26±1%) (Fig. 3B). The size of 
the extracellular vesicles was 160±18 nm and there were not significant differences 
among groups (Fig. 3C). MSC-derived EVs were visualized by electron microscopy as 
small vesicles, typically 40-80 nm in diameter (Figure 3D). Flow cytometry analysis of 
EVs attached to anti-CD63 beads revealed that they were at least 32%±3 positive for 
CD63, an exosome marker membrane protein, at 10µM of concentration (Fig. 3E). 
qRT-PCR analysis of miRNAs associated with TLR4: miR-146a; miR-155; miR-132; 
miR-21 and miR-335, which are involved also in immunosenescence process, found out 
that miR-146a, miR-155 and miR-132 decreased their expression until 93±3% with 
increase age donor. However, adult group presented the statistically significant highest 
expression of miR-335 (P<0.01) and pre-pubertal group presented the statistically 
significant highest expression of miR-21 (P<0.01) with respect the others (Figure 4 A-
D). TLR4 protein concentration by western was checked after 4 hours of 10 ng/mL 
lipopolysaccharides (LPS) treatment (Fig. 4 F, G) and it was observed a high increase in 
the response against LPS in pre-pubertal group. To explain these results MSCs from 
pre-pubertal group was transitory transfected with miRVana miR-21-5p and its 
expression was checked by qRT-PCR (Fig. 5 A). The transfected cells expressed 
statistically significant lower (P<0.05) levels of miR-21 than the same cells transfected 
with a mimic miRNA used as control. qRT-PCR analysis of DAMPS associated with 
TLR4 indicated that miR-21 inhibition promotes a statistically significant decrease of 
S100A4, S100A6 and HMGB1 with respect to MSCs control (Fig. 5 C, D, E). Nanog 
gene expression was checked by qRT-PCR and it was statistically significant higher 
(P<0.05) than control (Fig. 5B).  
Western analysis of proteins involved into immune response in miR-21 inhibited pre-
pubertal MSCs reveled out that LMNA/C, TLR4, mTOR, pAKT were statistically 
significant down-regulated (P<0.05) with respect to control cells (Fig.6 A-C), HMGB1 
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was also down-regulated in the inhibited cells. On the other way Wnt5a and AKT were 
up-regulated statistically significant (P<0.05) with respect to control cells (Fig. 6A, C). 
miR-21 inhibition did not affect the immune response in front of LPS treatment since 
TLR4 through pAKT/AKT were statistically significant (P<0.05) up-regulated (Fig. 
6D).  
 
DISCUSSION 
The use of MSCs has been adopted in cell-based therapy due to their multiple 
differentiation ability, the low expression of co-stimulatory molecules and 
immunosuppressive properties 17. Although EVs have long been considered cellular 
artefacts or dust, recent progress in this area indicates that EVs are intercellular 
information, that is, extracellular organelles that have multifaceted physiological and 
pathological functions in intercellular communication as well as inter-species and inter-
kingdom communication 18. Martins et al. 19 reported that EVs derived from human 
bone marrow MSCs had a regenerative potential that had been increasingly recognized. 
MSCs populations from different ageing groups were characterized by flow cytometry 
to check  percentage of positive cells for MSCs markers, CD29 and CD90, and were 
negative for hematopoietic markers (CD34, CD45) (Fig. 1A). We did not observe 
statistically significant differences between the MSCs markers into the different MSCs 
aging group studied (data do not shown). These results were coincident with the results 
published by Jin et al.20-22 indicating that MSCs have similar levels of surface antigen 
expression included MSCs from different tissues. Even the MSCs markers were as 
abundant as published by Harting et al.23. 
RNA-Seq analysis is an adequate technique to study gene expression modulation in 
complex systems 24,25. Our results by RNA-Seq analysis allowed the identification of 
9628 genes statistically significant modulated between groups (Fig.1B). Our study 
represents a step further from a previous iTRAQ-based study 21 where 210 differentially 
expressed proteins were detected. We used the R/Bioconductor package RamiGO which 
is an R interface to AmiGO that enables visualization of Gene Ontology (GO) trees 14. 
RamiGO provides easy customization of annotation, highlighting of specific GO terms, 
using of terms by P-value. We showed RamiGO functionalities in a genome-wide gene 
set analysis of genes differentially expressed comparing six chronologically different 
groups from bone marrow derived MSCs (Fig. 1C). We were interested in genes 
involved into inflammation mediated by chemokine and cytokine signaling pathway 
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(PO00031) which were modulated in infant, young and pubertal groups (Fig. 2). 
Focusing in this pathway,55 exosome markers were found using the bioinformatics 
platform ExoCarta 26. in concordance with our previous iTRAQ results based on 
quantitative proteomics 21. miRNAs involved into exosomes and their relationship with 
inflammation mediated by chemokine and cytokine signaling pathway were obtained 
out by open-source software for target predictions miRanda  and TargetScan. We 
focused then on the functional study of miRNAs expression involved in inflammation 
mediated by chemokine and cytokine signaling pathway into these groups and their 
EVs. EVs size was determined by NTA, which calculates the size from total 
concentration of the vesicles in solution. Also we followed the technique used by 
Gercel-Taylor et al. 27 who have reported their optimized method to measure the size 
distribution of cell-derived vesicles comparable to other analysis instrumentation. We 
found an increase in the production of MSC-derived EVs from adult group with respect 
to the others (Figure 3A). A rationale explanation for this fact is that calcium levels play 
a role in plasma membrane fusion events involved in adipose accumulation in bone 
marrow stromal cells with age 28. We previously found out levels of 
calcium/calmodulin-dependent protein kinase type II, caldesmon, calponin-1, calponin-
3 and calreticulin statistically significant increased in the adult group with respect to the 
others by quantitative proteomics (iTRAQ) analysis 21. In our present study, MSC-
derived EVs have a size in the range of diameter published by Vallabhaneni et al. 29 
(Figure 3A-C) with no significant differences between age groups. These data were 
validated by electronic microscopy (Figure 3D) and characterized by flow cytometry 
and they were more than 32% positives for CD63,  a tetraspanin mainly associated with 
membranes of intracellular vesicles that it is considered as an exosome marker by the 
International Society for Extracellular Vesicles (ISEV) 30,31 (Figure 3E). The acquired 
immune system shows a functional decline in ability to respond to new pathogens 
during ageing, whereas serum levels of inflammatory cytokines are increased with age 
32. Inflammaging is a new term coined by Olivieri et al. 33 to name those processes 
associated with age and their relationship with a loss of expression of TLR family, a 
process which could contribute to such inflammation imbalance. There is controversy 
on the role of TLR4 in pro-inflammatory and differentiation capacities from MSCs 34 
and further research thereby will provide helpful tools for regenerative medicine. We 
checked the following miRNAs associated with TLR4 contained in MSC-derived EVs. 
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miR-146a because is one of key TLR-induced miRNAs, inhibiting the TLR-signalling 
pathway by targeting IRAK1 kinase and TRAF6 ligase. miR-132 because is a target of 
IL1R associated kinase IRAK 4, a regulator of production inflammatory cytokine 35. 
miR-155 because is induced via TLR in macrophages  and exerts profound effect on the 
activity of immune cells 36,37. In our model we found decreased all these miRNAs 
contained in EVs with increasing age donor (Fig. 4A-C) suggesting an association 
among the decrease of immunologically active exosomes and the loss of capacity of 
activating immune system through the induction of anti-inflammatory cytokines and T 
cells. MSC-derived EVs from adult group contained the highest level of miR-335 (Fig. 
4D). This could be associated with cell senescence and loss the therapeutic capacity and 
linked to the reduced capacity to activate protein kinase D1 (PRKD1), which in turn 
reduces the activity of AP-1 transcription factor 38,39. miR-21 regulates negatively LPS-
induced lipid accumulation and inflammatory response in macrophages by the TLR4-
NF-kB pathway 40 which is involved in human MSCs during differentiation by 
regulating SPRY229. We found the highest level of miR-21 in MSC-derived exosomes 
from pre-pubertal group and the lowest level in adult group (Fig. 4E) hence TLR4 could 
be a target to understand role of miR-21 in differentiation of pro-inflammatory capacity 
depending of donor age. BM-MSCs from adult group have less therapeutic capacity due 
to TLR4-mediated regulation of bone marrow MSCs proliferation and osteogenic 
differentiation through Wnt3a and Wnt5a signalling 41. Conversely, TLR4 activation in 
MSCs from umbilical cord increased this differentiation to a certain extent 42. Our 
results indicated that TLR4 trend to increase with age and that the treatment with LPS 
did not affect to their immunological response, at short incubation times such us 4 hours 
(Fig. 4G). Wnt5a expression augments through TLR4 in response to inflammatory 
mediators, as LPS, in several stem cells types and regulated cytokine and chemokine 
production 43,44. Our results indicate that the inhibition of miR-21 produced an over-
expression of Wnt5a accompanied by a decrease of LMNA/C, a senescence marker 
(Fig. 6 A), suggesting a role in self-renewal and pluripotent capacities of the MSCs. The 
increase of Nanog detected by RT-PCR (Fig. 5D) strongly supports this supposition. 
The inhibition of miR-21 disrupts TLR4 through AKT/mTOR pathway since mTOR 
and pAKT were down-regulated (Fig. 6 B, C). Similar results were observed by Gharibi 
et al. 45 . These authors proposed that inhibition of AKT/mTOR pathway was affecting 
TLR4. The immunological response of pre-pubertal MSCs group statistically significant 
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increased when miR-21 was inhibited (Fig. 6D) with respect to normal one (Fig. 4F). In 
the other side, TLR4 and pAKT/AKT increased their expressions in miR-21 inhibited 
pre-pubertal MSCs group after treatment with LPS. This result  indicate that miR-21 
affect to DAMPS and TLR4 levels but no to the immunological response of the MSCs  
to outside agents as LPS (Fig. 6D) pointing that miR-21 could be a regulator of TLR4 
signalling 46.  
 
CONCLUSION 
Our results provide an insight into the mechanism involved in MSC aging and suggest 
possible interventions into miRNAs to maintain quiescence and function of MSCs and 
their derived extracellular vesicles prior to in vivo transplantation or as pharmacological 
agents in disease. 
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Figure 1.  
Characterization of mesenchymal stem cells A) Mesenchymal stem cells markers 
(CD29, CD90) and haematopoietic markers (CD34, CD45) signals measured by flow 
cytometry. B) Modified expression genes between age groups obtained in the RNA-seq 
analysis. C) Hierarchical clustering of genes from MSCs age groups grouped into 
metabolic pathways common in all of them. 
Figure 2.  
NGS study. Metabolic pathways with statistically significant changes between 
newborn, infant, young, pubertal and  pre-pubertal age groups categorized according to 
their function, biological process and cellular component. Age groups were shown 
because of increasing of differential genes involved into inflammation mediated by 
chemokine and cytokine signalling pathway. No genes involved in this pathway were 
found between young and pre-pubertal age groups and between pubertal and adult age 
groups. Small numbers on the right of each bar are the modulated genes involved in 
each process.  
Figure 3.  
Characterization of extracellular vesicles MSCs-derived. A) Number of particles by 
cell at different age groups by NTA assay. B)  Concentration of protein by cell at 
different age groups by NTA assay. C) Mean size of particles expressed in nm at 
different age groups by NTA assay. D) Extracellular vesicles isolated from MSCs of 
pre-pubertal group by microscopy electronic (bar= 100nm). E) APC-CD63 antibody 
signal measured by flow cytometry at different amounts (1, 5 and 10 µM) from Pre-
pubertal extracellular vesicles MSCs-derived using beads. 
Figure 4.  
Pro-inflammatory study from micro-RNA contained in mesenchymal stem cells-
derived extra-vesicles with age. A) miR-146a, B) miR-155, C) miR-132, D) miR-335 
and E) miR-21 expression using real-time reverse transcriptase PCR (qRT-PCR) 
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analysis normalized by expression of miR-16 used as housekeeping. F) Western blot 
analysis of TLR4 at different age of MSCs groups treated with LPS. B-actin was used 
as housekeeping. G) Densitometry analysis of western of TLR4 normalized with respect 
to b-actin. N=newborn; Y=young; PP=pre-pubertal and A=adult. 
Figure 5.  
Effect of miR-21-5p on DAMPS in mesenchymal stem cells from pre-pubertal 
group. A) miR-21-5p expression B) Nanog gene expression C) HMGB1gene 
expression D) S100A4 gene expression and E) S100A6 gene using real-time reverse 
transcriptase PCR (qRT-PCR) analysis normalized by expression of miR-16 and HPRT.  
Figure 6. 
Effect of miR-21-5p on senescence and immune response in mesenchymal stem 
cells from pre-pubertal group. A) Western blot analysis of LMNA/C and Wnt5a in 
pre-pubertal MSCs group with or without inhibition of miR-21 and their densitometry 
analysis normalized with respect to tubulin. B) Western blot analysis of TLR4, mTOR 
and HMGB1 in pre-pubertal MSCs group with or without inhibition of miR-21 and their 
densitometry analysis normalized with respect to tubulin. C) Western blot analysis of 
AKT pathway in pre-pubertal MSCs group with or without inhibition of miR-21 and 
their densitometry analysis normalized with respect to tubulin. D) Western blot analysis 
of AKT pathway and TLR4 in pre-pubertal MSCs group miR-21-5p inhibited with or 
without LPS treatment and their densitometry analysis normalized with respect to 
tubulin and B-actin. 
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Table I. Specific primers for real-time reverse transcriptase-polymerase chain reaction 
(qRT-PCR) amplification. 
 
 
Target mRNA ID Forward ( 5’-3’) Reverse ( 5’-3’) 
HMGB1 NM_012963.2 CCGGATGCTTCTGTCAACTT TTGATTTTTGGGCGGTACTC 
S100A4 NM_012618.2 AGCTACTGACCAGGGAGCTG CTGGAATGCAGCTTCGTCT 
S100A6 NM_053485.2 TGATCCAGAAGGAGCTCACC AGATCATCCATCAGCCTTGC 
NANOG NM_005103.4 ATGCCTCACACGGAGACTGT AAGTGGGTTGTTTGCCTTTG 
TLR4 NM_019178.1 GCAGAAAATGCCAGGATGATG AAGTACCTCTATGCAGGGATTAG 
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